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ABSTRACT 
 
Drug resistance is the major impediment to the success of cancer therapy. The PI3K/AKT 
pathway mediates a plethora of cellular functions, including cell survival, proliferation and 
differentiation. However, increased activation of this pathway has been correlated with 
drug resistance mechanisms. This pathway regulates the activity of FOXO transcription 
factors in a negative manner through AKT-dependent phosphorylations. The modulation of 
FOXO activity leads to a variety of cellular outputs, including cell cycle arrest and 
apoptosis that define this transcription factor as a tumour suppressor. Importantly, FOXO 
has also been shown to mediate the effect of many anti-cancer drugs, suggesting that it 
has an additional role in drug sensitivity and resistance. With this work, by studying the 
PI3K/AKT/FOXO axis in breast cancer, I have characterised its impact in drug sensitivity 
and resistance. I found that this axis is deregulated in breast cancer resistant cells. By 
extending my in vitro findings to clinical samples, I further elucidated the potential role of 
AKT and FOXO3a as indicators and predictors of treatment response in breast cancer. 
In addition, I have also characterised three novel downstream targets of FOXO3a - 
FOXP1, FOXM1 and VEGF – with important roles towards breast cancer progression and 
in the development of drug-resistance. By characterising these FOXO3a effectors, I 
unravelled a potential general mechanism by which FOXO3a represses gene target 
expression. 
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1.1 CANCER 
Regardless of sex, type or country, every year there is an increase in the number of 
diagnosed cancer cases. The more recent estimates from the International Agency for 
Research on Cancer (IARC) in 2008 indicate that around 12.7 million cancer cases and 
7.6 million cancer deaths occurred worldwide (Jemal et al 2011). Lung cancer remains the 
commonest, accounting for 1.2 million new cases per year, followed closely by breast and 
colorectal cancers. In 2008, just in the UK 309,500 people were diagnosed with cancer. 
Breast and prostate cancers are the more prevalent among the population accounting for 
23% and 24%, respectively, of all cases of cancers in the UK (UK 2011). The future trend 
predicts a rise in deaths from cancer worldwide to over 11 million in 2030 (GLOBOCAN 
2008 Section of Cancer Information accessed on 1/6/2011). Cancer cells break the most 
basic rules of behaviour by which multi-cellular organisms are built and maintained. 
Functional abnormalities of proteins involved in DNA repair, cell signalling, cell cycle 
control, programmed cell death, and tissue architecture have been identified to lead to 
cancers (Alberts 2002).  
 
1.1.1 CANCER GENETICS 
Most cancers derive from an individual abnormal cell that has undergone serial somatic 
mutations. Typically, a series of multiple mutations are required to transform a normal cell 
into a malignant cell. Chemicals, radiation or viruses that insert their DNA into the human 
genome can cause these mutations (Karakosta et al 2005). Cancers develop in slow 
stages from mildly aberrant cells and progress involving more rounds of mutation and 
natural selection. Therefore, most cancer cells are genetically unstable. The uncontrolled 
proliferation of cancer cells depends on defective control of cell division, death or cell 
differentiation. Many cancer cells escape a built-in limit to cell proliferation, and gradually 
gain the ability of a constant proliferative state and evasion of apoptosis (Deshpande et al 
2005). In 2000, Hanahan and Weinberg reviewed the axiomatic requirements of cancer 
cells as six behavioural properties which result ultimately in capabilities that allow for 
cancer cells to proliferate, survive and spread (Hanahan and Weinberg 2000). 
Generally cancers arise due to genetic alterations that occur in two types of genes – 
oncogenes and tumour suppressor genes, such as DNA repair genes. Recent advances in 
cancer genetics uncover the serial aberrations of proto-oncogenes and tumour suppressor 
genes (e.g. RAS, P53 mutations and/or allelic losses, hyper-expression of c-MYC and RB 
genes) in most cancer development at various stages. By definition, oncogenes are 
dominant, activated versions of normal genes (proto-oncogenes). In a normal cancer 
scenario, mutations in oncogenes drive gene expression activation leading to an 
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accelerating cell growth, loss of differentiation, avoidance of apoptosis and invasion. The 
vast majority of oncogenes are involved in pathways that normally serve to regulate cell 
division and survival. RAS and c-MYC are two of these oncogenes that have been 
extensively studied over the past years. 
RAS genes encode a family of membrane-associated small G proteins that was the first 
identified oncogene and approximately 30% of human tumours overexpress RAS proteins 
which can be activated by point mutations or amplifications. RAS activation is known to 
potentiate a variety of extracellular stimuli through activation of receptor tyrosine kinases 
(RTKs) (Downward 2003). Once in the active GTP-bound form, RAS can activate a 
number of intracellular signalling cascades, most notably the RAF/MEK/ERK signalling 
pathway. Active RAS binds to and activates the three closely related RAF proteins (c-RAF, 
B-RAF and A-RAF) (Tidyman and Rauen 2009), leading to its translocation to the plasma 
membrane where it phosphorylates and activates the mitogen-activated protein kinase 
kinases (MAPKKs), MEK1 and MEK2. These in turn phosphorylate and activate the 
mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase 1 and 2 
(ERK1 and ERK2). In addition to activating RAF/MEK/ERK signalling cascade, RAS also 
binds directly to and activate the class I PI3K proteins (Shaw and Cantley 2006). 
The oncogenic functions of the transcription factor c-MYC play a key role in well-known 
human cancers, such as Burkitt’s lymphoma as a result of chromosomal translocation and 
is often associated with bad prognosis (Pelengaris et al 2002). Additionally, c-MYC 
activation appears to be crucial at some stage during tumour development. c-MYC 
deregulation is a consequence of different signalling pathways, including the mitogen 
activated protein kinases (MAPKs) (Desbiens et al 2003), the phosphatidylinositol-3 kinase 
(PI3K) (Grumont et al 2002) and the signal transducer and activator of transcription (STAT) 
(Kiuchi et al 1999) pathways. c-MYC is a “master regulator” of large numbers of genes that 
virtually play a role in almost all the biological processes of a cell. However, its key 
biological function is to promote cell cycle progression (Hoffman and Liebermann 2008). 
This c-MYC proto-oncogene is known as an early-response gene and it allows cells to exit 
G0 and proliferate. Thus, c-MYC is crucial for normal cell proliferation and without it, cells 
would have a difficult task replicating themselves.  
 
Tumour suppressors are regarded as the guardians of the cells against the internal and 
external insults that they are constantly exposed to. They monitor critical checkpoints that 
drive the mitotic cycle, DNA repair, transcription, apoptosis and differentiation. Generally, 
tumour suppressors are transcription factors or signalling molecules that inhibit cell 
proliferation and prevent damaged or abnormal cells from becoming malignant as a result 
of cellular stress (e.g. hypoxia, ultraviolet radiation, DNA damage, oxidative stress, 
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telomere shortening or activated oncogenes) (Papazoglu and Mills 2007). Mutations or 
deletions result in their functional inactivation and creates an imbalance that potentiates 
tumorigenesis. Two of the most well characterised tumour suppressors are the 
retinoblastoma protein (pRB) and p53. 
The retinoblastoma tumour suppressor gene (RB) was one of the first tumour suppressor 
genes to be discovered and belongs to a family that consists of three genes – RB, p107 
and p130. Of these, only RB has been found to be inactivated in a variety of tumours 
(Sherr and McCormick 2002). Its main function is to prevent excessive cell proliferation by 
repressing the transcription of genes responsible for the progression through the G1 phase 
into S phase of the cell cycle thus, the integrity of RB pathway is essential for normal cell 
growth. Throughout cell cycle progression, RB is negatively regulated by fluctuations of 
phosphorylation events that culminate with the release of proteins associated with RB 
(Weinberg 1995). One of the proteins that form a determinant complex with RB is its main 
downstream target E2F transcription factor. E2F induces transcription of genes necessary 
for G1 to S phase progression. By interacting with E2F, RB prevents their transcriptional 
activity and restricts cell cycle progression. RB can also repress genes required for cell 
cycle progression by recruiting HDACs. 
The protein p53, also referred to as the ‘guardian of the genome’ (Lane 1992), is the most 
widely studied tumour suppressor gene due to the high frequencies of mutations found in 
human cancers - ~50% (Vousden and Lu 2002). The loss of p53 functions in cancer is 
most commonly achieved through a point mutation in TP53, the gene that encodes p53, or 
alternatively by defects in the signalling pathways that are upstream or downstream of p53, 
provides a selective advantage for clonal expansion, therefore loss or impaired of p53 
function is an integral step in cancer development. Another such example is in the case of 
Li-Fraumeni syndrome where patients have a high susceptibility to line development of 
diverse cancer types. In line with this, although viable almost all the P53 null mice develop 
cancers before six months of age (Lee et al 2001).  
When triggered by cellular stress, p53 is stabilised and activated through phosphorylation 
and other post-translational modifications to induce the expression of a set of target genes 
involved in DNA repair, differentiation, senescence, cell cycle arrest or apoptosis (Soussi 
et al 2006). Phosphorylation of p53 results in its activation through protein stabilisation by 
disruption of its MDM2 interaction, regulation of transactivation activity and nuclear re-
localisation (Pollard and Earnshaw 2002, Shieh et al 1999). The E3 ubiquitin ligase murine 
double minute 2 (MDM2) is a negative regulator of p53 that promotes p53 ubiquitination 
leading to its nuclear export and proteasomal degradation. Moreover, MDM2 null mice are 
embryonic lethal due to the elevated levels of p53-induced apoptosis, suggesting that 
MDM2 oncogenic role is to suppress normal p53 function (Jones et al 1995). Importantly, 
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p53 has been shown to engage in a negative feedback mechanism with MDM2, indicating 
that p53 expression is a fine-tuned mechanism (Batchelor et al 2009).  
1.1.2 CANCER EPIGENETICS 
The genome encodes two forms of information, genetic and epigenetic. In cancer, not all 
gene or protein expression deregulation arises from mutation in coding DNA; instead, 
activation of oncogenes and silencing of tumour suppressors can be a result of epigenetic 
factors. The epigenetic information is not contained in the DNA sequence itself but can still 
be transmitted from one cell to all its descendants. Epigenetic factors, including DNA 
methylation and post-translational modifications of histone can direct gene expression and 
cell fate (Bachman et al 2003).  
One of the major forms of epigenetic modification associated with transcriptional silencing 
in cancer cells is aberrant DNA methylation of CpG islands located in the gene promoter 
regions of genes. Hypermethylation may silence some tumour suppressor genes whereas 
hypomethylation may activate specific oncogenes. In normal cells, CpG islands are not 
usually methylated and can be found in up to 40% of the promoters regions of human 
genes (Esteller 2008). However, once methylation occurs in or around a gene promoter 
region, the transcriptional activation machinery can no longer bind and as a result gene 
expression is silenced. Contrarily, hypomethylation can inappropriately activate gene 
expression. One such example of a gene affected by hypomethylation includes the H-RAS 
oncogene (Feinberg and Vogelstein 1983).  
Another epigenetic factor that controls gene expression is histone post-translational 
modifications, including acetylation, methylation and phosphorylation. These modifications 
of histone tails make them key points for chromatin condensation/decondensation. 
Acetylation can occur on a range of proteins with diverse cellular functions, most notably 
histones (Yang and Seto 2008). This dynamic process is regulated by histone 
deacetylases (HDACs) and histone acetyltransferases (HATs) that remove or add acetyl 
groups from lysine residues on the histone tails, respectively. Acetylation results in a 
relaxation of the DNA-nucleosome structure, allowing the access of transcription factors 
and other associated proteins that can initiate gene transcription. On the other hand, 
deacetylation of histones by HDACs is associated with chromatin condensation and results 
in transcriptional repression (Marks et al 2001, Struhl 1998). DNA methylation is used as a 
marker to help define regions of transcriptionally active chromatin from transcriptionally 
inactive chromatin and determine the epigenetic state of cells. These marks involve 
methylation of lysine 9 in the tail of histone H3, and methylation of lysine 4 on histone H3, 
which mark transcriptionally inactive and active chromatin, respectively (Ruthenburg et al 
2007). Despite playing a crucial role in altering the epigenetic scenario of a cell, DNA 
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methylation appears to have a dominant effect over histone acetylation as inhibition of 
HDAC in cancer cells does not result in reactivation of hypermethylated (ie silenced) genes 
(Bachman et al 2003). 
 
1.2 BREAST CANCER 
Despite being the most prevalent disease affecting women in the UK, breast cancer is a 
heterogeneous disease that accounts for multiple genetic alterations. However, advances 
in research led to the identification of hereditary risk factors. Breast cancer type 1 (BRCA1) 
and breast cancer type 2 (BRCA2) susceptibility proteins have been found to harbour 
mutations that increase the predisposition to the development of breast as well as ovarian 
cancer thus, acting like tumour suppressor genes (Miki et al 1994, Wooster et al 1995). 
Yet, this hereditary form of breast cancer only accounts for a minority of the total number 
of cases, with the majority of cases being sporadic. The prognosis of patients with breast 
cancer can be categorised into low, intermediate and high risk, depending on the 
assessment of clinical and biological factors, including age at diagnosis, tumour size, 
lymph node status, tumour histological grading, expression of estrogen (ER) and 
progesterone (PR) receptors and HER-2 status (Goldhirsch et al 1998).  
Depending on the diagnosis, a patient will receive treatment, which includes surgery on the 
primary tumour, hormone therapy, radio- and chemo-therapy and targeted agent-therapy.  
 
1.2.1 ESTROGEN RECEPTOR (ER)  
The estrogen receptors (ERs) are members of a superfamily of nuclear hormone 
receptors, which comprises different transcription factors and transcriptional regulators, 
including the progesterone (PR) and the androgen receptors (AR) (Lonard et al 2007, 
Olefsky 2001). ERs are involved in the regulation of development, reproduction and 
metabolism (Nilsson and Gustafsson 2002). There are two main receptors – ER alpha 
(ERα) and ER beta (ERβ) – that transmit the physiological signalling in response to 17β 
estradiol (E2). E2 facilitates transcriptional changes in pathways involved in the promotion 
of cell proliferation, 
inhibition of apoptosis, stimulation of metastasis, and angiogenesis. Since their discovery 
several ERα and ERβ isoform species have been identified (Herynk and Fuqua 2004). 
Estrogen has been shown to be essential for normal breast tissue development as a study 
reported that in female aromatase-deficient patients, which are unable to convert steroids 
into estrogens, breast development was impaired whereas estrogen administration to the 
same patients reinstated normal breast development (MacGillivray et al 1998). The role of 
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estrogen signalling in breast cancer came from a study as surprisingly early as in the 
1880s where in post-menopausal women whom have had surgery to remove one or both 
of their ovaries, tumour regression was noted (Boyd 1899). Currently it is commonly 
accepted that continuous exposure to both exogenous and endogenous estrogens 
contributes to breast as well as prostate, ovarian, and endometrial cancer (Bosland et al 
2002, Deroo and Korach 2006, Hankinson et al 2004, Henderson and Feigelson 2000). 
Estrogen is also thought to contribute to the accumulation of genotoxic stress by 
increasing potentially damaging factors such as oxidative stress, which can contribute to 
tumour formation.  
ERα has six domains that comprise regions of conserved function and sequence. Two of 
those domains that are crucial for ER transcription activation function are AF-1 and AF-2. 
AF-1 is localised in the N-terminal region of the receptor and acts in a ligand-independent 
manner whereas the C-terminal AF-2 is responsible for the ligand-dependent 
transactivation functions of ERα. AF-1 and AF-2 act independently and synergistically in a 
promoter- and cell-specific manner (Beato et al 1995, Gronemeyer 1991). ERs exert a 
wide range of biological effects following activation in response to ligand binding or in a 
ligand-independent manner. In response to ligand-binding, ERα functions as a 
transcription factor, translocating from the extracellular membrane to the nucleus, binding 
to the estrogen response elements (EREs), in the promoter regions of ER target genes, 
and recruiting co-activator or co-repressor machinery that will determine whether gene 
transcription is activated or repressed (Ali and Coombes 2002). Yet, in the absence of 
ligand other growth factor receptors, such as epidermal growth factor receptor (EGFR) are 
able to induce signalling cascades that in turn phosphorylate and activate ERα (Britton et 
al 2006). Some of ER regulated genes include Cyclin D1, involved in cell cycle progression 
and the anti-apoptotic Bcl-2, determinant for apoptosis (Madureira et al 2006). 
 
1.2.2 BREAST CANCER TREATMENT  
ERα relevance in breast cancer is well established and around 70% of breast cancer 
cases exhibit increased ERα expression (ERα positive tumours) and a dependence on 
ERα-driven proliferation (Hayashi et al 2003). Thus, it is natural that ERα is one of the 
most targetable proteins in the treatment of breast cancer. Endocrine therapies have 
become the primary adjuvant treatment for breast cancer. They consist of anti-estrogens 
such as tamoxifen or fulvestrant, which bind and neutralise ER, and/or aromatase 
inhibitors (AIs) such as letrozole or exemestane, that will block the endogenous estrogen 
synthesis (Mauri et al 2006). Tamoxifen is a selective estrogen receptor modulator (SERM) 
that is used as the main form of adjuvant treatment in ERα positive breast cancer patients 
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that has been shown to improve relapse-free and overall survival. Several studies showed 
that the agonistic and antagonistic activity of tamoxifen results from the activation of AF-1 
and AF-2, respectively. Tamoxifen binds to ER and the complex dimerises and 
translocates to the nucleus, where it inhibits co-activator binding and promotes co-
repressor binding to the ER ligand-binding domain blocking the transcription of AF2, while 
AF1 remains active (Xu et al 2002). One third of women with ERα positive tumours treated 
with tamoxifen for 5 years will recur as incurable within 15 years (Goss et al 2008, 
Johnston 1997, Yamashita 2008). In around 15% of patients, tamoxifen-resistance is 
associated with the loss of ERα. However, the majority of tamoxifen-resistant patients 
remain positive for ERα expression and frequently respond to aromatase inhibitors or pure 
anti-estrogens, including ICI 182780 (also called fulvestrant and Faslodex). AIs are used to 
deprive tumours from estrogen; AIs inhibit the aromatase enzyme, which catalyses the 
conversion of androgens to estrogens (Winer et al 2005). Letrozole, the most potent non-
steroidal AI, was shown to reduce cell proliferation and cause tumour regression in 
estrogen-dependent cancers, showing that their clinical benefits were similar or even 
superior to tamoxifen (Baum et al 2002, Miller and Jackson 2003). AIs are currently used 
as first-line therapy for metastatic disease and as second-line agents in cases of tamoxifen 
resistance.  
For breast cancer patients whose tumours fail to respond to endocrine treatment or for 
those that lack estrogen receptors, cytotoxic chemotherapy agents, including taxanes 
(Paclitaxel and Docetaxel) and anthracyclines (Epirubicin and Doxorubicin), represent an 
option for treatment (Ali and Coombes 2002, Wenzel et al 2002).  
The first anthracyclines, including doxorubicin, were extracted from the pigment producing 
Streptomyces peucetius in the 1960’s are one of the most effective anticancer drugs ever 
developed. However, the clinical use of doxorubicin, as with other anticancer drugs proved 
challenging due to its high toxicity effects in healthy tissues, including cardiomyopathy and 
congestive heart failure. Epirubicin, a semi-synthetic derivative of doxorubicin, was 
discovered due to the need for novel anthracyclines that showed superior activity and a 
better cardiac tolerability (Weiss 1992). The pharmacokinetic and metabolic changes 
introduced in epirubicin approved the clinically use of double the dose of epirubicin 
compared to doxorubicin without an impact in its activity but with a reduction in 
cardiotoxicity (Robert 1993). Two key adjuvant breast cancer trials comparing 
cyclophosphamide–epirubicin–fluorouracil (CEF) with cyclophosphamide–methotrexate–
fluorouracil (CMF), and comparing epirubicin (E-CMF) with CMF, both reported a gain in 
overall survival of 7% after 5 years for patients treated with anthracyclines (Levine et al 
2005, Poole et al 2006). One of the main mechanisms associated with the anti-cancer 
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activity of anthracyclines includes initiation of DNA damage by interference with 
topoisomerase II. 
Topoisomerases are ubiquitous enzymes responsible for maintaining DNA topology by 
over- or under-winding of DNA with a key role in DNA replication and transcription. These 
dual-action enzymes cause transient single-stranded (Topoisomerase I) or double-
stranded (Topoisomerase II) DNA breaks and after new DNA is generated they covalently 
reseal it (Froelich-Ammon and Osheroff 1995). Topoisomerase II is particularly important 
since they are the main target of anthracyclines, specifically doxorubicin. These drugs 
“explore” the dualistic nature of topoisomerases enzymes by enhancing their rate of DNA 
cleavage and by impairing their ability to reseal DNA breaks. Anthracyclines are known to 
intercalate into DNA, induce the formation of reactive oxygen species (ROS) and inhibit 
topoisomerase II among other actions. Additionally, anthracyclines induce DNA damage, 
activate ataxia teleangiectasia mutated kinase (ATM), induce p53 nuclear translocation 
and lead to cell cycle arrest or apoptosis (Minotti et al 2004, Zhou and Elledge 2000). 
Nevertheless, anthracyclines can also induce apoptosis in a DNA damage or p53 
independent manner by inducing the release of cytochrome c from mitochondria and inhibit 
downstream activity of signalling pathways, including the PI3K/AKT (Clementi et al 2003, 
Laurent and Jaffrezou 2001).  
Paclitaxel (Taxol) was the first natural product shown to stabilise microtubules and is the 
prototype of the taxane family. Taxanes exert their cytotoxic effects in the G2/M phase of 
the cell cycle by blocking cell cycle progression through centrosomal impairment, induction 
of abnormal spindles and suppression of spindle microtubule dynamics. A meta-analysis of 
13 clinical trials involving women with early-stage breast cancer showed that the disease-
free survival (DFS) and overall survival (OS) were significantly improved with the 
incorporation of taxanes to the anthracycline-based regimens (De Laurentiis et al 2008). 
Despite an initial response to taxane and anthracycline-based chemotherapies, tumours 
eventually become insensitive to treatment and disease recurs.  
These chemotherapy regimens are also used for the treatment of patients with metastatic 
breast cancer; however, treatment options for these group of patients is limited especially 
for those in which response rates are low or whom resistance against anthracyclines and 
taxanes has developed (Roozrokh and Stahlfeld 2002). Therefore, it is essential to develop 
suitable newer predictive factors to select optimal therapy for each subset of patients 
(Walgren et al 2005).  
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1.2.3 PREDICTIVE MARKERS 
Predictive markers are crucial indicators of the efficacy of a treatment by means of 
predicting the sensitivity or resistance in response to a particular therapy. The 
improvements made on breast cancer classification lead to the identification of some 
predictive markers such as ER, PR and HER-2 that proved useful for predicting prognosis 
and for establishing guideline-based recommendations. In 2000, Perou et al classified 
breast tumours according to their gene expression patterns using cDNA microarrays 
(Perou et al 2000). This study grouped breast cancers into five distinct types, including two 
ER- and PR-positive groups, called luminal A and B, a HER-2 overexpressing group, a 
basal-subtype group and a normal basal-like group. The majority of basal-like tumours are 
characterised by the absence of staining for ER, PR, and HER-2 receptors and therefore 
they are referred as triple negative breast cancers (TNBC) (Sorlie et al 2001). However, a 
small number of basal-like tumours have been found to express one or more of these 
receptors thus basal-like tumours are not synonymous with TNBC. Several studies showed 
that TNBC correlate with a poorer clinical outcome (Abd El-Rehim et al 2005, Sorlie et al 
2003). Of all breast cancer cases, 80% are ER- or PR-positive and the remaining cases 
are HER-2 overexpressing tumours. The presence of ER and/or PR are good predictors of 
endocrine treatment response in breast cancer patients. ER and/or PR expression is an 
independent prognostic factor in breast cancer (Burcombe et al 2005). However, in 
regards to chemotherapy treatment, ER negative tumours respond better than ER positive 
tumours. 
The transmembrane receptor tyrosine kinase HER-2 (neu, C-erbB2), is one of the most 
extensively studied biomarkers in breast cancer. Its overexpression and amplification is 
found in approximately 20–25% of early breast cancers (Bartlett et al 2001, Slamon et al 
1989) and is commonly associated with increased tumour aggressiveness, increased risk 
of recurrence and reduced survival. As well as HER-2, overexpression of other HER family 
members has been shown to increase proliferation in vivo (Tovey et al 2004). Therefore, 
the predictive power of HER-2 elucidated for the requirement of more aggressive 
treatment. Women with tumours exhibiting high HER2 expression were shown to benefit 
from increasing doses of adjuvant anthracyclines in terms of relapse-free survival when 
compared with women with low HER2 expression tumours (Muss et al 1994). The 
discovery that HER-2 and TOP2A (topoisomerase II) are located in close proximity on 
chromosome 17q together with the fact that anthracyclines directly target TOP2A raised 
the possibility of assessing TOP2A expression as a predictive marker of anthracycline 
response (Di Leo et al 2002, Pritchard et al 2008). TOP2A amplification is mostly restricted 
to HER-2 positive breast cancers and is rarely encountered in tumours that lack HER-2 
gene amplification. In fact, some studies reported that TOP2A deletion or amplification 
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linked with HER-2 amplification leads to a worse prognosis but greater response to 
anthracycline containing regimens (O'Malley et al 2009).  
With the discovery and characterisation of novel molecular targets, targeted treatments 
that allow differentiating between malignant and benign cells gradually emerged. 
Consistently, there are current drug targeted therapies for HER-2-positive breast cancers 
in clinical use, including trastuzumab (Herceptin) and lapatinib (Browne et al 2009), and 
bevacizumab for HER-2-negative breast cancer.  
Currently, there are no standard recommendations in the clinical management of TNBC. 
Since TNBC is null for all three receptors, ER, PR and HER-2, neither hormonal nor 
targeted therapies are available options thus, for patients with this subtype of breast 
cancer the primary treatment relies on conventional systemic chemotherapy. In an attempt 
to identify new predictive markers related to cell proliferation, cell cycle, angiogenesis and 
signal transduction, especially in TNBC cases, some candidate genes were shown to play 
an important role in its pathogenesis, including the epithelial growth factor receptor 
(EGFR), c-KIT, P53, poly ADP-ribose polymerase1 (PARP1) and vascular endothelial 
growth factor receptor (VEGFR) (Podo et al 2010).  
 
 
1.3 RESISTANCE TO CANCER THERAPY 
A great progress has been made in the development of newer and better tolerated anti-
cancer drugs for the treatment of breast cancer during the past years. However, most of 
the drugs currently used for the treatment of breast cancer are associated with acquired 
resistance, which is for the time being the major hurdle in cancer research. Resistance to 
chemotherapy can develop prior to drug treatment (intrinsic resistance) or may develop 
over time after drug exposure (acquired resistance) (Giaccone and Pinedo 1996). 
 
1.3.1 GENERAL RESISTANCE MECHANISMS 
Multidrug resistance is defined by simultaneous cross-resistance to anti-cancer drugs that 
differ in their chemical structures, modes of action and molecular targets. There are two 
main mechanisms thought to be involved in multidrug development, reduced drug 
accumulation and enhanced capacity of the tumour to counteract the cytotoxic effects of 
the drugs (Figure 1) (Polgar and Bates 2005, Scotto et al 1986). 
There are two mechanisms by which cancer cells can reduce drug accumulation based on 
the strategies of drug uptake. The first mechanism involves decreased expression or 
activity of transporter molecules that regulate the uptake of hydrophilic chemotherapeutic 
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drugs such as folate antagonists and cisplatin. The second one encompasses an 
upregulation of transporters associated with energy dependent efflux of a wide variety of 
hydrophobic chemotherapeutic agents that enter cells freely by diffusion through the 
plasma membrane, including taxanes (e.g. paclitaxel and docetaxel), vinca alkaloids and 
anthracyclines (e.g. doxorubicin, daunorubicin, and epirubicin) (Gottesman et al 2002). 
Examples of such transporter molecules include P-glycoprotein (P-gp), also called MDR1, 
the multidrug-resistance-associated protein MRP1 and the breast cancer resistance 
protein (BCRP). These proteins play a crucial physiologically role in cellular protection from 
endogenous substrates. These transporters are often found to be overexpressed in cancer 
(Longley and Johnston 2005). Malignant cells have a further enhanced capacity to 
counteract the cytotoxic and/or cytostatic effects of therapeutic agents. It involves 
amplification of proliferation and survival signals (alteration in cell cycle checkpoint, 
deregulation of apoptotic mechanisms, activation of oncogenes, including HER-2, c-MYC, 
RAS, MDM2, BCR-ABL, or mutant P53), increased DNA damage repair (e.g. O6-
methylguanine-DNA methyltransferase, topoisomerase II, p21WAF1/CIP1), nucleoside 
and nucleobase salvage pathways, and altered drug metabolism as well as mutation or 
overexpression of the drug targets (e.g. cytochrome P-450 reductase and BCR-ABL) 
(Figure 1) (Raguz and Yague 2008, Stavrovskaya et al 1998, Tsuruo et al 2003). 
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Figure 1. Mechanisms involved in drug resistance. 
Reduced drug accumulation can occur by inhibition of membrane transporters used by hydrophilic 
drugs to access the cell or by active export of hydrophobic drugs from the cell. Other mechanisms 
include activation of cell repair or detoxification systems and inhibition of apoptosis. [Adapted from 
(Gottesman et al 2002)]. 
 
1.3.2 BREAST CANCER THERAPIES AND RESISTANCE 
The multifunctional hormonal action of estrogen as well as the presence of a ligand-
independent activation mechanism together with the interaction and cross-talk between 
estrogen and a variety of growth factors or cytokine driven signal transduction pathways 
have led to intense investigation into the mechanism of action of estrogen and endocrine 
resistance. Many mechanisms have been proposed to help understand the loss of 
therapeutic responsiveness to endocrine therapies. The main mechanism of acquired 
resistance to tamoxifen is the loss of ERα expression or ERα mutations yet, only 15-20% 
of breast cancer patients lose ERα expression (Gutierrez et al 2005) and as few cases as 
less than 1% exhibit mutations in this receptor (Herynk and Fuqua 2004). 
Several studies have shown that endocrine resistance is associated with a crosstalk 
between ER and receptor tyrosine kinase signalling, including HER-2 (De Laurentiis et al 
2005). Furthermore, increased expression of EGFR and PI3K activity has also been 
associated with endocrine resistance (Jordan et al 2004, McClelland et al 2001). 
Moreover, induction of EGF-mediated growth response and MAPK activation were also 
shown to compensate for the estrogen-deprivation in MCF-7 cells (Martin et al 2003, Miller 
et al 1994). Conversely, in the presence of specific tyrosine kinase inhibitors 
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responsiveness to endocrine treatment was restored and reversed tamoxifen-resistant 
tumour growth (Gee et al 2003). Deregulation of estrogen target genes is yet another 
mechanism by which breast cancer cells can overcome endocrine sensitivity. 
Overexpression of the estrogen-targeted cell cycle regulators c-MYC and Cyclin D1 occurs 
frequently and has been associated with altered sensitivity to endocrine therapies. Indeed, 
overexpression of these genes has been shown to suppress anti-estrogen-induced growth 
arrest (Prall et al 1998) modulating sensitivity to anti-estrogens in vitro. 
Estrogen co-repressors and co-activators are also crucial for governing the agonistic or 
antagonistic mode of action of SERM and subsequently have been associated with 
resistance to anti-estrogens in breast cancer. Decreased levels of nuclear receptor 
corepressor (NCOR) have been associated with a shorter DFS. Accordingly, the absence 
of silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) has been 
correlated with reduced DFS and OS (Girault et al 2003, Green and Carroll 2007). 
Another possibility why some ER-positive patients fail to respond to tamoxifen therapy 
relates to failure of converting tamoxifen to its active metabolite, endoxifen, a reaction 
catalyzed by cytochrome P4502D6 (CYP2D6). Certain polymorphisms in the CYP2D6 
gene originate different phenotypes that can metabolise with poor to ultra-rapid efficacy 
(Jin et al 2005). Patients with a poor metaboliser genotype for CYP2D6 have impaired 
conversion of tamoxifen and thus are less likely to benefit from tamoxifen therapy. 
Although there is still controversy as to what is the significance of the different CYP2D6 
genotypes some studies suggested that patients with a genotype responsible for a low 
CYP2D6 activity had a higher disease recurrence rate compared to those with a high 
metabolism genotype (Dezentje et al 2009). 
Taxane-resistance has been linked to defects in its various targets, including the class III 
β-tubulin expression, Aurora-A, Bcl-2, and Tau. Overexpression of Bcl-2 elicits resistance 
to docetaxel (Noguchi 2006) whereas increased tau expression can be associated with a 
decrease in response to neoadjuvant paclitaxel. Accordingly, silencing Tau can restore 
paclitaxel sensitivity (Rouzier et al 2005). Similarly to tamoxifen metabolism, taxanes 
action is also altered by faster metabolising enzymes activity or defective cytochrome 
P450 (CYP3A4 and CYP2C8) that culminate in a reduction of the active drug 
concentration in the plasma. 
Anthracycline resistance develops by a multitude of processes, including overexpression 
of P-glycoprotein and the breast cancer resistance protein (BCRP) (Faneyte et al 2002, 
Fojo and Menefee 2007), topoisomerase II mutations, overexpression of DNA repair 
mechanism and deregulation in the apoptotic signalling (e.g. specific mutations in p53 are 
associated with doxorubicin resistance and culminate in early relapse in breast cancer) 
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(Minotti et al 2004). Following the progress made in understanding the molecular basis of 
cancer a new era has been initiated with the emergence of biologically targeted therapies. 
Trastuzumab, the recombinant monoclonal antibody that attaches to and blocks HER-2-
mediated signalling (Yarden and Sliwkowski 2001) and lapatinib, the small-molecule 
inhibitor that binds to both HER-2 and EGFR (HER-1), thereby blocking any downstream 
signalling from these receptors (Moy and Goss 2006) are two such examples of 
breakthroughs in targeted therapy. Although they have proven useful in the treatment of 
the more aggressive form of breast cancer, each of these compounds has a response rate 
of approximately 30% as single agents for the HER-2 positive breast cancer cases. The 
remaining 70% of patients will not benefit from treatment with either agent. Moreover, for 
patients who respond to treatment the relapse comes within one year suggesting that 
these HER-2 positive tumours have resistant mechanisms to counteract the effect of these 
agents (Nahta et al 2006). Mutation in the PIK3CA gene (Berns et al 2007), loss of 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) (Nagata et al 2004) 
and overexpression of insulin-like growth factor receptor (IGF-1R) have been suggested to 
contribute to herceptin rather than lapatinib resistance mechanisms. Indeed, a HER-2/IGF-
1R heterodimer has been found in trastuzumab-resistant breast cancer cell lines but not in 
sensitive cells and disruption of this complex can re-sensitise cells to trastuzumab 
treatment (Nahta et al 2005). Another potential mechanism of trastuzumab-mediated 
resistance is the presence of truncated isoforms of the HER2 receptor (e.g. p95 HER-2 
and HER2Δ16) lacking the extracellular trastuzumab-binding domain. The p95 HER-2 
mutant isoform is found in around 60% of all HER-2 positive tumours (Scaltriti et al 2007). 
The HER-2 splice variant, HER2Δ16 has enhanced transforming activity when compared 
to wild-type HER-2 (Esteva et al 2002). The HER family is known for its ability to form 
dimers amongst different members. For example, the heterodimers EGFR/HER-2 and 
HER-2/HER-3 were found in aggressive breast cancers and EGFR/HER-2 complex has 
been shown to associate with worst prognosis (Suo et al 2002). Pertuzumab is a new 
generation of monoclonal antibodies that binds to a distinct epitope of HER2 and prevents 
dimerization between different HER members thus, this drug might proof useful for the 
existing trastuzumab-resistant cases (Franklin et al 2004).  
Lapatinib-acquired resistance has been shown to be mediated by enhanced estrogen 
receptor signalling as a consequence of FOXO3a activation (Xia et al 2006). This example 
illustrates one of the biggest obstacles in cancer therapy, the immense network complexity 
and the cross-talks between different transduction pathways. Nevertheless, it appears 
conflicting that lapatinib resistance arises from its potent proliferative inhibitory effect. 
Unlike trastuzumab, lapatinib-resistance mechanisms do not appear to involve IGF-1R and 
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in fact lapatinib has been shown to inhibit IGF-1R signalling in trastuzumab-resistant cells 
(Nahta and Esteva 2006). 
Resistance mechanisms have been described across the anti-cancer therapeutic field for 
almost every available drug used for the treatment of breast cancer. Therefore, in order to 
achieve a better clinical management of breast cancer there is a need for the discovery of 
new markers that can predict both response and resistance to specific treatments and a 
deeper knowledge of the molecular mechanisms that allow for resistance to develop. 
Importantly, the comprehension of the mechanistic side of resistance has to be addressed 
in a wider integrative cellular scale and move towards the implementation of broader 
therapies that will account for resistance.  
 
1.4 PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) SIGNALLING 
PATHWAY 
Phosphoinositide 3-kinase (PI3K) activity was first characterised over 25 years ago, co-
purifying with oncoproteins pp60 v-src and polyoma middle T antigen (Whitman et al 
1985). This family of enzymes are dual specificity protein and lipid kinases that are able to 
phosphorylate proteins on serine/ threonine residues. They catalyse the addition of 
phosphate to the 3-OH position of the inositol ring within lipids, termed 
phosphatidylinositols (PtdIns) - which are present on the intracellular space of the cell 
membrane – converting phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3). Through successive phosphorylations, this 
family of enzymes provides critical signals for a wide range of biological processes, 
including regulation of cell size, proliferation, survival, metabolism, glucose transport, 
ageing, malignant transformation, cytoskeletal reorganisation, angiogenesis, invasion and 
metastasis, differentiation, membrane trafficking and chemotaxis (Fruman and Cantley 
2002, Okkenhaug and Vanhaesebroeck 2003). The diverse range of functional effects 
reflect the existence of a PI3K enzyme family, which consists primarily of three main 
classes each containing a range of subunits and isoforms, distinct from each other due to 
their substrate specificity and lipid products (Engelman et al 2006). The class I PI3Ks are 
the most studied PI3Ks. These heterodimeric enzymes are composed of a p110 subunit 
that contains the catalytic domain and a p85 subunit which facilitates the translocation of 
the catalytic domain and contains the regulatory domain. Class I PI3K enzymes are sub-
divided into class IA and class IB, downstream of tyrosine kinases receptors and G-protein 
coupled receptors, respectively. Class IA enzymes have three types of p110 catalytic 
subunit (p110α, p110β, p110γ) and five types of regulatory/adaptor subunits (p85α, p55α, 
p50α, p85β, p85γ). The 3 catalytic isoforms are encoded by 3 separate genes (PIK3CA on 
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chromosome 3q26.3, PIK3CB on 3q22.3, PIK3CD on 1q36.2 for p110α-γ, respectively). 
The regulatory subunits p85α, p55α and p50α are derived from a single gene (PIK3R1 on 
5q13.1) by alternative splicing, whereas p85β and p55γ are encoded by distinct genes 
(PIK3R2 on 19q13.2-13.4 , PIK3R3 on 1p34.1). Of these, p85α is the most abundantly 
expressed and important, as all p110 subunits need p85α to function in vitro (Okkenhaug 
and Vanhaesebroeck 2001). The p85 subunit contains two Src homology 2 (SH2) domains 
which allow binding to the p110 catalytic subunit. Class IB contains a p110γ catalytic 
subunit that binds to a different regulatory subunit, termed p101 and is activated by G-
protein coupled receptors (Djordjevic and Driscoll 2002). The role of PI3K activity in 
physiology and pathology has been investigated by studies using knock-out mice models. 
Of these, p110α and p110β KO mice died in utero between days 9.5 and 10.5, while 
double heterozygous p110α+/- p110β+/- mice grew normally, suggesting a role in foetal 
development (Bi et al 1999). Class IA PI3K regulate the proliferation, differentiation and 
development of various inflammatory cells. They are activated by cytokine and antigen 
recognition by T cell-, B cell-, Fc receptors. As a result, they regulate inflammatory 
responses such as chemotaxis, polarisation, migration, phagocytosis, NO synthesis and 
exocytosis (Koyasu 2003, Stephens et al 2002). Class II PI3K family are monomeric and 
do not contain a regulatory subunit. They act downstream of various receptors, including 
EGFR and TNFα receptor. Mammalian class III PI3K is homologous to Saccharomyces 
cerevisiae Vps34p. Similarly to class I PI3K, class III PI3K are heterodimers consisting of a 
catalytic and regulatory subunit.  
The class I PI3K proteins can be triggered by hormones, cytokine or growth factors and 
result in proliferation, survival and motility of most cell types. They are essential for 
development and function of inflammatory cells physiologically, and are important in 
lymphoproliferative and autoimmunity diseases. Constitutive activation drives cell 
proliferation and protects cells from apoptosis, and this is frequently seen in cancers 
(Burgering and Medema 2003). The biological effects of PI3Ks are mediated by their lipid 
products. Therefore, their effects can be antagonised with metabolism of PtdIns regulated 
by phosphoinositide phosphatases, such as PTEN which counteracts PI3K signalling by 
dephosphorylating PIP3. Importantly, PTEN is frequently deleted or mutated in cancers, 
resulting in constitutive PI3K hyperactivation (Maehama and Dixon 1998). Somatic 
tumours such as glioblastoma, prostate cancer, endometrial cancer, and ovarian cancer 
have shown to harbour PTEN mutations. Moreover, knockout mice lacking PTEN develop 
cancer, establishing PTEN as a tumour suppressor (Liu et al 1999, Vivanco and Sawyers 
2002, Wisniewski et al 1999). 
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 In summary, class I PI3Ks is the most extensively studied due to their defined role in the 
development of cancer, whereas class II and III proteins have not yet been shown to be 
linked with oncogenesis (Maiese et al 2008). 
 
1.4.1 AKT AS THE MAIN EFFECTOR 
When a growth stimuli is received by the cell through an extracellular receptor, it causes 
the activation and recruitment of the PI3K heterodimer, to the plasma membrane where it 
interacts with and phosphorylates its substrate PIP2, generating PIP3. PIP3 accumulation 
on the plasma membrane acts as a “docking site” for proteins that contain a pleckstrin 
homology (PH) domain, such as the cAMP-dependent cGMP-dependent and protein 
kinase C (AGC) family members, including the phosphoinositide–dependent kinase 1 
(PDK1), atypical protein kinases C (PKC), phospholipase C-γ (PLC-γ) and the 
serine/threonine kinase (AKT or PKB) (Cantley 2002, Toker and Newton 2000, Wymann 
and Pirola 1998). Activation of AKT is strongly associated with the proliferative and pro-
survival activities of PI3K. PIP3 accumulation on the plasma membrane leads to the 
recruitment of AKT to the plasma membrane. This results in a close proximity with PDK1, 
which then activates AKT by phosphorylation on threonine residue 308 (T308), within its 
catalytic site (activation loop), leading to its activation and release into the intracellular 
space to phosphorylate its downstream targets (Engelman 2009, Fu and Tindall 2008). 
Additionally, AKT is also phosphorylated on serine residue 473 (S473) within the C-
terminal hydrophobic motif (HM), by the mammalian target of rapamycin (mTOR) complex 
2 (Jacinto et al 2006). Upon phosphorylation on both sites – T308 and S473 – AKT was 
shown to have increased catalytic activity in vitro (Alessi et al 1996, Scheid et al 2002) 
highlighting the importance of both phosphorylation sites on its activity. Studies on the 
implication of differential phosphorylation on these sites have proposed that while the 
phosphorylation of T308 is essential for AKT activation, phosphorylation of S473 might 
determine substrate specificity significance. In mouse embryonic fibroblasts that lack 
mTORC2 component SIN1, AKT is phosphorylated on T308 rather than on S473. AKT 
activity is still detected although its levels are considerably lower but the effect of impaired 
phosphorylation on S473 affects a number of AKT downstream targets, most notably the 
forkhead transcription factors (Brunet et al 1999, Guertin et al 2006, Jacinto et al 2006). 
Once activated, AKT relocates to the nucleus where it recognises and phosphorylates 
serine and threonine residues within a consensus motif, which for many targets causes 
functional inhibition (Figure 2). Among these targets are proteins such as the FOXO 
forkhead transcription factors (Kops and Burgering 1999), BH3-containing protein BAD 
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(Datta et al 1997), the E3 ubiquitin ligase MDM2 (Mayo and Donner 2001) and many other 
of its targets.  
Three AKT isoforms or family members, termed AKT1 (PKBα), AKT2 (PKBβ) and AKT3 
(PKBγ) have been described in mammals (Toker and Yoeli-Lerner 2006, Vivanco and 
Sawyers 2002). These isoforms originate from different genes but share more than 80% 
homology on the protein level. In humans, AKT1 and AKT2 are expressed in all tissue and 
cell types, whereas AKT3 expression is restricted to the brain and testes. Knockout mice 
highlighted the different phenotypes that arise from the loss of each AKT isoform. Akt1-/- 
mice displays impaired growth as well as reduced bodyweight, Akt2-/- mice are 
hyperinsulemic and hyperglycaemic and Akt3-/- mice have defects in brain development. 
Yet, all knockout mice are viable suggesting the existence of compensatory mechanisms 
between the AKT isoforms (Franke 2008). 
 
1.4.2 THE ROLE OF PI3K/AKT PATHWAY IN CANCER  
PI3K/AKT signalling pathway is important in cancer development and response to therapy. 
Overexpression of RTKs, loss of function mutations within PTEN and activating mutations 
within PIK3CA (p110α) all lead to increased AKT activity which promotes tumour survival 
and cancer progression. PIK3CA mutations and amplification have been reported in a 
variety of cancers, including those of colorectal, breast, lung, ovarian and cervical (Ma et al 
2000, Samuels and Velculescu 2004, Shayesteh et al 1999). Furthermore, approximately 
30% of mutations in this gene have been found in ductal carcinomas in situ (DCIS) and 
invasive ductal breast carcinomas (IDC). PIK3CA mutations enhance p110α activity, 
highlighting its oncogenic potential and its ability to mediate PI3K-dependent proliferation 
and cancer progression. In addition, PIK3CA activation has been correlated with poor 
prognosis and radiation resistance in glioblastoma multiforme (Chakravarti et al 2004). 
Somatic mutations within AKT1 have been found in 8% of breast cancer patients. This 
mutation allows the binding of AKT to the extracellular membrane bypassing with PIP3 
accumulation, promoting the phosphorylation of AKT on S473 (Carpten et al 2007). 
Recently, AKT2 and HER2 dual overexpression in mammary epithelial has been shown to 
markedly increased pulmonary metastasis (Dillon et al 2009). Additionally, amplification of 
AKT2 is found in ovarian cancer and AKT3 in steroid insensitive breast cancers (Hennessy 
et al 2005). Somatic deletions or mutations in the negative AKT regulator, PTEN, are found 
in 12-60% of a variety of cancers and can result in permanent PI3K/AKT activation (Lian 
and Di Cristofano 2005).  
As a result of the constitutive activation of PI3K/AKT pathway, AKT can inhibit apoptotic 
signals by phosphorylating BAD, procaspase-9 and FOXO forkhead transcription factors. 
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On the other hand, AKT can induce anti-apoptotic activity by phosphorylating cAMP 
response element binding protein (CREB) and IkB kinase (Fresno Vara et al 2004). In 
addition, it can regulate localisation of substrates, such as with inhibition of GSK3, allowing 
β-catenin to translocate to the nucleus and induce expression of genes like cyclin D1, 
leading to pRB hyperphosphorylation. Similarly, it phosphorylates anti-proliferative 
regulators, such as p21Cip1 and p27Kip1 in the cytoplasm, disabling them from their cell 
cycle arrest functions. All of these events indicate a tumourigenic role of AKT and thus, 
drug inhibitors for the components of the PI3K/AKT pathway could be beneficial for cancer 
treatment. Several studies have shown that increased activity of the PI3K/AKT axis is 
associated with failure of gefitinib and trastuzumab, EGFR and HER-2-targeted therapies, 
respectively (Jones et al 2004, Lu et al 2001). Indeed, PI3K inhibitors have been shown to 
reverse the resistance to chemotherapeutic drugs in various cancers, including in cases of 
acute leukaemia (Neri et al 2002a). 
  
1.5 FORKHEAD TRANSCRIPTION FACTORS 
Forkhead box proteins are a large family of transcriptional regulators that are characterised 
by a winged-helix domain, through which they bind DNA. The conserved forkhead domain 
with nuclear localisation signals (NLS) is also referred as winged helix domain because of 
the 3-D structure of two loops (wings) at the C-terminal, three α-helices at the N-terminal 
and three β-sheets, forming a structure which is similar in appearance to the wings of a 
butterfly (Burgering 2008, Weigel et al 1989). The first member of this family was identified 
in Drosophila. The 110 amino-acid DNA binding domain (DBD) is evolutionary conserved 
and over 100 forkhead genes have been identified from yeast to human, but not in plants. 
At least 46 members have been identified in the human forkhead box (FOX) gene super-
family (Katoh 2004). Since their discovery, a unified nomenclature for the forkhead family 
members was revised in 2000 and proteins became known as FOXs, named after their 
‘forkhead box’. Forkhead proteins in chordates were divided into 15 classes or subfamilies 
and has since been expanded to 19, each subfamily termed A-S (FOXA-FOXS), based on 
their sequence similarity and structure, not their function (Kaestner et al 2000). Three 
clusters of FOX genes are found on human chromosomes: FOXD2-FOXE3 locus (1p33), 
FOXC1-FOXF2-FOXQ1 locus (6p25.3) and FOXC2-FOXF1-FOXL1 locus (16q24.1) 
(Katoh 2004). All forkhead transcription factors bind to DNA with the core consensus 
sequence RYMAAYA (R=A/G, Y=C/T, M=A/C) (Kaufmann et al 1995, Overdier et al 1994, 
Pierrou et al 1994) or TRTTTAY (YRKTTRT) in reverse complement (Costa et al 2001). 
This transcription factor family bind DNA as monomers except for FOXP, which requires 
dimerization (Li et al 2004b). This super-family is further grouped into two classes, based 
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on the presence or absence of a C-terminal region in the forkhead domain. The majority of 
FOX proteins belong to class I with a C-terminal basic region, whereas FOXH, FOXM, 
FOXN, FOXO and FOXP are in class II (Katoh 2004). 
Functionally, forkhead proteins are involved in a variety of biological processes, 
including cell cycle regulation (FOXM1, FOXO, FOXA1, FOXG1, FOXK1), cellular 
survival (FOXO), metabolism (FOXA, FOXC, FOXO), immunoregulation (FOXP3, 
FOXJI, FOXN1, FOXO, FOXD2, FOXP1) and embryonic development (all except 
FOXB, FOXG, FOXK, FOXO, FOXQ, FOXS). Therefore, deregulation of various FOX gene 
expression through gene amplification, retroviral integration, chromosomal translocation, or 
transcriptional regulation can lead to congenital disorders or carcinogenesis (Lehmann et 
al 2003, Wijchers et al 2006). 
 
 
 
 
 
Figure 2. Schematic representation of FOXO3a, FOXP1 and FOXM1. 
Depicted is a representation of the structure of FOXO3a, FOXP1 and FOXM1. As shown in the 
figure, the location of the forkhead DNA-binding domain (DBD) can vary amongst FOX proteins. 
Also represented are the nuclear localisation sequence (NLS) and nuclear export sequence (NES) 
that mediate nuclear import and export of FOXO3a, respectively. FOXP1 contains a repressor 
domain and a leucine-zipper-like motif (LZ), crucial for dimerisation; FOXM1 also contains an N-
terminal repressor domain as well as a transactivation domain (TAD). 
 
1.5.1 FORKHEAD SUBFAMILY (M) - FOXM1 
FOXM1, also known as HNF-3, HFH-11 or Trident, is another member of the Forkhead 
box superfamily of transcription factors. There are three splice variants of the human 
FOXM1 protein: A, B and C. Both FOXM1B and FOXM1C are the transcriptionally active 
variants (Laoukili et al 2007) whereas FOXM1A is transcriptionally inactive due to 
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disruption of the transactivation domain, while retaining a functional DNA binding domain 
(Figure 2), which might have dominant-negative effects (Ye et al 2007). 
FOXM1 is ubiquitously expressed in all embryonic tissues, especially in proliferating cells 
of epithelial and mesenchymal origin, while in adults its expression is only observed in 
actively proliferating tissues, including the thymus and testes (Korver et al 1997, Yao et al 
1997). Foxm1-/- mice die in-utero, due to failure to enter mitosis. FOXM1 expression is 
restricted to cells progressing through the cell cycle being almost undetectable in 
quiescent cells. Its expression is crucial for the G1/S and G2/M cell cycle phase 
progression, increasing through S phase into G2 and mitosis. Therefore, FOXM1 is a 
critical regulator of cell cycle progression through the transcriptional activation of the pro-
proliferation genes, such as cyclin B, polo-like kinase-1 (PLK1) and cell division cycle 
protein 25b (CDC25b), and repression of cyclin-dependent kinase inhibitors (CDKIs), 
p21Cip1 and p27Kip1, inhibiting their activity and promoting their cellular degradation (Costa 
2005, Kim et al 2006, Major et al 2004, Wang et al 2002). FOXM1 transcriptional activity is 
controlled by its phosphorylation status: FOXM1 phosphorylation increases as cells 
progress from G1/S to G2/M phases and dephosphorylation of FOXM1 coincides with exit 
from mitosis (Fu et al 2008). FOXM1 phosphorylation is controlled mainly by the 
Raf/MEK/ERK signalling cascade (Ma et al 2005) and the CDK2-Cyclin E complex (Major 
et al 2004). Additionally, pRB phosphorylation by Cyclin D1-CDK4 may be a necessary 
step to contribute to the relieve of FOXM1 repression by disrupting their direct interaction, 
and increased expression of cyclin D1, often observed in breast cancer may further drive 
the phosphorylation of FOXM1 (Wierstra and Alves 2006b).  
The role of FOXM1 in tumorigenesis has also been documented. FOXM1 overexpression 
has been identified in many different cancer types, including those of the brain, breast, 
lung, liver and prostate and has been shown to promote tumourigenesis (Myatt and Lam 
2007), by driving the cell cycle and proliferation through the regulation of its downstream 
targets. FOXM1 can also activate genes involved in angiogenesis and metastasis, such as 
VEGF and matrix metalloproteinases (MMP), MMP2 and MMP-9 (Wang et al 2007). 
Furthermore, FOXM1 amplification is also seen in breast cancer suggesting that FOXM1 is 
an oncogene (Spirin et al 1996). 
 
1.5.2 FORKHEAD SUBFAMILY (P) - FOXP 
In 1993, Li and Tucker identified and cloned the first FoxP1 cDNA and named it QRF-1 
(glutamine rich factor 1/ B-cell derived DNA binding protein). At the same time mouse 
homologues Foxp1, Foxp2 and Foxp4 were identified from a screen for new forkhead 
family members in mouse lung (Banham et al 2001, Lu et al 2002b, Shu 2001). Human 
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FOXP3 was later isolated from a patient with IPEX (immuno-dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome) (Chatila et al 2000) and shown to 
cause the disease scurfy in mice (Brunkow et al 2001, Schubert et al 2001, Wildin et al 
2001). FOXP3 shares only 22% identity with FOXP1, while FOXP2 and FOXP4 share 
more than 50% identity with FOXP1 (Ensemble data). This subfamily binds DNA as homo- 
or heterodimers with other FOXP subfamily members, unlike other FOX proteins that bind 
as monomers. FOXP subfamily members contain a highly conserved C-terminal forkhead 
DNA binding domain. Uniquely, this subfamily contains an N-terminal zinc finger and a 
leucine zipper essential for DNA binding and transcriptional activity, respectively (Figure 2) 
(Li et al 2007b, Li et al 2004b, Shu 2001). FoxP forkhead domains are the most divergent 
amongst all family members; however, there is an 84 amino acid region homology within 
the DNA-binding domain (Brunkow et al 2001, Chatila et al 2000, Li and Tucker 1993, Shu 
2001). All of the FOXP proteins have been proposed to act as transcriptional repressors. 
For example, Foxp1 and Foxp2 were shown to act as transcriptional repressors in the lung 
by repressing the mouse CC10 promoter and the human SP-C promoter (Shu 2001). 
Moreover, characterisation of the N-terminal region of Foxp1, Foxp2 and Foxp4 found the 
presence of a domain favouring the interactions with corepressor molecules, such as 
CtBP-1 (Li et al 2004b). In addition, ectopic Foxp3 expression in primary murine T cells 
has been showed to repress IL-2 expression (Hori et al 2003) and in Jurkat cells FOXP3 
expression, resulted in a reduction in IL-2 production following cross-linking of cell-surface 
CD3 (Schubert et al 2001). The importance of this subfamily of transcription factors in 
development and disease is better elucidated in knock-out mice models. Foxp2 knockout 
causes severe motor impairment and premature death in mice (Shu et al 2005), while 
Foxp4 homozygous null mice die at E12.5 (Li et al 2004c). The well-studied Foxp3–/– mice 
phenotype succumbs to a lethal autoimmune syndrome which results from a CD4+CD25+ 
regulatory T cell deficiency (Fontenot et al 2003). Finally, Foxp1-null mice exhibit severe 
defects in the cardiac valve morphogenesis, which lead to embryonic death at E14.5 
(Wang et al 2004), resulting in abnormal B-cell development and differentiation (Hu et al 
2006) and impacts, in cooperation with Foxp2, in dramatic morphological defects in the 
lung (Shu et al 2007). Furthermore, the coordinated actions of Foxp1 and Hox proteins are 
determinant for motor neuron diversity (Dasen et al 2008). Together these studies reveal 
the significant contribution of Foxp1 for the heart, B-cell, lung and neuron development. 
Importantly, spontaneous mutations in mouse and human diseases affect all the FoxP 
subfamily members. FOXP1 expression is deregulated in a variety of tumours. It is 
enhanced in mucosa-associated lymphoid tissue (MALT) lymphoma through several 
recurrent chromosomal translocations (Streubel et al 2005) or amplifications (Lenz et al 
2008). However, its expression is downregulated or cytoplasmic localised in other solid 
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tumours such as breast tumours, lung carcinomas, head and neck squamous cell 
carcinomas and early endometrial adenocarcinomas (Banham et al 2001, Banham et al 
2005, Giatromanolaki et al 2006). Furthermore, FOXP1 maps to a region in 3q14.1 that is 
associated with loss of heterozygosity (LOH) in various tumour types (Banham et al 2001).  
FOXP2 expression is diffused in organs such as the brain, lung, heart and gut. Its 
importance in development has been shown in the lungs by inhibition of genes related to 
the differentiation of pulmonary epithelial cells (Shu 2001). Furthermore, various studies 
have demonstrated that FOXP2 is an active and vital factor at several stages of brain 
development, from embryo to adult in rats (Takahashi et al 2003) and mice and in human 
embryos (Ferland et al 2003, Lai et al 2003). A single arginine-to-histidine missense 
mutation (R553H) in the FOXP2 forkhead domain has been linked to abnormal 
development of neural structures that are important for speech and language (Enard et al 
2002, Lai et al 2001).  
The seemingly less pleiotropic gene of this group, FOXP3, has been extensively studied in 
the past and present due to its impact in immune responses in autoimmunity by controlling 
Treg development and functionality (Fontenot et al 2003, Hori et al 2003). However, 
FOXP3 expression is also found in epithelial cells from organs such as breast, thymus, 
prostate and lung (Chang et al 2005, Chen et al 2008). Frameshift mutations in Foxp3 
result in the production of a functionally inactive, truncated protein product that lacks the 
forkhead DNA binding domain. These mutations were identified to cause the X-linked 
phenotype of the scurfy mouse, suggesting that FOXP3 is essential for normal immune 
homeostasis (Brunkow et al 2001). Similarly, mutations in FOXP3 human ortholog gene 
result in the fatal, recessive disorder which is characterised by immune dysfunction, 
polyendocrinopathy, enteropathy and X-linked inheritance (IPEX) (Bennett et al 2001). 
Another study identified a 3-base-pair deletion in the leucine-zipper dimerisation domain, 
which might allow FOXP3 to homo- or heterodimerise and therefore its mutation could 
result in aberrant function (Chatila et al 2000). In addition, a germline mutation of Foxp3 
resulted in a high rate of spontaneous breast cancer and increased susceptibility to 
carcinogens in the mouse. Moreover, in human breast cancer samples widespread 
deletion and somatic mutations of FOXP3 have also been observed (Zuo et al 2007b). 
Furthermore, in prostate cancer chromosomal deletions, somatic mutations and epigenetic 
silencing of FOXP3 gene has also been observed (Wang et al 2009). Recent studies have 
characterised the role of FOXP3 role as a tumour suppressor gene in human cancers 
through identification of some of its targets. FOXP3 has been shown to repress gene 
expression through the forkhead DNA-binding element in the ErbB2 (Zuo et al 2007b) and 
Skp2 promoters (Zuo et al 2007a). Furthermore, in a HER2/ERBB2 negative breast 
carcinoma cell line (MCF-7), FOXP3 has also been shown to suppress growth and induce 
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cell death (Zuo et al 2007a). However, FOXP3 does not always act by repressing 
expression of target genes. FOXP3 has been shown to mediate p21Cip1 gene induction by 
disrupting HDAC2 and HDAC4 binding in a specific site in p21Cip1 locus (Liu et al 2009). 
Foxp4 was initially implicated in carcinogenesis where it was shown to be reduced in both 
kidney and larynx carcinomas (Teufel et al 2003). FOXP4 is expressed in different 
embryonic and adult tissues including, lung, intestine, heart, liver, kidney, testis and brain 
(Lu et al 2002b, Takahashi et al 2008, Teufel et al 2003). Various studies have suggested 
that Foxp4 may have an evolutionarily conserved role in early brain development and 
patterning amongst different species (Schon et al 2006, Takahashi et al 2008). FOXP4 is 
beginning to be the subject of studies in human cancers. Sjoblom et al identified a single 
FOXP4 somatic mutation in breast carcinomas in a highly conserved motif in vertebrates 
(Sjoblom et al 2006). In addition, a study aiming to identify genetic factors that contribute to 
prostate cancer risk in the Japanese population, mapped FOXP4 to a prostate cancer 
susceptibility region (Takata et al 2010). 
 
1.5.3 FORKHEAD SUBFAMILY (O) - FOXO 
Mammalian FOXO proteins are orthologues of the transcription factor abnormal Dauer 
Formation 16 (DAF-16) identified in the nematode Caenorhabditis elegans (C. elegans), 
which was found to be an integral component of metabolic insulin signalling and longevity 
(van der Horst and Burgering 2007). In mammals FOXO transcription factors consists of 
four members: FOXO1, FOXO3, FOXO4 and FOXO6. Their structure contains four 
domains: the highly conserved DNA binding domain (DBD) that defines all forkhead 
proteins, a nuclear localisation signal (NLS) downstream of the DBD, a nuclear export 
sequence (NES) and a C-terminal transactivation domain (Figure 2). These FOXO 
isoforms share sequence homology within the DBD. The human FOXO1, FOXO3 and 
FOXO4 genes were first identified as sites of chromosome breakpoints in cancers. 
Chromosomal translocations disrupting the human FOXO gene have been associated with 
leukaemia and alveolar rhadomyosarcoma (Anderson et al 1998, Borkhardt et al 1997, 
Galili et al 1993, Hillion et al 1997). Notably, only FOXOs have been identified in fusion 
oncoproteins, probably due to their 90-130Kb large introns that exist within the genes and 
can act as common targets of breakpoints (Anderson et al 1998). Such evidence points to 
a role of FOXO factors in tumour development and the transforming activity of the forkhead 
transactivation domain (So and Cleary 2002, So and Cleary 2003). 
FOXOs are ubiquitously expressed but with varying expression levels. Of all, FOXO3 (or 
FOXO3a) has the broadest expression pattern in embryo and adult tissues (Furuyama et 
al 2000, Greer and Brunet 2005) and FOXO4 is more tissue specific (Biggs et al 2001). 
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Highest expression levels for FOXO1, FOXO3, and FOXO4 are also found in adipose 
tissue, brain and heart, respectively. On the other hand, FOXO6 mRNA is found mostly in 
the developing brain (Jacobs et al 2003). The three FOXO genes found in brain, FOXO1, -
3a and -6, have different expression patterns suggesting that FOXO isoforms share 
overlapping as well as distinct roles. Deletion of specific FOXO genes in mice has revealed 
both redundant and non-redundant effects for FOXO proteins.  
Foxo1 null embryos are embryonic lethal due to defective angiogenesis (Furuyama et al 
2004), whereas Foxo3a and Foxo4 null mice are viable and normal. Foxo3a-/- females 
have premature ovarian failure, a common cause of infertility and aging in women and 
suggest that Foxo3 normally helps to maintain a resting follicle pool (Castrillon et al 2003). 
Foxo3a deletion also leads to spontaneous lymphoproliferation and organ inflammation. 
Foxo3a-/- mice also produce hyperactivated helper T cells with increased rates of 
proliferation and cytokine production (Lin et al 2004). Unlike Foxo1- and Foxo3a-, Foxo4-
deficient mice do not exhibit any abnormalities (Hosaka et al 2004). Foxo6 null mice are 
not yet generated. Although the gene knock-out studies revealed functional differences 
between the three FOXOs, the possibility of functional redundancy still remains. The 
generation of the inducible triple knock-out (Foxo1/3/4-/-) mouse model highlighted this. 
Following conditional deletion of the three Foxo genes, mice developed lymphoblastic 
thymic lymphomas and haemangiomas yet, the disruption of only two Foxo genes 
originated mild haemangiomas and no lymphomas. These results indicate that FOXOs are 
functional redundant tumour suppressors (Paik et al 2007).  
 
1.5.4 FOXO TARGETS AND FUNCTIONS 
As transcription factors, FOXO proteins elicit their effect on the cellular phenotype by 
activating the transcription of their target genes. FOXO proteins bind to a promoter with the 
consensus sequence (termed DBE for DNA binding element), 5’-TT(G/A)TTTAC-3’ 
(Furuyama et al 2000). A large number of gene promoters contain the DBE (Xuan and 
Zhang, 2005) which can explain their diversity in function. Once bound to DNA, the FOXO 
transactivation domain initiates gene transcription either as transcriptional activators or 
repressors, probably depending on the range of associated co-factors that they recruit. 
Since FOXO proteins regulate a plethora of targets with distinct physiological activities only 
some of them will be mentioned. 
One of the functions that initially was attributed to FOXO activation was the regulation of 
cell cycle. The cell cycle is regulated by the coordinated action of multiple cyclin/cyclin 
dependent kinases (CDK), which phosphorylate and regulate a variety of substrates that 
are indispensable for cell cycle progression. p27Kip1 and p21Cip1 are members of Cip/Kip 
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family of CDK inhibitors that bind to both cyclin and CDK subunits inhibiting the activities of 
cyclin D-, E-, and A-CDK complexes (Besson et al 2008). 
Firstly, FOXO blocks G1 progression by repressing cyclin D1 and D2 either directly 
(Ramaswamy et al 2002) or indirectly through Bcl6/STAT5 (Fernandez de Mattos et al 
2004, Schmidt et al 2002). FOXO also promotes cell cycle arrest at the G1/S boundary 
phase by upregulating the cyclin dependent kinase inhibitors p27Kip1 (Medema et al 2000) 
and p21Cip1 (Seoane et al 2004). The overexpression of FOXO3a and FOXO4 were shown 
to induce the expression of p27Kip1, disrupting the cyclin D/CDK4 and Cyclin E/CDK2 
complexes causing a cell cycle arrest at the G1 cellular checkpoint (Medema et al 2000). 
Moreover, the pro-oncogene c-myelocytomaosis (c-MYC) was shown to repress FOXO3a 
activity leading to loss of p27Kip1 expression, an event which is observed in B-cell 
lymphomagenesis (Dansen and Burgering 2008). The regulation of p27Kip1 by FOXO3a 
was also shown to be important in the induction of apoptosis in both B and T cells through 
loss of Interleukin 3 (IL-3) and Interleukin 2 (IL-2) mediated survival, respectively (Dijkers 
et al 2000b, Stahl et al 2002). Additionally, FOXO promotes mitotic entry but not exit by 
upregulating PLK and cyclin B (Alvarez et al 2001). FOXO can also cause an arrest in cells 
at the G2/M checkpoint by induction of growth-arrest and DNA-damage inducible protein α 
of 45 kDa (GADD45α), which interferes with the G2/M transition by inducing the 
dissociation of cyclin B/CDK1 and by inhibiting CDK1 activity (Tran et al 2002, Wang et al 
1999). Thus, the two checkpoints important for stress response can be both mediated by 
FOXO factors. Moreover, FOXO prevents the re-entry into the cell cycle by 
transcriptionally upregulating cyclin G2 (CCNG2) (Martinez-Gac et al 2004) and activation 
of pRB related pocket protein p130 (Kops et al 2002b). p130 associates in a complex with 
E2F transcription factor 4/5 (E2F4/5) and leads to the exit of cell cycle to a reversible 
quiescence state.  
Programmed cell death, also known as apoptosis, is induced either by intrinsic or extrinsic 
pathways. In the extrinsic pathway activation of death receptor triggers the formation of a 
death inducing signalling complex and consequently leads to the activation of caspases 
(Guicciardi and Gores 2009). In contrast, intracellular stress can induce apoptosis by 
activating the pro-apoptotic protein Bcl-2, which mediate the release of cytochrome c from 
the mitochondrial membrane leading to caspase-9 activation and subsequently 
downstream effector caspases, which will execute the apoptotic programme (Brunelle and 
Letai 2009). FOXO has been reported to target both death receptor and mitochondrial 
pathways. The activating ligand, tumour necrosis factor (TNF) cytokine family member, 
FasL (Fas ligand) was one of the first identified targets of the AKT/FOXO signalling 
pathway (Brunet et al 1999). Ectopic expression of a constitutively active FOXO3a mutant 
was found to increase FasL promoter activity in luciferase assays. Furthermore, cells 
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deficient in components of the FasL signalling cascade failed to undergo apoptosis 
following expression of FOXO3a, suggesting that the Fas-mediated axis is required for 
induction of apoptosis by FOXO3a in Jurkat cells (Brunet et al 1999). Overexpression of 
FOXO1 and FOXO3a also induced apoptosis through upregulation of tumour necrosis 
factor-related apoptosis inducing ligand (TRAIL). Promoter reported assays further 
demonstrated that TRAIL is a direct transcriptional target of FOXOs (Modur et al 2002). In 
addition, FOXO1 was shown to bind and directly regulate the tumour necrosis factor 
receptor-associated death domain (TRADD) (Rokudai et al 2002). While most reports 
show that activation of FOXO proteins induces apoptosis, one particular study by Jonsson 
et al. suggested that FOXO may also contribute to increase survival of neutrophils through 
transcriptional repression of FasL promoter (Jonsson et al 2005). Apparently, FOXO 
activates different genes differently in distinct cell types and environment depending on 
appropriate cofactors. Nevertheless, the presence of multiple FOXO targets in both cell 
cycle arrest and apoptosis pathways ensure an efficient result even when target genes are 
expressed differentially through combinatory effects. 
Cytokine deprivation of bone marrow-derived Ba/F3 cells results in the activation of 
FOXO3a and cytochrome c release, DNA laddering and induction of apoptosis, through 
the induction of the pro-apoptotic Bcl-2 family member Bim, whereas overexpression of 
Bcl-2 can rescue cells from FOXO3a-induced apoptosis (Dijkers et al 2000a). The 
regulation of Bim expression by FOXO3a was also shown to play an important role in 
survival of activated T cells (Stahl et al 2002). Further studies into the regulation of Bim by 
FOXO3a have shown that it is possible for the pro-apoptotic function of FOXO proteins to 
be exploited therapeutically. Treatment of chronic myelogenous leukemia (CML) cell lines, 
driven by the BCR-ABL chimeric oncogene (Chen et al 2010b) and cell lines 
overexpressing BCR-ABL, with the BCR-ABL inhibitor STI571 leads to the activation of 
FOXO3a and increased FOXO3a-dependent Bim expression, resulting in the induction of 
apoptosis. Moreover, the induction of Bim expression by STI571 treatment was lost when 
the cellular pool of FOXO3a was abrogated using siRNA. Furthermore, Bim silencing also 
abrogated the induction of apoptosis in STI571 treated cells (Essafi et al 2005). 
Subsequent studies in MCF-7 breast cancer cell lines have shown that FOXO3a also 
drives the expression of Bim in response to the chemotherapeutic agent paclitaxel, 
inducing apoptosis (Sunters et al 2003). However, Bim fails to be upregulated by active 
FOXO mutants in growth arrest cells (Burgering and Medema 2003) and its expression is 
not induced in the PTEN-deficient cells, such as LNCaP prostate cells, when transduced 
with a FOXO1-encoding adenovirus (Ramaswamy et al 2002). Nevertheless, a more 
recent report showed that FOXO3a also upregulates another Bcl-2 family member Puma 
following IL-2 withdrawal. Bim-/- and Puma-/- mouse derived T cells have been shown to be 
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resistant to apoptosis after IL-2 deprivation, demonstrating that regulation of both Bim and 
Puma by FOXO3a is critical for apoptosis in the absence of cytokines (You et al 2006a).  
FOXO proteins have also been found to be key sensors of oxidative stress through the 
regulation of genes involved with detoxification and DNA repair. Reactive oxygen species 
(ROS), which include oxygen free radicals, nitric oxide and hydrogen peroxide are 
produced as by-products from exogenous sources such as, ultraviolet (UV) and ionising 
radiation (Essers et al 2004), in addition to a result of metabolic processes that take place 
within the mitochondria. ROS has been shown to be important in some cell signalling 
pathways and cell cycle progression, but excessive ROS accumulation can be detrimental 
to the cell and can lead to the induction of cell cycle arrest and apoptosis. When these 
cellular processes are perturbed, disproportionate ROS accumulation can damage 
proteins, lipids and DNA leading to cellular transformation and cancer (Benhar et al 2002).  
Initial protection against oxidative stress involves FOXO mediated upregulation of 
antioxidant enzymes manganese superoxide dismutase (MnSOD). Activation of FOXO3a 
has been shown to increase the expression of MnSOD through direct binding to its 
promoter in a colon carcinoma cell line (Kops et al 2002a). In addition to MnSOD, 
increased catalase expression by FOXO3a has been found to decrease oxidative stress 
resulting in increased survival (Nemoto and Finkel 2002). The analysis of the 
haematopoietic cells in the bone marrow of Foxo1/3/4-/- mice reveals reduced numbers of 
haematopoietic stem cells (HSCs), while the number of myeloid progenitors in peripheral 
blood was increased, suggesting that FOXOs are crucial for maintaining HSCs in a 
quiescent state. In HSCs from Foxo1/3/4-/- mice, the levels of ROS and apoptosis were 
also increased. Treatment of mice with the antioxidant N-acetyl-cysteine was sufficient to 
rescue the Foxo1/3/4-/- HSCs phenotype, demonstrating that FOXO-mediated resistance to 
oxidative stress is critical for homeostasis of the HSC compartment in vivo (Tothova et al 
2007). FOXOs can also protect cells from DNA damage by increasing the rates of DNA 
repair. The G2/M checkpoint is activated following DNA damage, which pauses the cell 
cycle and allows the cell time to repair the damage before continuing to divide. Gadd45α 
acts as a sensor to cellular stress and is known to promote the activation of the G2/M 
cellular checkpoint, allowing time for DNA repair mechanisms to be initiated. Activation of 
FOXO3a increased Gadd45α at both mRNA and protein levels and restored expression of 
an UV-damaged luciferase construct, suggesting that FOXO3a upregulates DNA damage 
repair mechanisms. Moreover, the FOXO3a-induced DNA damage repair response was 
compromised in Gadd45α-/- cells, arguing that Gadd45α expression is indispensable for 
FOXO3a-mediated DNA repair (Tran et al 2002). A subsequent study reiterated the 
importance of FOXO3a in regulating Gadd45α expression and showed that FOXO4 could 
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also promote Gadd45α expression and initiate DNA repair mechanisms (Furukawa-Hibi et 
al 2002). 
Through regulation of multiple transcriptional targets, FOXO proteins modulate various 
cellular functions, including proliferation, apoptosis and stress resistance. As a result, their 
loss of function is implicated in predisposition to cancer (Accili and Arden 2004, Hillion et al 
1997, Parry et al 1994) and oxidative stress related diseases, such as neurodegenerative 
diseases (Morris 2005). 
1.5.5 REGULATION OF FOXO TRANSCRIPTION FACTORS 
To achieve successful regulation of this repertoire of target genes, the activity of FOXO 
transcription factors is regulated by a range of post-translational processes including 
phosphorylation, ubiquitination, acetylation and methylation, which allows the activation of 
specific subsets of genes that influence cell fate (Calnan and Brunet 2008). These can be 
induced by growth factors, hormones, metals and chemicals, and are important for cell 
cycle control, development, differentiation and adaptation to environment. Of all 
modifications, AKT-mediated phosphorylation, which induces cytoplasmic translocation, is 
the most studied. The PI3K/AKT/FOXO signalling axis is evolutionary conserved and in C. 
elegans. The activation of an orthologue of the insulin receptor, DAF-2, results in activation 
of the PI3K orthologue, AGE-1, which in turn induces activation of the orthologue of AKT 
(Dorman et al 1995, Kimura et al 1997). The DAF-2 pathway negatively regulates the 
induction of a stress-resistant stage known as dauer formation. This larval stage (dauer) in 
which the worms lower their metabolism and can survive longer is dependent on the 
FOXO transcription factor DAF-16 as the long-lived phenotype is reverted in daf-16 
deficient organisms (Lin et al 1997). This pathway is homologous to the mammalian 
PI3K/AKT pathway (Larsen et al 1995). Upon growth factor activation, AKT is recruited to 
the plasma membrane but also translocates to the nucleus where it phosphorylates its 
nuclear targets (Burgering and Medema 2003, Meier et al 1997). All FOXO family 
members, except for FOXO6, contain multiple AKT consensus sequences for 
phosphorylation by AKT and these sites are conserved throughout evolution, from C. 
elegans to mammals. Three AKT phosphorylation motifs are found in FOXO1, FOXO3a 
and FOXO4 at residues designated 1, 2 and 3 (Figure 3) (Furukawa-Hibi et al 2002, Kops 
and Burgering 1999, Lin et al 1997) which are equivalent to T32, S253, S315 of FOXO3a 
(Takaishi et al 1999). FOXO6 however does not have the third motif and is constitutively 
localised in the nucleus (Jacobs et al 2003, van der Heide et al 2005). 
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Figure 3. Schematic representation of AKT phosphorylation sites in FOXO. 
Representation of the AKT phosphorylation sites in FOXO1, FOXO3a and FOXO4 and their 
respective amino acid locations. T and S refer to threonine and serine residues, respectively. 
 
 
The phosphorylation of FOXO3a at T32 and S253 results in an interaction with the 
chaperone protein 14-3-3, which provides a NES (Lopez-Girona et al 1999) and blocks 
nuclear import through interfering with the NLS in the forkhead domain (Rena et al 1999), 
thereby shifting the localisation of FOXOs from the nucleus into the cytoplasm, inhibiting 
FOXO3a activity (Greer and Brunet 2005). The nuclear export of the FOXO:14-3-3 
complex is facilitated by chromosomal region maintenance 1 (CRM1) and Ran GTPase 
(Burgering and Kops 2002). In the absence of growth factor signalling, AKT and other AGC 
family members are unable to phosphorylate FOXO3a and the rate of import of 
unphosphorylated FOXO3a exceeds that of export, resulting in a predominantly nuclear 
localisation (Figure 4) (Brownawell et al 2001). Similar to FOXO, FOXA2 is the only other 
forkhead transcription factor that is also regulated by the AKT-mediated translocation 
control (Wolfrum et al 2003). 
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Figure 4. Regulation of FOXO subcellular localisation by AKT. 
A) In the presence of stimulatory signals, the activated AKT phosphorylates and inhibits FOXO. 
This results in nuclear export into the cytoplasm, by association with 14-3-3 protein. B) In 
unstimulated cells, FOXO transcription factors are active in the nucleus and can modulate the 
expression of genes regulating diverse processes, including proliferation, apoptosis and response 
to cellular stress. 
  
52 
 
Other kinases have also been identified to promote the cytoplasmic redistribution of FOXO 
factors and they include serum and glucocorticoid kinase (SGK) (Brunet et al 2001), casein 
kinase 1 (CK1) (Rena et al 2002), dual specificity tyrosine-phosphorylated and regulated 
kinase 1a (DYRK1) (Woods et al 2001) and IKK (Hu et al 2004). Similar to AKT, SGK is 
also activated by PI3K, translocates to the nucleus (Buse et al 1999) and phosphorylates 
FOXO3a on the same residues as AKT. CK1 phosphorylates FOXO1 at S322 and S325 
only after S319 phosphorylation by AKT/SGK; DYRK1 phosphorylates FOXO1 at S329 
independent of AKT. IKKβ has also been shown to phosphorylate FOXO3a on S644 
leading to its nuclear exclusion and promoting its degradation by the proteasome. This 
regulation was independent of AKT, suggesting that multiple mechanisms, such as 
increased IKK signalling, are increased to inhibit the tumour suppressor function of FOXO 
family members (Arden 2004, Hu et al 2004). Not all the phosphorylation events that target 
FOXO represent negative regulation and cytoplasmic retention. In response to oxidative 
stress, FOXO is phosphorylated at serine or threonine residues not targeted by AKT and 
yet this results in nuclear accumulation of FOXO. In fact, oxidative stress has been shown 
to trigger phosphorylation of FOXO4 by the stress kinase JNK. This phosphorylation 
results in nuclear translocation of FOXO4 and increases its activity; however, this 
phosphorylation is not conserved in FOXO1, FOXO3a or FOXO6 (De Ruiter et al 2001, 
Essers et al 2004). One possible explanation is the quenching of 14-3-3 by JNK prevents 
the association of 14-3-3 with FOXO (Tsuruta et al 2004). Although oxidative stress stimuli 
can activate FOXO, they do not always confer stress resistance. The upstream activator of 
MAPK pathway, MST1 phosphorylates FOXO on a conserved site within the DBD, 
resulting in the disruption with 14-3-3 and promotion of nuclear translocation (Lehtinen et 
al 2006). Additionally, phosphorylation of FOXOs can induce their poly-ubiquitination and 
subsequently proteasomal degradation. The phosphorylation of FOXO1 by AKT results in 
nuclear exclusion but also promotes the interaction with the F-box protein SKP2, which 
induces both poly-ubiquitination and degradation of FOXO1 (Huang et al 2005). 
Another example involves the downstream effector of the RAS/MEK pathway, ERK, which 
phosphorylates FOXO3a on S294, S344 and S425 to promote its retention in the 
cytoplasm, where the interaction with MDM2 is increased. Poly-ubiquitination by MDM2 
results in the degradation of FOXO3a by the proteasomal pathway (Yang et al 2008). 
Finally, triggered by oxidative stress, FOXO4 has also been shown to become mono-
ubiquitinated resulting in nuclear translocation and increased transcriptional activity. The 
de-ubiquitinating enzyme herpes virus-associated ubiquitin-specific protease 
(USP7/HAUSP) was found to negatively regulate this process (van der Horst et al 2006). 
Indeed, HAUSP had previously been identified as a regulator of p53 ubiquitination, 
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competing with MDM2 and modulating its post-translational status, reiterating the 
similarities between FOXO and p53 regulation (Li et al 2002, Li et al 2004a). 
Acetylation is another post-translational FOXO regulatory control. Acetylation is required 
for FOXO functions, especially under oxidative stress and attenuates their transcriptional 
activity. FOXOs are acetylated by the acetyl transferases p300 and the cyclic-AMP 
responsive element binding (CREB)-binding protein, while SIRT1 mediates the 
deacetylation of FOXO proteins (Calnan and Brunet 2008). This post-translational 
modification is evolutionary conserved as in C. elegans, the orthologue Sir2 increases the 
lifespan of the worm in a daf-16-dependent manner, indicating that DAF-16 is positively 
regulated by acetylation (Tissenbaum and Guarente 2001). 
SIRT1 has been showed to bind FOXO1 at LXXLL motif at 459-463 amino acids, 
enhancing its function for gluconeogenesis, DNA repair, stress resistance and cell cycle 
arrest, but not apoptosis (Vogt et al 2005). Similarly, expression of SIRT1 increased 
FOXO3a-induced cell cycle arrest and resistance to oxidative stress but inhibited 
FOXO3a-induced cell death. Acetylation appears to influence the functional outcome of 
FOXO proteins by stimulating only a specific subset of FOXO target genes (Brunet et al 
2004).  
FOXO proteins can interact with other transcription factors contributing to the functional 
endpoint of FOXO activity. For example, β-catenin of Wnt signalling pathway, a 
proliferative signalling molecule, binds to FOXO and enhances oxidative stress response 
and is thus sequestered from its oncogenic effect with T-cell factor (TCF) (Essers et al 
2005); FOXO interaction with Smad (similar to mothers against decapentaplegic) is 
triggered in response to transforming growth factor β (TGFβ) activation. FOXO factors bind 
to the phosphorylated, nuclear localised Smad protein complexes and result in activation 
of p21Cip1. The p21Cip1 transactivation is inhibited when FOXG1 binds to the FOXO-Smad 
complexes in response to PI3K activation (Seoane et al 2004). There are a number of 
parallels between FOXO proteins and p53. Both proteins induce cell cycle arrest, 
apoptosis and DNA repair; they also share a considerable number of target genes, 
including p21Cip1, GADD45α and Puma; finally they are regulated by similar modifications 
such as phosphorylation and acetylation (Renault et al 2011). All these similarities suggest 
that both transcription factors may share the same regulatory complex. p53 and FOXO 
seem to inhibit each other. p53 can induce SGK to inhibit FOXO function (You et al 2004), 
while FOXO physically interacts with p53 and inhibits its function through suppression of 
the SIRT1 promoter (Nemoto et al 2004). Conversely, FOXO3a has been reported to lead 
to stabilisation of p53 and activate p53-dependent apoptosis (You et al 2006b). In 
summary, growth factor signalling induces phosphorylation and inactivation of FOXO, 
while stress stimuli phosphorylate and activate FOXO. Nevertheless, FOXO proteins are 
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activated in the presence of both growth factors and stress stimuli (Brunet et al 2004, 
Wang et al 2005), indicating that stress-induced signalling is predominant in the activation 
of FOXOs. Eventually, the decision on longevity and stress resistance is favoured over 
apoptosis if SIRT1 is present. 
 
1.5.6 FOXO AND CANCER 
Through regulation of distinct intracellular events, FOXO factors have been proposed to 
act as tumour suppressors. Loss of FOXO function can lead to tumour development due to 
increased proliferation, decreased DNA repair and thus increased genomic instability. In 
addition, its interactions with both tumour suppressors and oncogenes are evidence of 
their involvement in carcinogenesis. The results of interacting with Smad/p21Cip1, β-catenin 
and p53 eventually enhance FOXO functions in cell cycle arrest and stress resistance. 
Consistently, the PI3K/AKT pathway is frequently hyperactivated in cancer resulting in 
FOXO inactivation (Engelman 2009). Furthermore, FOXO reactivation either by ectopic 
expression or by inhibition of PI3K culminated in induction of apoptosis in a variety of 
cancers (Essafi et al 2005, Sunters et al 2003, Yamamura et al 2006). The analysis of the 
inducible Foxo1-/-, Foxo3-/- and Foxo4-/- mouse model demonstrated FOXO role as tumour 
suppressors (Paik et al 2007). 
The loss of FOXO3a mRNA and protein expression has been observed in lung 
adenocarcinoma (LAC) and non-small cell lung cancer (NSCLC). In 24.2% of LAC 
samples, FOXO3a expression was lost due to homozygous deletion and a further 60.6% 
displayed a significant loss of FOXO3a expression (Mikse et al 2010), further supporting 
that FOXO3 functions as a tumour suppressor.  
The suppression of FOXO3a activity through overactivation of upstream regulatory 
pathways has been implicated in breast cancer tumour progression; for example, in tumour 
cell lines harbouring PTEN mutations, FOXO1 and FOXO3a are retained in the cytoplasm 
resulting in their inhibition. However, reintroduction of functional PTEN or overexpression 
of FOXO family members results in a G1 cell cycle arrest and induction of apoptosis, 
highlighting the importance of PI3K hyperactivation in breast cancer and its suppression of 
FOXO proteins, promoting tumour progression and survival (Medema et al 2000, 
Nakamura et al 2000). 
Since the activity of FOXO proteins is regulated by signalling pathways that are upstream 
of the transcription factors and that these pathways are frequently hyperactivated in 
cancer, compounds that impair this hyperactivation are potent activators of FOXO proteins. 
Probably the best examples are the targeted therapies, including gefitinib, lapatinib and 
trastuzumab which target EGFR, EGFR and HER-2, and HER-2 respectively, resulting in 
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the inhibition of the PI3K/AKT axis and subsequently inhibiting tumour growth. In fact, we 
and others have shown that FOXO3a is indirectly activated in response to lapatinib and 
gefitinib treatment, and that this activation modulates the induction of apoptosis (Hegde et 
al 2007, Krol et al 2007, McGovern et al 2009). Because FOXO proteins are commonly the 
cellular targets of most the anti-cancer drugs, it is logical to assume that the 
PI3K/AKT/FOXO3a axis is also involved in mediating drug-resistance. Indeed, some 
studies support the positive correlation of drug efflux transporter activity and PI3K/AKT 
pathway. Moreover, FOXO3a has also been found to induce MDR1 expression (Hui et al 
2008a). Drug resistant cells exhibit increase PI3K/AKT and drug treatment induces AKT 
activity (Plo et al 1999). This increase in AKT activity is thought to be responsible for 
cisplatin (Asselin et al 2001) and paclitaxel resistance (Mabuchi et al 2002). ROS induces 
the insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation and activates p21Ras to 
interact with PI3K/p110, resulting in AKT activation (Rodriguez-Viciana et al 1996). Since 
most chemotherapeutic drugs induce activation of the PI3K/AKT pathway and 
subsequently lead to the inactivation of FOXO proteins, this axis appears to be an 
inevitable step target for cancer therapy. 
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1.6 OVERALL AIMS AND THESIS OUTLINE 
FOXO transcription factors have been implicated in a variety of cellular functions that are 
impaired in carcinogenesis. Furthermore, they have also been shown to mediate the effect 
of many chemotherapeutic drugs. Thus, FOXO activity is expected to have a role in 
chemotherapy sensitivity. However, when drug-resistance mechanisms develop, survival 
of cancer cells relates to hyperactivation of AKT and thus removal of FOXO tumour 
suppressive functions. My hypothesis is therefore that FOXO3a has a role in apoptosis 
and cell cycle arrest mediated by anti-cancer drugs as well as development of 
chemoresistance. However, despite the potential importance of FOXO proteins in 
tumorigenesis and drug resistance, their regulation, modes of action and functions are not 
clearly defined and understood. In this thesis, I explored the regulation, mechanisms of 
action and functions of FOXO proteins through studying the regulation of a number of 
putative FOXO target genes in breast cancer.  
Firstly, I explored the role of the PI3K/AKT/FOXO3a axis in drug response and drug-
resistance, in sensitive and resistant breast cancer cell lines and validated my in vitro 
results in tumour patient samples (Chapter 3). Among some of the newly identified 
transcriptional targets of FOXO were FOXP1 and VEGF. I confirmed and validated that 
these genes are indeed regulated by FOXO3a and may contribute to FOXO3a-mediated 
resistance in breast cancer cell lines, in Chapter 4 and Chapter 5, respectively.  
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 CELL CULTURE 
2.1.1 CELL LINES 
The human breast carcinoma cell lines MCF-7, SKBR3, T47D, MDA-MB-453, MDA-MB-
231, MDA-MB-468, BT474, BT549, CAL51, ZR751, ZR7530, HBL-100 and CAMA-1 were 
cultured in Dulbecco’s modified eagle medium (DMEM) (GIBCO-BRL UK). The medium 
was supplemented with 10% foetal calf serum (FCS) (First Link Ltd, Birmingham, UK), 
2mmol/L glutamine and 100U/mL penicillin/streptomycin (Sigma-Aldrich, Poole, UK). Cells 
were maintained at 37°C in a humidified incubator with an atmosphere of 10% CO2.  
MCF-10A cells were cultured in DMEM/Ham’s F-12 (1:1 mix; Sigma) supplemented with 
5% (v/v) horse serum, 10ng/mL insulin, 5mg/mL hydrocortisol, 100ng/mL cholorotoxin, 
20ng/mL epidermal growth factor, 100U/mL penicillin and 100μg/mL streptomycin (all 
supplements from Sigma, UK). 
The mouse embryonic fibroblasts (MEF) were derived from wildtype (WT) and Foxo1/3/4-/- 
knockout mice. Cells were cultured in DMEM and supplemented as described above for 
MCF-7 cells. 
The leukaemic naïve K562 and the resistant derivate KD30 cells were obtained from Dr 
Ernesto Yague (MRC Clinical Sciences Centre, London, UK) these cells were cultured in 
RPMI (Sigma) with 10% foetal bovine serum (First Link Ltd, Birmingham, UK) 
supplemented with 2mM L-glutamine, penicillin and streptomycin in 5% CO2. KD30 were 
generated by one-step exposure of K562 cells to 30nM doxorubicin for over 4 weeks 
(Yague et al 2003).  
 
The doxorubicin-resistant MCF-7-DoxR, the MCF-7-EpiR (also known as MCF-7-DoxR, 
cross-resistant to Epirubicin), and the MCF-7-CisR cells were derived from the parental 
MCF-7. MCF-7-DoxR, MCF-7-EpiR, and MCF-7-CisR were generated previously in the 
laboratory and were cultured as described above and supplemented with 0.01mg/ml 
doxorubicin and 1 µM/ml cisplatin, respectively. The lapatinib-resistant BT474 cells (BT474 
LapR) were derived from the parental BT474 cells and were generated (by myself) by 
continuous addition of 1µM/ml of lapatinib to the supplemented DMEM described above. 
The two estrogen-independent and endocrine-resistant cell lines, LCC2 and LCC9, were 
derived from MCF-7/LCC1 (Clarke et al 1994) by stepwise in vitro selection with prolonged 
tamoxifen (LCC2) and fulvestrant (ICI 182780) (LCC9) treatment as described (Brunner et 
al 1993, Brunner et al 1997). Following in vitro selection, they were maintained in modified 
IMEM-phenol red free with 5% charcoal-stripped FBS. R27 is another endocrine-resistant 
cell line derived from its parental MCF-7 with prolonged tamoxifen treatment in vitro. LCC2, 
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LCC9 and R27 breast cell lines were kindly provided by Dr. Robert Clarke (Georgetown 
University Medical School, Washington D.C.). 
The 4-hydroxytamoxifen (4-OHT) inducible cell lines were grown in phenol-red free DMEM 
medium (Invitrogen, Paisley, UK) supplemented with 10% double-charcoal stripped serum 
(Globepharm Ltd). 
Adherent cells were grown and split at approximately 80% confluency, twice a week. 
Media was aspirated and the cell monolayer was washed in warm PBS and then detached 
by the addition of 1x trypsin-EDTA. After 2 min at 37°C, the trypsin was inactivated by the 
addition of complete media. The cells were then counted by use of a haemocytometer and 
seeded in the appropriate media volume into plates. Cells were not cultured for more than 
40 passages. Suspension cells were directly diluted into new flasks. 
2.1.2 CELL LINE PRESERVATION  
Cells were detached from the monolayer with trypsin, as described above, washed in 
complete media and spun down at 1200rpm for 5 min. The cell pellet was then 
resuspended in FCS with 10% DMSO. 1ml aliquots were transferred to cryotubes and 
slowly frozen in a freezing container (VWR International) at -80°C overnight before storage 
in liquid nitrogen. Suspension cells were collected by centrifugation at 1200rpm for 5 min. 
The following steps are similar to those described above for adherent cells. When 
defrosting cells, the cryotubes were defrosted rapidly in a waterbath (~37°C) washed in 
complete media, then spun at 1200rpm for 3 min to remove any DMSO-containing media 
and the pellet was resuspended in 10ml of fresh supplemented medium in a 25cm2 flask. 
 
2.1.3 CHEMICALS 
Cisplatin (Onco-tain DBL, Leamington Spa) was maintained as a stock solution (3.3M) at 
room temperature (RT) and diluted in fresh media prior to treatment. Paclitaxel (Imperial 
College Healthcare, UK) was maintained as a stock solution (6mg/ml) at 4°C. Lapatinib 
(LC laboratories, USA) was dissolved in DMSO and stored at -20°C at a concentration of 
1mg/μl. Epirubicin (2mg/ml in 0.9% sodium chloride) and Doxorubicin (2mg/ml in 0.9% 
sodium chloride) were obtained from Imperial College Healthcare, UK and stored in 
solution at 4°C. Trichostatin A (TSA; Sigma, Poole, UK).  
 
2.1.4 GENERATION OF STABLE CELL LINES 
For the generation of stable cell lines, the optimal concentration of neomycin (G418, 
GIBCO) was determined with a killing curve for MCF-7 cells. The selected dose was the 
minimum that killed all cells by day 14, while the maintenance dose was the one that 
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inhibited cell proliferation. 12µg of the plasmid of interest or empty vector (control) were 
transfected into cells using Fugene 6 transfection reagent (Roche, UK). MCF-7 cells were 
then selected with neomycin 24 h after transfection for at least 2 weeks until cell 
proliferation was established. During this period, medium was changed every 2-3 days. 
 
2.2 PROTEIN ANALYSIS 
2.2.1 PREPARATION OF TOTAL PROTEIN LYSATES 
Whole cell protein extracts were prepared by initially harvesting cells and washing the cell 
pellet in PBS before centrifuging at 2000rpm for 5 min. The supernatant was discarded 
and pellets were frozen at -80°C until lysis was performed. Frozen pellets were lysed in 2 
volumes of NP40 lysis buffer [(1% (v/v) Nonidet P-40, 150mM NaCl2, 50mM Tris-HCl (pH 
7.6), 5mM EDTA, 1mM DTT, 1mM NaF, 2mM PMSF, 1mM sodium orthovanadate and 
“Complete” protease inhibitor cocktail, as instructed by the manufacturer (Roche 
Diagnostics, Burgess Hill, West Sussex, UK)] at 4oC for 20 min. Insoluble lysate material 
was removed by centrifugation at 13000rpm for 10 min at 4°C. The supernatant was 
transferred to a clean eppendorf tube and its protein concentration was determined. 
Protein concentration was determined using the Bio-Rad Dc protein assay (Bio-Rad 
Laboratories, CA, USA), as instructed by the manufacturer. Absorbance was read at 
750nm for each of the experimental samples as well as the non-protein containing control. 
Protein concentrations were determined by the equation absorbance x 25 = µg/µl.  
 
2.2.2 SODIUM DODECYL SULPHATE-POLYACRYLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGE) AND WESTERN BLOTTING 
To separate the proteins, 20µg of protein lysate was added to an equal volume of 2x 
sample buffer (200mM Tris-HCl pH 6.8, 6% sodium dodecyl sulfate (SDS), 2mM EDTA, 
10% 2-mercaptoethanol, 10% glycerol, 0.02% bromophenol blue) and incubated for 10 
min. Samples were then spun at 1000rpm for 1 min, loaded into the sacking wells and 
fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) for 2 h at 80V using a 
Mini-Protean III apparatus (Bio-Rad Laboratories, Hemel Hempstead, UK). The recipe for 
buffers and gels used in SDS-PAGE is illustrated in Appendix 2. Once the proteins had 
been separated by SDS-PAGE, they were transferred to 0.45μm Protran nitrocellulose 
membranes (Schleicher and Schuell, Whatman, Brentford, UK) using a wet tank blotting 
system (Bio-Rad Laboratories Trans-Blot Cell) in transfer buffer for 90 min at 90V at RT. 
Membranes were then blocked with 5% (w/v) bovine serum albumin (BSA) in Tris buffered 
solution with 0.05% Tween-20 (TBST, pH 7.5) for 30 min at RT and then incubated with 
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the primary antibody of choice (Appendix 1) in 5% BSA-TBST overnight at 4oC. 
Membranes were then washed 4 times, every 10 min with 50ml of TBST at RT, prior to 
incubation with either anti-mouse or anti-rabbit secondary antibody coupled to horseradish 
peroxidase (Dako, Ely, Cambridgeshire, UK) at 1:3000 dilution for 30 min at RT and 
visualised using the ECL detection system (GE Healthcare, UK). The list of primary 
antibodies used is included in Appendix 1. Antibodies against Tubulin or Actin were used 
as a loading control. 
 
2.2.3 SUBCELLULAR FRACTIONATION 
The subcellular fractionation assay was done by using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Perbio, Belgium). Cells were pelleted and resuspended in 200μl ice-
cold CER I solution with protease inhibitors and vortexed vigorously on the highest setting 
for 15 sec. After incubation on ice for 10min, 11μl ice-cold CER II solution was added to 
the tube. The tube was then vortexed for 5 sec and incubated on ice for 1 min. This 
mixture was further vortexed for 5 sec on the highest setting and then centrifuged at 
maximum speed on a desktop centrifuge for 5 min at 4°C. The supernatant containing the 
cytoplasmic extract was transferred to a clean pre-chilled tube and the insoluble fraction 
was further mixed with 100μl ice-cold NER solution with protease inhibitors. The tube was 
vortexed for 15 sec on the highest setting and incubated on ice for 10 min. The same 
procedure was repeated for a total of 40 min. Finally, the tube was centrifuged at 
maximum speed for 10 min and the supernatant was collected for the nuclear fraction. 
 
2.3 RNA ANALYSIS 
2.3.1 TOTAL RNA EXTRACTION 
Total RNA was isolated from mammalian cells using the RNeasy Kit (Qiagen, Crawley, 
UK). Frozen cell pellets were disrupted by adding 350μl buffer RLT with 10% β-
mercaptoethanol. Samples were homogenised by pipetting, then 350μl 70% ethanol was 
added and 700μl of total sample was added to a spin column placed in a 2ml collection 
tube and microcentrifuged for 15 sec at 10000rpm. The flow through was discarded and 
700μl of buffer RW1 was added to the RNeasy spin column. This was microcentrifuged for 
15 sec at 10000rpm and the flow through discarded again. Next, 500μl of buffer RPE was 
added to the spin column and microcentrifuged at 10000rpm for 15 sec. The flow through 
was discarded and this step was repeated, followed by a 2 min centrifugation at 10000rpm. 
The RNeasy column was then transferred to a new collection tube. 30µl of RNase-free 
water was added directly to the spin column membrane and the column was 
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microcentrifuged for 1 min at 10000rpm to elute RNA. The purity and concentration of RNA 
was determined by measuring the spectrophotometric absorption at 260nm and 280nm. 
 
2.3.2 REAL TIME QUANTITATIVE-PCR (RT-QPCR) 
2μg of total RNA was reversed-transcribed to first strand cDNA using the Superscript III 
first strand synthesis system (Invitrogen). 1μl of random primers and 1μl 10mM dNTP mix 
was added to 2μl of total RNA and made up to a total volume of 13μl with sterile RNase 
free water. The sample was heated at 65°C for 5 min to denature then placed on ice for at 
least 1 min. The samples were then mixed with 4μl 5x first strand buffer, 1μl 0.1M DTT, 1μl 
RNaseOUT and 1μl Superscript III RT, to a final volume of 20μl per sample. The mixture 
was incubated at 25°C for 5 min then heated at 50°C for 50 min. The reaction was 
terminated by heating at 70°C for 15 min. By pooling equal amounts of all diluted cDNA 
samples, a cDNA standard was obtained. Four serial 1:4 dilutions (1/4, 1/16, 1/64 and 
1/256) of the standard in water were done for generation of standard curve points, 
including a blank sample. As a control the established housekeeping genes L19 or TBP 
were used to normalise gene expression between samples. 
The resulting cDNA samples were used as a template for RT-qPCR, which was performed 
with an ABI PRISM® 7700 Sequence Detection System (Applied Biosystems) using 2x 
SYBRGreen Mastermix (Applied Biosystems) according to manufacturer’s instructions. 
Gene specific primers were designed using ABI Primer Express Software (Applied 
Biosystems). Primers with amplicon size 50-150bp spanning intron/exon boundary were 
selected whenever possible to avoid amplification of contaminating genomic DNA. 
The reaction mix contained 2μl of sample and 23μl of SYBR Master Mix and primers to a 
final volume of 25μl. All measurements were performed in triplicate. The TAQMAN 7900 
Real-time PCR machine was used. Efficiency of PCR was obtained from the slope of the 
standard curve. 
 
2.3.3 PRIMER OPTIMISATION 
JAK2, CXCR4, FOXP1, p27Kip1 and APOBEC3G primer sets were optimised with 10ng 
cDNA standard to determine the minimum concentration required for maximum yield and 
minimum non-specific amplification in each cell line. Dilutions of 50-900nM of forward and 
reverse primers in different combinations were tested. The concentration that gave the 
lowest Ct value (10-35) with standard DNA and highest Ct value (40) with water was 
selected for use in further experiments. The concentrations of primers used to amplify 
FOXO3a, FOXM1, VEGF, PIK3CA, IGF1R, L19 and TBP were optimised by previous 
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members in the lab (E. Lam’s laboratory, Imperial College, London). Primers used for RT-
qPCR are summarised in Error! Reference source not found..  
 
 
    
  
       
Human gene Forward (5'-3')   Reverse (5'-3')     
FOXO3a TCTACGAGTGGATGGTGCGTT CGACTATGCAGTGACAGGTTGTG 
FOXM1 TGCAGCTAGGGATGTGAATCTTC GGAGCCCAGTCCATCAGAACT 
FOXP1 TCAGTGGTAACCCTTCCCTTA GTACAGGATGCACGGCTTG  
JAK2 GGAAGCGACCTGGAAGCATGA GGCCTCGAATCTGTTGGCTC 
CXCR4 ACCAGAAGAAACTGAGAAGCATGA GAGGAGGTCGGCCACTGA  
p27Kip1 GAATAAGGAAGCGACCTGCAA TCTTCTGTTCTGTTGGCTCTTTTGT 
APOBEC3G TGAAAACAAAGGGTCCCTCAAG GGAATACACCTGGCCTCGAA 
IGF1R GGATATTGGGCTTTACAACCTG GGCTTATTCCCCACAATGTAGTT 
PIK3CA AAATGAAAGCTCACTCTGGATTCC TGTGCAATTCCTATGCAATCG 
VEGF GAAGTGGTGAAG TTCATGGATGTC  CGATCG TTCTGTATCAGTCTTTCC  
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA  
TBP ACGAACCACGGCACTGAT AACCCAACTTCTGTACAACTCTAGCA 
            
Mouse gene Forward (5'-3')   Reverse (5'-3')     
FOXO3a CCGGACAAAGGGCTCACT GGCACACAGCGCACCAT  
FOXP1 GGATTAAGTCTCCCAAGAGGAATG GCCACTGACACGGGAACCT 
p27Kip1 GGACCAAATGCCTGACTCGT CGCTTCCTCATCCCTGGAC  
      
Table 1. List of primers used for RT-qPCR 
 
2.4 DNA ANALYSIS 
2.4.1 PLASMID CONSTRUCTS AND EXPRESSION VECTORS 
The constitutively active form of FOXM1, pcDNA3-ΔN-FOXM1, was generated by deletion 
of the FOXM1 N-terminal repressor domain (Wierstra and Alves 2006a) and was cloned by 
Jimmy Kwok (PhD student, Prof Eric Lam’s lab). 
The constitutively active FOXO3a mutant vectors, pcDNA3-FOXO3a(A3) and pcDNA3-
FOXO3a(A3):ER were cloned by previous lab members. 
The HDAC2WT and HDAC2C262A/C274A expression vectors were a kind gift from Dr Antonella 
Riccio (University College London, UK). 
FOXP1 was cloned into pcDNA3 vector (Invitrogen, Paisley UK) (pcDNA3-FOXP1) by 
previous lab members.  
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The FOXP1 cDNA fragment generated by PCR from pcDNA3-FOXP1 vector was cloned 
into pEGFP-C1 (Clontech, CA) vector, generating the final pEGFP-C1-FOXP1 vector 
(FOXP1:GFP). 
The VEGF promoter was cloned by Dr Alexa Stavropoulou; the VEGF promoter constructs 
FHRE mutant 1 (VEGF pro-mut1) and FHRE mutant 2 (VEGF pro-mut2) were generated 
by introduction of mutations into the forkhead response elements (FHRE) using the 
QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA). 
 
2.4.2 DNA QUANTIFICATION 
The concentration of DNA was measured by using a ND-1000 spectrophotometer 
(NanoDrop Technologies) which measures instantly the DNA concentration upon the 
addition of 1μl of sample. 
 
2.4.3 SUBCLONING 
2.4.3.1 RESTRICTION DIGESTS 
Available restriction enzyme sites were examined with NEB cutter version 2. 
Approximately 1µg of plasmid DNA was digested by restriction endonucleases (New 
England Biolabs, Hertfordshire, UK) for 3 h at room temperature (RT) or overnight with 
appropriate buffers at suggested temperature according to protocols supplied by New 
England Biolabs. 
 
2.4.3.2 LIGATION 
DNA fragments with compatible over-hanging ends were covalently joined by T4 DNA 
ligase (New England Biolabs) simultaneously at room temperature for 1 hour or overnight 
at 16°C. The vector: insert molar ratio was usually 1:3 or 1:4 in a 10μl final volume 
reaction. 1-2μl of the ligation reaction was used for transformation. 
 
2.4.3.3 AGAROSE GEL ELECTROPHORESIS 
DNA fragments mixed in a final 1x Orange G loading dye (6x, Promega, Southampton, 
UK) were separated by electrophoresis in 1-2% (w/v) agarose gel (incorporated with 
0.5μg/ml ethidium bromide) in Tris-acetate–EDTA (TAE) buffer. 1% gel was used to 
visualise DNA fragment of size 500bp to 10kb; 2% gel for 50bp to 2kb. The gel image was 
recorded with a UVIpro Gel Documentation system (Uvitec, Cambridge, UK). 
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2.4.3.4 EXTRACTION AND PURIFICATION OF DNA 
Where applicable, DNA was purified with PCR purification Kit, Reaction cleanup Kit or Gel 
extraction kit (Qiagen, Crawley, West Sussex, UK) according to the manufacturer’s 
instruction. Ethanol precipitation was used when concentration of DNA was desired; 0.1 
volumes of 3M sodium acetate (pH 5.2) and 2.5 volumes of 100% ethanol were added to 
the DNA solution. The mixture was stored at -80oC for at least 20 min and then centrifuged 
at 14000rpm for 30 min at 4oC. The pellet was washed with 70% ethanol, re-centrifuged for 
5 min, air-dried and resuspended in an appropriate volume of 10mM Tris buffer or sterile 
water. 
 
2.4.3.5 PCR SUBCLONING 
Two restriction enzyme sites capable of digestion in the same buffer and preferably with 
incompatible ends were selected from the multiple cloning region in the vector plasmid. 
They were then added into the 5’- end of the PCR primers with one in the forward primer 
and one in the reverse primer. Three additional bases were added in front of the restriction 
recognition site for efficient cleavage at the end of DNA fragment. PCR was performed 
according to Taq PCR Handbook (Qiagen) using 1ng plasmid DNA. The PCR product was 
then digested and subcloned into the desired plasmid cloning vector in a desired 
orientation. 
 
2.4.3.6 BACTERIA TRANSFORMATION AND CULTURE 
1μl of DNA (<10ng) and 20-50μl competent cells were incubated on ice for 30 min. XL-1 
Blue supercompetent cells from Stratagene (Amsterdam Zuidoost, The Netherlands) were 
used for subcloning ligated DNA. The cells were then heat shocked at 42oC for 45 sec and 
returned to ice for 2 min. The transformed cells were then spread on agar plates with 
appropriate selection antibiotics (ampicillin 100μg/ml in water or kanamycin 50μg/ml in 
water). 
A single colony was picked from a plain LB agar plate and inoculated in 5ml of LB broth 
(Sigma) with suitable selection antibiotics, at 37oC for 6 h in a shaking incubator. 1ml of 
this culture was then added to 250ml LB in a 500ml flask and left to shake in the 37oC 
incubator overnight. 
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2.4.3.7 PLASMID MINIPREP AND MAXIPREP 
DNA was purified from the overnight-grown culture using a Miniprep Plasmid Purification 
Kit (Qiagen). For isolation of larger amounts of DNA a Maxiprep Plasmid Purification Kit 
(Qiagen) was used. Both Kits were used according to the manufacturer’s instructions. 
 
2.4.3.8 SITE-SPECIFIC MUTAGENESIS  
Mutagenesis of the two potential forkhead binding sites on the VEGF promoter cloned into 
a pGL3-Basic vector was achieved by using the QuickChange II Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). According to the protocol provided, 
oligonucleotides complementary to the VEGF promoter template were designed to contain 
alterations to enable nucleotide changes as appropriate.  
 
5'-Oligonucleotide-3' 
Site 1 (-178) ATCCCTCTTCTTTTTTCTTGGGCATTTTTTTTTAAAACTGTATTGT 
Site 2 (-319) 
 
TTGCTCTACTTCCCCGGGTCACTGTGGATTTTGGGGGCCAGCAGA 
 
The mutant strand synthesis reaction was performed using PCR with the following cycling 
parameters: (1) 95°C 30 sec; (2) 95°C 30 sec; (3) 55°C 1 min; (4) 68°C 7 min; (5) Go to (2) 
×29; (6) 4°C for ever. Generally, each reaction was prepared in a final volume of 25μl, 
containing 100ng of non-mutated template plasmid, 2.5μl of 10×reaction buffer, 0.7μl of 
both forward and reverse primers (100ng/μl), 1μl of dNTP mix, 3μl of Quick solution and 
1μl of Pfu Ultra HF DNA polymerase (2.5U/μl). 
 
2.4.4 POLYMERASE CHAIN REACTION (PCR) 
PCR amplification was performed using a Taq DNA polymerase Kit (Qiagen) with a Gene 
Amp® PCR system 9700 (Applied Biosystems). Reaction solutions contained 1μg DNA 
template, 0.5μM primers, 200μM dNTP, 0.5U Taq DNA polymerase in a 25μl reaction. The 
PCR was performed on a Gene Amp® PCR system 9700 (Applied Biosystems) using the 
following program: denaturation step for 1 min at 94oC, annealing for 1-2 min at 55-65oC 
depending on the oligonucleotides used, extension at 72oC for 1 min for 33 cycles followed 
by a final extension for 10 min at 72oC. Optimisation of the primer annealing temperatures 
was performed by a gradient of increasing temperatures from 50-65oC for 35 cycles, 
followed by change of magnesium concentration. 
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2.5 TRANSFECTION OF PLASMID DNA AND EXPRESSION VECTORS 
Cells were seeded into six well plates or 10cm3 dishes to a confluency of approximately 
60%. Plasmid DNA was transfected using a ratio of Fugene 6 (μl) to DNA (μg) of 3:1. After 
15 min of incubation, the fugene/DNA mixture was added directly to each well or plate and 
the cells were incubated for 6h at 37°C, after which the cells were washed in warm PBS 
and fresh media was added. 24 h after transfection, cells were either directly harvested for 
western blot and RT-qPCR analysis or re-plated for further experiments. 
 
2.6 LUCIFERASE REPORTER ASSAYS 
Luciferase assays were performed with the LucLite Luminescence Reporter Gene Assay 
System (Perkin ElmerTM Life Sciences, Milan, Italy) coupled with coelenterazine (Lux 
Biotechnology, Edinburgh, UK), according to manufacturer’s instructions. Cells were lysed 
in 1xLucLite Reagent for 15 min at RT. 100µl of lysate were transferred to a 96 well 
microplate and firefly luciferase activity was read with TopCount Luminometer (Perkin 
ElmerTM Life Sciences). Afterwards, 25μl of RenLite reagent [Coelenterazine (50μg/ml) in 
Renilla Buffer (0.5M HEPES, pH7.8, 40mM EDTA)] was added and left in the dark for 20 
min at RT before measurement for Renilla luciferase activity. The relative luciferase activity 
was determined by dividing firefly luciferase activity by renilla luminescence values. 
Reporter assays were performed in triplicates and repeated at least three times. 
 
2.7 RNA INTERFERENCE  
For the work in this thesis, genes were silenced using the SMARTpool TM product Insert – 
Version 2.0 (DHARMACON, RNA technologies). The SMARTpool siRNAs used were: 
FOXO3a (L-003007-00), siHDAC1 (L-003493-00), siHDAC2 (L-003495-00), FOXP1 (L-
004256-01) and GFP (P-002048-02-20). The transfection reagent used was 
Oligofectamine (Invitrogen Ltd, UK).  
Cells were plated into 6-well plates at 60% confluency 16 h prior to transfection. For each 
well, 70μl of optiMEM (Life Technologies Gibco/BRL, Paisley, UK) was mixed with 5μl of 
oligofectamine and incubated at RT for 10 min. This solution was then mixed with 250μl 
optiMEM and 7.5μl of the specific siRNA oligonucleotide for each gene, with a resulting 
final concentration of 50nM. After 25 min incubation, 160μl optiMEM were added to each 
mix and 500μl were then added to the wells, which had been washed immediately before 
with warm PBS. After 4 h of incubation at 37°C, 2ml of normal media, with 10% FCS, were 
added to each well. Two types of controls were used for the siRNA experiments. As a 
negative control, cells were transfected with a non-specific/non-targeting siRNA (NSC D-
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001210-01-05, Dharmacon). This served to distinguish sequence specific silencing from 
non-specific effects. Another control used was the untreated or Mock control, where cells 
were cultured without any siRNA treatment. This allows detection of any cellular effects 
caused by the transfection event or delivery process and determines target gene level. 24-
48 h post-transfection, cells were either harvested or re-plated for further protein and 
mRNA analysis by Western blotting or RT-qPCR.  
 
2.8 FLUORESCENCE ACTIVATED CELL SORTING (FACS) ANALYSIS 
Cells were harvested, washed and resuspended in 1ml PBS. Cells were fixed by 
resuspension in 90% ethanol in PBS and stored at -20°C until analysis. For analysis, 
samples were centrifuged at 2000rpm to remove the ethanol, washed twice in PBS, and 
stained with propidium iodide (50μg/ml) and RNase A (5μg/ml) for 1 h at RT in the dark. 
Samples were analysed on a FACSDiva flow cytometer (BD Biosciences) using the 
FACSDivaTM (BD Biosciences) acquisition software. Graphical results represent the % of 
cells (Y-axis) in each phase of the cell cycle determined by their DNA content (X-axis).  
 
2.9 SULPHORHODAMINE B (SRB) ASSAY 
The SRB assay is used for examination of cell proliferation/viability as the colorimetric 
measurement of the bound dye allows a measurement of cellular protein content. Cells 
were seeded in a 96 well plate at a density of 3000 cells/well and incubated overnight. On 
the day of harvesting, cells were fixed with 100µl cold 40% (w/v) trichloroacetic acid (TCA) 
and incubated for 1 h at 4°C. Plates were washed five times with slow running tap water 
and then 100µl of SRB solution (0.4% SRB in 0.1% acetic acid) were added. Plates were 
left at RT for 1 h, then washed with 1% acetic acid to remove any unbound dye. The plates 
were left to air-dry overnight and then stored. To read the plates, 100µL Tris (10mmol/L) 
was added to each well to solubilise the bound sulforhodamine B dye and placed on a 
rotator for 30 min to evenly distribute the dye. The plates were then read at 492nm using 
the Sunrise plate reader (Tecan Group Ltd, Mannedorf, Switzerland). 
 
2.10 IMMUNOHISTOCHEMICAL (IHC) STAINING  
In the tissue microarray used in this thesis, 133 breast cancer cases which were 
diagnosed between the years 1992 to 2001 with clinical follow-up data, were retrieved from 
the records of the Department of Pathology, Queen Mary Hospital, Hong Kong. The age of 
patients at diagnosis ranged from 30 to 90 years old, with a mean of 53 years. Histological 
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sections of all cases were reviewed by pathologists. The representative paraffin tumour 
blocks were chosen as donor block for each case and used for construction of tissue 
microarray blocks. Of all cases, 38 tumour cases had non-tumour tissues available for 
comparison with their tumour counterparts in protein expression studies. A total of 120 
cases could be assessed and scored for FOXO3a, P-AKT, VEGF, FOXM1 and FOXP1 
expression. The expression pattern and subcellular localisation were correlated with 
clinical stage, histological type, histological grade, lymph node metastasis, survival time, 
HER-2 overexpression status, and ER and PR status. Slides were loaded into a rack and 
placed in an oven at 70°C for 1 h to melt the paraffin around the tissue sample. To remove 
the embedding material, the samples were deparaffinised and rehydrated. This was done 
by sequentially placing the slides and rack in xylene twice for 10 min, 100% ethanol for 10 
min, 70% ethanol for 10 min and finally in tap water. The slides were then placed in 1l of 
pre-warmed citrate buffer (0.01M sodium citrate, pH 6) and then heated for 15 min at full 
power in a microwave for antigen retrieval. This allowed recovery of the antigenicity of the 
tissue which had been masked by formalin fixation. After 20 min of cooling at RT, the 
slides were transferred rapidly to a dish containing warmed PBS and washed twice in PBS. 
To block endogenous peroxidase activity, which may result in high, non-specific 
background staining, slides were then immersed in 3% H2O2 in methanol for 10 min at 
room temperature. This resulted in the irreversible inactivation of endogenous peroxidase. 
Slides were then washed again twice in PBS for 5 min. The dilution of antibody used was 
determined by first performing a titration of antibody dilutions, to optimise tissue staining 
whilst eliminating excessive background or non-specific staining. For example, for 
optimisation of FOXO3a staining with the FOXO3a anti-rabbit polyclonal antibody, the 
following dilutions were used: 1:100, 1:200, 1:400, 1:800 and 1:1600. Omission of primary 
antibody was used as a negative control. Sensitivity and staining quality was then imaged 
on light microscopy and the most appropriate dilution selected for subsequent staining. 
The same procedure was used for optimisation of P-AKT, FOXP1, FOXM1 and VEGF 
antibodies. 
The primary antibodies were added to each sample and the slides were incubated 
overnight at 4°C in a closed humidified incubation chamber. On the following day, the 
slides were washed three times in PBS. Then 4-5 drops of DAKO Polymer was applied on 
each section and incubated at room temperature for 30 min. The slides were washed 
again in PBST for two changes. Chromogen DAB/substrate reagent solution (DAKO REAL 
EnVision Detection System, DAKO, Denmark) (one drop of DAB in 1ml substrate reagent) 
was freshly prepared and 200μl of the reagent were added onto each section for 3 min 
incubation until colour development could be observed. Colour development was stopped 
by washing the slides in tap water. The sections were counterstained in Haematoxylin 
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(DAKO, Denmark) for 5 min and de-stained in acid-alcohol for 5 sec. The slides were 
placed in Scott tap water until the sections grossly turned bluish, followed by washing them 
in running tap water. Finally the slides were dehydrated with increasing concentrations of 
ethanol followed by clearing in xylene. Slides were mounted by adding one drop of 
mounting media (Histolab Products, Gothenburg, Sweden) to each sample, then covering 
the sample with a coverslip. Slides were allowed to dry before examining under the 
microscope.  
The staining was assessed at high power (×40) under a light microscope. The intensity 
and percentage of staining either in the cytoplasm or in the nucleus were scored in a semi-
quantitative method. The intensity of staining was scored as follows: 1 = weak, 2 = 
moderate, 3 = strong, while the percentage of cells positively stained was scored as 
follows: 1 = < 25%, 2 = < 50%, 3 = 75%, 4 = > 75%. The final score for each case was 
obtained by multiplying the score of intensity with the score of percentage. 
 
2.11 IMMUNOFLUORESCENT STAINING 
Cells were seeded in four-well chamber culture slides (BD Falcon, Erembodegem, 
Belgium). 24 h following plating, the appropriate treatments were added to the wells and 
left for the required time. Cells were then washed twice with warm PBS and fixed with 4% 
formaldehyde in PBS for 10 min at RT. The fixative was removed and the cells were 
washed four times with PBS for 5 min. The cells were then permeabilised with 0.2% triton 
in PBS for 10 min, washed again three times with PBS, followed by blocking with 5% goat 
serum in 10% BSA for 30 min at RT. The primary anti-rabbit FOXO3a (H144, Santa Cruz 
Biotechnology), anti-rabbit FOXP1 (ab16645, Abcam) or anti-rabbit ERα (sc-543, Santa 
Cruz) antibodies were added at a dilution of 1:100 in 10% BSA blocking solution and the 
cells were incubated for 1 h, before further washing with PBS three times for 5 min. The 
secondary antibody (Alexa-Fluor 488 anti-rabbit, Invitrogen) was then added (1:500 
dilution in 10% BSA) and the cells were incubated in the dark for 45 min. The cells were 
washed again three times in PBS for 5 min each. Cells were then incubated in DAPI 
(Invitrogen) for nuclear staining (1:1000 dilution in 10% BSA) for 20 min in the dark. The 
chamber was removed from the slides and one drop of Vectashield mounting medium 
(Vector laboratories Inc., Burlingame, CA) was added on each well, covered with a glass 
coverslip and sealed with clear nail polish. The slides were analysed using a Zeiss 
confocal laser scanning microscope with the respective software (Zeiss Ltd). 
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2.12 CHROMATIN IMMUNOPRECIPITATION (ChIP) 
Cells at 90% confluence in 100mm culture dishes with or without drug treatment were 
cross-linked for 10 min at 37°C with fomaldehyde (Sigma). Cells were then rinsed in ice-
cold PBS and scraped of the dish in 1ml of scraping buffer (recipes for the buffer used, see 
Appendix 3). After washing in PBS, Buffer I and Buffer II sequentially, the cell pellet was 
resuspended in 300μl Lysis buffer and sonicated (12 min in total with 30 sec on and 30 sec 
off). After removing the insoluble fraction, the cell lysate was mixed with 300μl buffer D and 
100μl was then taken as the INPUT control. Dynabeads Protein A (Invitrogen Dynal A.S., 
Oslo, Norway) were first washed with TSE I buffer three times before binding with the 
primary antibody (1μg) overnight at 4ºC, while dynabeads with IgG were used as negative 
control. The primary antibodies used for immunoprecipitation were the anti-FOXO3a (H-
144), anti-FOXM1 (C-20), anti-ERα (sc-543), anti-H4K16 (all from Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), anti-H3K9 (Cell Signalling Technologies), anti-
HDAC2 and anti-FOXP1 (both from Abcam), and the anti-IgG control (DAKO, USA). A total 
of 500μl sonicated lysate was then added to the dynabeads and rotated overnight at 4ºC. 
After washing the dynabeads five times with TSE I and twice with TE buffer, 100μl of 
Elution buffer were added to the dynabeads and the mixture was rotated at RT for 1 h. The 
eluted supernatant was then transferred to a collection eppendorf while 100μl fresh elution 
buffer was added to elute one more time at RT for 1 h. Finally, a total of 200ul of sample 
were de-crosslinked by incubation at 65ºC overnight. Qiagen PCR Purification Kit 
(QIAGEN, UK) was used to extract DNA from the de-crosslinked sample. Approximately 
30μl of DNA were eluted from each sample and 3μl of each were used in one PCR 
reaction later. The primer sequences used in the PCR are listed below. 
   FOXO binding sites Forward (5'-3') Reverse (5'-3') 
VEGF promoter TCCGGGTTTTATCCCTCTTC TCTGCTGGTTTCCAAAATCC 
FOXP1 promoter site1 TGCAGAATCAGATTAGCAGCAATC CAATTCATCCTCTGATCTTGTTTTTC 
FOXP1 promoter site2 ACGGGAGAGAGGGAGAAAGG GTTTTGCCATCAGTGACAGTTGA 
FOXP1 promoter site3 CCCCGCTCTCCTTCAACTG GGACAGGCTAGAATGTGAGTTTCC 
 
Analysis of the PCR products was performed on a standard 2% (w/v) agarose gel by 
electrophoresis in Tris-acetate-EDTA buffer. After amplification, PCR products were 
visualised on an ethidium bromide-stained 2% agarose gel, using a Transiluminator. 
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2.13 PULL-DOWN USING BIOTIN-LABELLED OLIGONUCLEOTIDES 
Biotinylated oligonucleotides (Invitrogen) were coupled to streptavidin beads (Sigma) in a 
solution containing 100µl PBS, 10µl FCS, 20µl of a 50% slurry of streptavidin-agarose 
beads (Sigma) and 1µl of annealed biotinylated oligonucleotide. Beads were left to 
incubate with the oligonucleotides while rotating for 2 h at RT. Following incubation, the 
oligo-coupled beads were spun down at 12000rpm on a bench top centrifuge for 2 min. 
The supernatant was discarded and 50 µg of nuclear lysate was diluted in 2x volumes of 
low salt and added to each of biotinylated oligo-coupled beads along with 1µg of sheared 
salmon sperm DNA and competitor non-biotinylated double stranded oligonucleotides 
containing a wild-type, high affinity or mutant consensus site for prospective binding 
proteins. Samples were incubated with rotation at 4oC for 1 h and subsequently incubated 
at 30oC for 10 min. The beads were then washed 6 times in PBS containing protease 
inhibitors. Beads were separated from the washing buffer by centrifugation at 3000rpm for 
2 min, loading buffer was added and the samples were then loaded in an SDS-PAGE gel 
and the prospective binding proteins detected by western blotting. The sequences of 
oligonucleotides used for pull down assays are summarised below. 
 
Oligonucleotides Sequence 
WT FOXO3a F Biotin Biotin-GTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTAAA 
WT FOXO3a F GTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTAAA 
WT FOXO3a R TTTAAAAAAAATGTTTAAGAAAAAAGAAGAGGGAT 
MT FOXO3a F Biotin Biotin-GTTTTATCCCTGTTCTTTTTTCTTGGGCATTTTTTAAA 
MT FOXO3a F GTTTTATCCCTCTTCTTTTTTCTTGGGCATTTTTTAAA 
MT FOXO3a R TTTAAAAAAAATGCCCAAGAAAAAAGAAGAGGGAT 
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2.14 ENZYME-LINKED IMMUNO SORBANT ASSAY (ELISA) 
VEGF and FGF7 concentrations were measured by a quantitative sandwich enzyme 
immunoassay (Quantikine ELISA R&D). Microplates were pre-coated with a specific VEGF 
or FGF7 monoclonal antibody and 50µl of assay diluent RD1W were added to the wells. 
200µl of either cell supernatants or standards were loaded in triplicates to the wells and 
were left to incubate at room temperature in order for the soluble VEGF or FGF7 to bind to 
the immobilised antibody. After washing four times with 400µl of washing buffer, 200µl of 
VEGF or FGF7 conjugate (an enzyme-linked VEGF or FGF7 polyclonal antibody solution) 
was added to the wells. The plates were incubated for 2 h at RT. After washing, 200µl of 
substrate solution were added to the wells and colour was developed. After 20 min 
incubation, 50µl of top solution were added. The colour change was then stopped and its 
optical density was measured at 450nm (Sunrise-Tecan) within 30 min. 
 
2.15 CO-IMMUNOPRECIPITATION 
Co-immunoprecipitation (Co-IP) was performed to detect protein-protein interactions. The 
proteins were extracted using a Co-IP lysis buffer (50mM Hepes pH 7.5, 150mM NaCl, 
2mM EDTA, 10% glycerol (v/v), 0.5% Triton-X (v/v), 10mM NaF, 10mM β-
Glycerophosphate pH7.3, 0.1mM Na3VO4, 100U/ml aprotinin, 10µg/ml leupeptin and 1mM 
PMSF), which has a suitable formulation to perform the precipitation of the target protein 
and co-precipitation of binding partners/protein complexes. The lysates were pre-cleared 
with agarose beads (15µl per sample) for 30 min. After centrifugation, the supernatant was 
transferred to a new eppendorf tube. Protein concentration was then determined and 0.3-
0.5mg of protein extract was incubated with the antibody and beads for 2-3 h rotating at 
4˚C. The antibodies used in this step were the same as the ones used for ChIP except for 
the FOXP1 antibody. Immunoprecipitates were then washed, by centrifugation, 3 times 
with the same lysis buffer and samples were prepared for separation on a SDS-PAGE gel.  
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CHAPTER 3 
PI3K/AKT/FOXO3A AXIS IN 
CHEMORESISTANCE 
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3.1 INTRODUCTION  
The PI3K/AKT signalling pathway has been well documented to regulate a plethora of 
fundamental biological processes including those involved in enhanced cell proliferation 
and growth. Thus, it is not surprising that this signalling axis has also been implicated in 
tumorigenesis (Hennessy et al 2005, Jiang and Liu 2008). In cancer cells, in addition to 
various receptor tyrosine kinases (RTKs), such as HER-2, many other upstream molecules 
feed into the PI3K/AKT activity and culminate in increased cell proliferation, cell survival, 
angiogenesis, invasion and metastasis (Browne et al 2009, Tokunaga et al 2006). As a 
consequence of its aberrant expression in cancer cells, many reports have showed that 
the PI3K/AKT pathway is associated with therapeutic resistance (Campbell et al 2001, 
Clarke et al 2001a, Clarke et al 2001b). FOXO3a is one of a panoply of downstream 
targets, negatively regulated by AKT, which functions as an obstacle for cell proliferation 
and growth (Brunet et al 1999, Kops et al 2002b). FOXO3a has been showed to serve as 
therapeutic target in various cancers by mediating the cytotoxic and cytostatic effects of 
several chemotherapeutic drugs. For example, in breast cancer cells paclitaxel has been 
shown to induce the nuclear translocation and accumulation of FOXO3a to induce 
apoptosis (Sunters et al 2003). Furthermore, ER-negative breast cancer cells are 
sensitised to tamoxifen by OSU-03012, a small-molecule inhibitor of PDK1, through 
activating FOXO3a (Weng et al 2008). Various studies have shown that FOXO3a mediates 
the cytotoxic effects of cisplatin in oral squamous cancer (Mauri et al 2006), colon cancer 
(Ligibel and Winer 2005), ovarian cancer (Baum et al 2002) and bladder cancer (Giaccone 
and Pinedo 1996). Similarly, in CML cells, the cytotoxic effect of doxorubicin is also 
mediated by the nuclear accumulation of FOXO3a (Hui et al 2008a, Hui et al 2008b). 
However, sustained FOXO3a activation by doxorubicin also promotes drug-resistance and 
survival of leukaemic cells by activating the expression of genes important for drug efflux 
(e.g. ABCB1) and survival (e.g. PIK3CA) (Hui et al 2008a, Hui et al 2008b, Yang and Hung 
2009). 
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3.2 AIMS & OBJECTIVES 
FOXO3a is undoubtedly a transcription factor preferentially targeted by cancer therapeutic 
drugs. Furthermore, in cancer cells FOXO3a expression mediates the drug impact and 
determines the cellular decisions that eventually lead to survival or death. However, the 
molecular mechanisms behind FOXO3a-mediated sensitivity and chemoresistance are 
currently unclear. As a consequence, it is reasonable to study the PI3K/AKT/FOXO 
pathway and its impact on drug sensitivity or resistance in breast cancer and explore its 
use as prognostic clinical tools. 
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3.3 RESULTS 
3.3.1 Tamoxifen-resistant breast cancer cell lines are sensitive to doxorubicin 
treatment 
In order to assess the resistance profile of different breast cancer cell lines in vitro, I 
analysed the proliferation rate of a panel of chemotherapy sensitive and resistant breast 
cancer cell lines treated with tamoxifen or doxorubicin. LCC2, LCC9 and R27 are MCF-7 
(LCC1) endocrine-resistant derivate cell lines. Cell proliferation was determined by SRB 
assays following the incubation of cells with increasing amounts of tamoxifen for six days. 
The results showed that both the parental MCF-7 and the R27 derivative cell lines are 
sensitive to tamoxifen while LCC2 and LCC9, as well as the BT474 cells are resistant to 
tamoxifen treatment up to concentrations of 5μg/ml (Figure 5). I also generated a cytotoxic 
chemotherapy resistant MCF-7 cell line through continuous exposure up to 10μM 
doxorubicin. The proliferative analysis of this MCF-7DoxR cell pool, confirmed that its 
proliferation is not significantly affected by doxorubicin treatment when compared to the 
parental MCF-7 cells proliferation which was severely inhibited when incubated with 
＞5μM of doxorubicin (Figure 6A). Similarly, the multidrug resistant breast carcinoma cell 
line MDA-MB-231 also displayed resistance to 1μM of doxorubicin, a dose that effectively 
inhibited the parental MCF-7 cell proliferation (Figure 6B). Notably, the tamoxifen-resistant 
BT474 cells as well as the MCF-7 derived cell lines, including LCC2, LCC9 and R27, were 
all found to be sensitive to doxorubicin treatment at 1μM (Figure 6C). 
These results showed that the MCF-7 DoxR and MDA-MB-231 cell lines represent 
advanced breast cancers of poor prognosis with limited treatment options. This finding 
corroborates with the clinical evidence that breast cancers which failed endocrine 
treatments are often intrinsically resistant to cytotoxic chemotherapy (Greenberg et al 
1996). 
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Figure 5. Effects of tamoxifen on cell proliferation of a panel of breast cancer cell 
lines.  
MCF-7(LCC1), LCC2, LCC9, R27 and BT474 cells were treated with 0 to 10µM of tamoxifen for 6 
days. Cell proliferation was determined by SRB assay. Points, mean of three independent 
experiments; bars, SD. 
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Figure 6. Effects of doxorubicin on cell proliferation of a panel of breast carcinoma 
cell lines. 
A) MCF-7 and the derived MCF-7 DoxR cells were treated with 0 to 10μmol/L of doxorubicin for 0, 
24, and 48 h. B) MCF-7, MCF-7 DoxR, MDA-MB-231, BT474, and LCC9 cells were treated with 
1μmol/L of doxorubicin for 0, 24, and 48 h. C) MCF-7(LCC1), LCC2, LCC9, R27 and BT474 cells 
were treated with 1μmol/L of doxorubicin for 0, 24, and 48 h. Cell proliferation was determined by 
SRB assay. Points, mean of three independent experiments; bars, SD. 
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3.3.2 Predominant nuclear FOXO3a localisation in doxorubicin but not tamoxifen-
resistant cell lines 
To explore the potential role of FOXO3a and its upstream regulator AKT in the 
development of drug-resistance, I examined the basal expression levels of both the total 
and phosphorylated forms of FOXO3a and AKT in the tamoxifen and doxorubicin drug 
sensitive as well as resistant breast cancer cell lines. Western blot analysis showed that 
the basal levels of P-AKT (S473), FOXO3a and P-FOXO3a (T32) were higher in the 
tamoxifen-resistant cell lines compared to the sensitive parental MCF-7 (LCC1) cells 
(Figure 7A), suggesting that PI3K/AKT activity is enhanced in endocrine resistant cells.  
Interestingly, P-AKT and total AKT were expressed at similar levels in the doxorubicin 
sensitive MCF-7 and resistant MCF-7 DoxR and MDA-MB-231 cells. By comparison, the P-
FOXO3a expression was low in the MCF-7 DoxR while in MDA-MB-231 cells P-FOXO3a 
expression was higher. The reason for this decrease in FOXO3a activity in MDA-MB-231 
is unclear. Nevertheless, the expression levels of FOXO3a were high in both the MCF-7 
DoxR and MDA-MB-231 cells (Figure 7B). These results indicate that in doxorubicin 
resistant cells, especially in MCF-7 DoxR, there is a substantial amount of active FOXO3a 
and this non-phosphorylated FOXO3a escapes the negative regulation of AKT further 
suggesting that the AKT-FOXO3a axis is uncoupled in doxorubicin resistant cells. Because 
of this result, I next examined the subcellular localisation of FOXO3a in the cytoplasmic 
and nuclear extracts of these tamoxifen and doxorubicin drug sensitive and resistant 
breast cancer cell lines (Figure 8A). Tubulin and Lamin B were used as controls for 
cytoplasmic and nuclear fractions, respectively. Western blotting results showed that 
FOXO3a was present at considerably higher levels in the cytoplasmic compartment 
compared with the nuclear fractions in all doxorubicin sensitive breast cancer – MCF-7, 
BT474, LCC2, LCC9 and R27. In contrast, in the doxorubicin-resistant breast cancer cells, 
MCF-7 DoxR and MDA-MB-231, FOXO3a expression was higher in the nuclear 
compartment of these cells (Figure 8A). These results suggest that FOXO3a expression is 
predominantly nuclear in the doxorubicin-resistant cells whereas in the doxorubicin-
sensitive cells and also in the tamoxifen-resistant BT474, LCC2 and LCC9 cells lines, 
FOXO3a expression is primarily cytoplasmic. 
To confirm the subcellular fractionation results and to directly visualise the subcellular 
distribution of FOXO3a in the two doxorubicin-sensitive and in the drug-resistant, I 
performed immunofluorescence staining (Figure 8B). Consistently with my previous 
results, FOXO3a staining was primarily located in the cytoplasm of the doxorubicin-
sensitive MCF-7 and BT474 cell lines whereas this localisation shifted to the nucleus in 
doxorubicin-resistant MCF-7 DoxR and MDA-MB-231 cells (Figure 8B). This result further 
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indicates that nuclear FOXO3a localisation could be associated with the development of 
cytotoxic drug-resistance. 
 
 
Figure 7. Expression of total and phosphorylated AKT and FOXO3a in a panel of 
tamoxifen and/or doxorubicin sensitive and resistant breast carcinoma cell lines. 
A) The tamoxifen sensitive MCF-7 (LCC1), and resistant LCC2, LCC9, R27 and BT474 cells as well 
as the B) doxorubicin sensitive MCF-7 and resistant MCF-7-DoxR and MDA-MB-231 cells were 
cultured in normal growth medium and used for western blot analysis for P-AKT (S473), total AKT, 
P-FOXO3a (T32), total FOXO3a and Tubulin. 
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Figure 8. Subcellular location of FOXO3a in a panel of tamoxifen and/or doxorubicin 
sensitive and resistant breast carcinoma cell lines. 
A) Cytoplasmic and nuclear protein lysates were prepared and protein expression levels were 
analysed by Western blotting using specific antibodies against against FOXO3a, Lamin B and 
Tubulin. B) Cells were stained for FOXO3a with ALEX488 (green). DAPI (blue) were also applied to 
visualise the nuclei. 
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3.3.3 Doxorubicin induces FOXO3a nuclear relocation in drug-sensitive cells 
To explore the potential role of FOXO3a in drug response and resistance, I assessed 
FOXO3a expression in the cytoplasmic and nuclear fractions of the sensitive MCF-7 and 
the resistant MCF-7 DoxR and MDA-MB-231 cells. Cell extracts were analysed by Western 
blot following doxorubicin treatment over a 24 h timecourse. Tubulin and Lamin B were 
probed as controls for effective nuclear and cytoplasmic fractionation. As shown in Figure 
9. Doxorubicin treatment causes a nuclear relocation of FOXO3a expression.FOXO3a 
expression levels increased in the nucleus, and this was accompanied by a reciprocal 
decrease in levels in the cytoplasm in the sensitive cells, 12 and 24 h following doxorubicin 
treatment (Figure 9. Doxorubicin treatment causes a nuclear relocation of FOXO3a 
expression.A). In contrast, FOXO3a expression levels remained unchanged in both the 
cytoplasmic and nuclear fractions of the resistant MCF-7 DoxR and MDA-MB-231 cells in 
response to doxorubicin. Notably, FOXO3a nuclear accumulation was more pronounced in 
MCF-7 DoxR than in MDA-MB-231. 
Again, to support my subcellular fractionation results, I performed immunofluorescence to 
determine the subcellular distribution of FOXO3a in both doxorubicin-sensitive and the 
drug-resistant cells in the absence or presence of doxorubicin for 16 h (Figure 9B). 
Consistent with the results in Figure 5A, FOXO3a relocated to the nucleus in the 
doxorubicin-sensitive MCF-7 cells following doxorubicin treatment, while in the 
doxorubicin-resistant cells FOXO3a subcellular distribution remained largely unchanged 
even upon doxorubicin treatment (Figure 9B).  
Together these results suggest that doxorubicin causes FOXO3a to relocate to the nuclear 
compartment in the drug-sensitive breast cancer cells and confirmed my previous data in 
Figure 8A, that FOXO3a expression is predominantly nuclear in the resistant cells.  
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Figure 9. Doxorubicin treatment causes a nuclear relocation of FOXO3a expression. 
The doxorubicin sensitive MCF-7 and resistant MCF-7-DoxR and MDA-MB-231 cells were treated 
with 1μmol/L doxorubicin. A) Cytoplasmic and nuclear protein lysates were prepared at the times 
indicated after doxorubicin treatment and protein expression levels were analysed by Western 
blotting using specific antibodies against FOXO3a, Lamin B and Tubulin.  B) The cells were 
cultured in four-well chamber culture slides and treated for 16 h with or without 1μmol/L doxorubicin, 
before being fixed in 4% formaldehyde. FOXO3a expression was visualised with a specific antibody 
against FOXO3a followed by the addition of ALEX488 (green) labeled anti-rabbit antisera. DAPI 
(blue) was also applied to visualise the nuclei. 
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Figure 9. Continued. 
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3.3.4 Ectopic FOXO3a expression results in proliferative arrest and enhances AKT 
phosphorylation in cytotoxic drug sensitive cells 
To determine the role of FOXO3a in drug response, I investigated the effects of the 
overexpression of FOXO3a in the drug sensitive MCF-7 cell line. To this end, I transiently 
transfected MCF-7 cells with empty vector (pcDNA3) or an expression vector encoding a 
constitutively active FOXO3a(A3), in which all three AKT-phosphorylation sites were 
mutated to alanine. FOXO3a overexpression was confirmed by Western blot and RT-
qPCR results (Figure 10A & 10B). The results also showed that FOXO3a overexpression 
resulted in enhanced AKT phosphorylation without altering total AKT expression levels. 
This is consistent with a previous report from our laboratory, where FOXO3a was shown to 
engage in a negative feedback mechanism to increase PI3K/AKT activity through induction 
of PIK3CA gene in leukaemic cells (Hui et al 2008b). Furthermore, this result also supports 
the notion that FOXO3a enhances the expression of PIK3CA transcriptionally (Figure 
10B). I also examined the effect of overexpressing FOXO3a on cell proliferation in MCF-7 
cells by SRB assay. FOXO3a overexpressing cells displayed an attenuated cell 
proliferation, indicating that doxorubicin inhibition of cell proliferation is at least in part 
FOXO3a-mediated in the cytotoxic chemotherapeutic resistant breast cancer cells (Figure 
10C). 
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Figure 10. Overexpressed active FOXO3a results in cell proliferation arrest and AKT 
phosphorylation in drug-sensitive breast cancer cell line MCF-7. 
MCF-7 cells were transiently transfected with the constitutively active FOXO3a(A3) or control 
vector. A) Western blot analysis for FOXO3a, P-AKT (S473), AKT and Actin. B) The transfected 
cells were also examined by RT-qPCR analysis for FOXO3a and PIK3CA mRNA expression. TBP 
mRNA was used as an internal control. C) SRB assays were performed on these transfected cells, 
indicating that the ectopic expression of FOXO3a(A3) decreases the cell proliferation rate. 
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In order to confirm the observation that FOXO3a regulates AKT activity, scramble control 
and FOXO3a-specific shRNAs were used to knockdown the expression of the endogenous 
FOXO3a in the doxorubicin-sensitive BT474 cell line which exhibited enhanced PI3K/AKT 
activity as previously shown in Figure 7. The effect of silencing FOXO3a with shRNAs in 
BT474 cells was confirmed at protein level by Western blot analysis (Figure 11A) and 
mRNA level by RT-qPCR (Figure 11B). Importantly, silencing FOXO3a dramatically 
reduced the P-AKT levels (Figure 11A) and induced a reduction in the levels of PIK3CA 
transcripts (Figure 11B).  
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Figure 11. Knockdown of FOXO3a expression decreases AKT phosphorylation and 
PIK3CA mRNA expression.  
BT474 cells were transiently transfected with FOXO3a or control shRNA, and 24 h after transfection 
cells were analysed by A) Western blot using specific antibodies as indicated and by B) RT-qPCR. 
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3.3.5 FOXO3a activation promotes AKT phosphorylation but not proliferative arrest 
in drug-resistant breast cancer cells 
To study the effects of FOXO3a induction and activation in drug-resistant breast cancer 
cells, I made use of a stably transfected MDA-MB-231 cell line with an expression vector 
that encodes for the hormone binding domain of the estrogen receptor (ER) fused to 
FOXO3a(A3), the constitutive active FOXO3a mutant described previously. In these MDA-
MB-231-FOXO3a(A3):ER cells, FOXO3a activity can be conditionally induced by treatment 
with 4-OHT. MDA-MB-231 cells were used as a control. Whole cell lysates as well as 
nuclear extracts were analysed by Western blotting and RT-qPCR (Figure 12A & 12B). 
Treatment of MDA-MB-231-FOXO3a(A3):ER cells with 4-OHT induced the relocation of 
FOXO3a from the cytoplasm to the nucleus fractions. Furthermore, this FOXO3a induction 
and nuclear relocation resulted in enhanced AKT phosphorylation without significantly 
altering its total expression levels and enhanced PIK3CA (p110α) levels. This increase in 
AKT phosphorylation, and thus in PI3K/AKT activity can be attributed to FOXO3a 
induction, as this response was absent in the control MDA-MB-231 cells (Figure 12A). 
Consistent with this, RT-qPCR results further showed that treatment with 4-OHT induced 
the expression of the FOXO3a target genes, PIK3CA and IGFR1 (Figure 12B). The 
nuclear relocation of FOXO3a(A3):ER in response to 4-OHT induction was further 
validated by immunofluorescence staining of ER in MDA-MB-231-FOXO3a(A3):ER cells 
(Figure 13A). The staining results confirmed that following 4-OHT addition 
FOXO3a(A3):ER relocalised from the cytoplasm into the nucleus. I also studied whether 
the induction of FOXO3a affects the cell proliferative rate of the drug-resistant MDA-MB-
231 cell line. Cells were stimulated with 4-OHT for 0, 24 and 48 h and SRB assay 
performed for both MDA-MB-231 and MDA-MB-231-FOXO3a(A3):ER cells. As showed in 
Figure 13B, there were no significant changes in the rate of cell proliferation on these 
MDA-MB-231 cells, suggesting that the anti-proliferative function normally attributed to 
FOXO3a is deregulated in the cytotoxic drug-resistant cells. 
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Figure 12. FOXO3a induces AKT phosphorylation, PIK3CA and IGFR1 gene 
expression in the drug-resistant MDA-MB-231 breast carcinoma cells.  
MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 1µM of 4-OHT for the 
indicated times. A) Total and nuclear extracts were prepared at the times indicated, and the 
expression levels determined for the indicated antibodies by Western blotting. B) mRNA expression 
was analysed for PIK3CA, and IGFR1 using RT-qPCR and normalised with L19 mRNA. All data 
shown represent the averages of data from three experiments, and the error bars show the 
standard deviations.  
92 
 
 
Figure 13. FOXO3a induction does not result in proliferative arrest in the drug 
resistant MDA-MB-231 breast carcinoma cells. 
A) MDA-MB-231-FOXO3a(A3):ER cells were cultured in 4-well chamber slides and treated for 16 h 
with or without 1µM of 4-OHT as in the previous Figure, before being fixed in 4% formaldehyde. 
FOXO3a(A3):ER was visualised with a rabbit polyclonal antibody against ERα followed by the 
addition of ALEX488 (green) labeled anti-rabbit antisera. DAPI (blue) were also applied to visualise 
the nuclei. B) SRB assays were performed on these cytotoxic resistant MDA-MB-231 cells, 
indicating that the induction of FOXO3a(A3) has little effect on the cell proliferation rate of the drug 
resistant breast carcinoma cells. Statistical analysis was done using t-test , P=non-significant. 
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3.3.6 FOXO3a function is deregulated in the drug-resistant breast cancer cells 
To further test and confirm that in drug-resistant cells there is a deregulation of the anti-
proliferative function of FOXO3a, I transiently transfected the doxorubicin-resistant MCF-7 
DoxR cells with either the empty vector or the vector encoding for the constitutively active 
FOXO3a(A3). The cells were then incubated with increasing amounts of doxorubicin 
ranging from 0 to 10µM and cell proliferation was determined by SRB assay for 0, 24 and 
48 h. Overexpression of the active FOXO3a was confirmed at protein level by Western 
blotting (Figure 14A) and did not result in any significant decreases of the cell proliferation 
rate (Figure 14B), indicating that this known anti-proliferative FOXO3a function is 
deregulated in drug-resistant cells. 
To further assess the effects of FOXO3a activation on drug-resistance in breast cancer 
cells, MDA-MB-231-FOXO3a(A3):ER cells were subjected to subcellular fractionation 
following incubation with 4-OHT over a timecourse and the cytosolic and nuclear protein 
fractions were assessed by Western blotting (Figure 15A). The result showed that after 4 h 
of 4-OHT incubation there was an increase in the nuclear levels of FOXO3a accompanied 
by a decrease on its cytoplasmic levels, indicating that FOXO3a activity increased (Figure 
15A). FOXO3a activation also resulted in an increase of AKT activity as revealed by its 
readout, P-FOXO3a (T32) expression which was also increased. It was noticeable that at 
24 and 48 h after FOXO3a(A3):ER induction, there was an accumulation of the 
endogenous levels of FOXO3a which is consistent with the late induction in AKT activity. 
MDA-MB-231-FOXO3a(A3):ER cells were then incubated with both the vehicle (ethanol) or 
4-OHT and treated with a dose titration of doxorubicin for 48 h. The proliferative rate for 
both conditions was determined by SRB assay. As shown in Figure 15B, doxorubicin 
doses ≥ 2µM, elicited a significantly decrease in the proliferation rates of the vehicle-
treated cells in comparison with 4-OHT-treated cells, suggesting that the vehicle-treated 
cells are sensitive to higher doses of doxorubicin. Importantly, the result also showed that 
activation of FOXO3a(A3):ER by 4-OHT protected MDA-MB-231-FOXO3a(A3):ER cells 
against the anti-proliferative effects of higher doxorubicin levels (Figure 13). These data 
(Figure 15A) confirms that FOXO3a function is deregulated in drug-resistant breast cancer 
cells.  
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Figure 14. Overexpressed active FOXO3a has little effect on cell proliferation and 
drug sensitivity of the drug resistant breast cancer cell line MCF-7 DoxR. 
MCF-7 DoxR cells were transiently transfected with the constitutively active FOXO3a(A3) or control 
pcDNA3. A) The transfected cells were analysed by Western blot for FOXO3a and Tubulin 
expression. B) The cells were then treated with 0 to 10µM of doxorubicin for 0, 24, 48 and 72 h and 
SRB assays were performed on these cells after 48 h.  
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Figure 15. Induction of FOXO3a can confer resistance to the MDA-MB-231 cells. 
Cells were treated with 200nM of 4-OHT and collected at 0, 4, 8, 24 and 48 h. A) Cytoplasmic and 
nuclear extracts were prepared and analysed by western blotting for the indicated antibodies. B) 
SRB assays were performed on untreated and 4-OHT-treated cells after 48 h of treatment with 
various concentration of doxorubicin. Statistical analysis was done using t-test. **, P<0.01, 
significant. 
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3.3.7 Nuclear FOXO3a expression in breast cancer tissue is significantly associated 
with lymph node metastasis and poor survival in invasive ductal carcinoma.  
Not many studies have addressed the significance of FOXO3a expression in breast cancer 
patient samples; however, the very few that did produced conflicting results. Hu et al (Hu 
et al 2004) have found that cytoplasmic expression of FOXO3a correlated with 
phosphorylated AKT and associated with poor survival in breast cancer. Yet, another study 
found that nuclear rather than cytoplasmic FOXO3a was significantly associated with 
lymph node metastasis (Jin et al 2004). In order to confirm and validate my in vitro findings 
in breast cancer patient samples and to explore the potential use of the AKT/FOXO3a 
signalling axis as prognostic markers in breast cancer, immunohistochemical staining was 
performed to assess the expression patterns of FOXO3a and P-AKT. The results, 
summarised in Table 2, showed that in tumours the staining of FOXO3a was found 
localised in both nucleus and cytoplasm. Two representative cases, in Figure 16A, show 
the expression patterns of FOXO3a staining in both tumour and non-tumour samples. 
Example of two tumour cases showing corresponding FOXO3a and P-AKT staining 
patterns are shown in Figure 16B. FOXO3a cytoplasmic staining (p<0.0001, Chi-Square 
test) was also significantly associated with P-AKT staining, confirming that the activated P-
AKT negatively regulates FOXO3a and relocates it from the nucleus to cytoplasm in most 
breast cancer samples.  
As the majority of tumour samples are invasive ductal carcinoma, the above parameters 
were re-analysed for cases of invasive ductal carcinomas only. This new analysis showed 
that the nuclear staining of FOXO3a marginally correlated with lymph node positivity 
(p=0.052, Chi-Square test). Furthermore, FOXO3a nuclear staining was also significantly 
associated with shorter survival time (p=0.014, log-rank test) (Figure 17). Interestingly, 
using the comparison scoring system NC or C>N previously described (Hu et al 2004), 
the NC FOXO3a staining of all cases irrespective of histological types was positively 
associated with the P-AKT staining (p=0.039, Chi-square test). This suggests that the 
AKT/FOXO3a signalling axis uncoupling is associated with lymph node metastasis and 
poor survival in invasive ductal carcinoma. Together these data indicate that the function of 
FOXO3a and its control by AKT have been deregulated in breast cancer associated with 
lymph node metastasis and poor survival, and this indicates cancer progression and 
treatment failure, respectively. 
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Table 2. FOXO3a immunoreactivity in all cases. 
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Figure 16. Representative expression patterns of FOXO3a and P-AKT in tissue 
microarray. 
Tumour tissue samples obtained from breast cancer patients that had been formalin-fixed and 
paraffin-embedded were immunohistochemically stained with FOXO3a and P-AKT (T308) 
antibodies. A) Representative FOXO3a staining patterns in both tumour and non-tumour cases. B) 
Two representative tumour cases showing corresponding FOXO3a and P-AKT staining patterns 
(magnification x 170). 
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Figure 17. Survival analysis with nuclear FOXO3a staining in invasive ductal 
carcinoma cases.  
Of the 120 cancer samples assessed, there were 94 cases of invasive ductal carcinoma. The 
correlation between nuclear FOXO3a expression and survival was studied using Kaplan Meier 
analysis (P=0.014) and was considered significant at p<0.05.  
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3.4 DISCUSSION 
Although anti-cancer therapy produces an initial overall reduction in cell proliferation, in the 
long-term there is residual cell cycle progression and survival that suffice to maintain 
tumour growth. There are multiple mechanisms whereby breast cancer cells can bypass 
normal endocrine responsiveness and develop resistance to both endocrine- and chemo-
therapy (Geisler and Lonning 2001). Indeed, it has been shown that signalling pathways 
such as EGFR, HER2, MAPK, HIF-1α and PI3K/AKT are key regulators of cell cycle and 
cell proliferation events that circumvent ER-mediated gene transcription and growth in 
resistant breast cancer cells (Martin et al 2003, Nicholson et al 1999). Yet, the knowledge 
regarding the involvement of these signalling pathways in such processes comes mainly 
from in vitro cell line models, which not always reflect the heterogeneity of breast cancers 
and thus are limited in their clinical relevance. In this chapter, I explored not only the 
impact of the PI3K/AKT/FOXO axis in different resistant cell line breast cancer models but 
I further validated my in vitro results in breast cancer patient samples.  
The PI3K/AKT signalling pathway has already been shown to play a vital role in tamoxifen 
and cytotoxic chemotherapeutic drug-resistance (Campbell et al 2001, DeGraffenried et al 
2003, Faridi et al 2003, Frogne et al 2005). For instance, enhanced AKT activity has been 
reported to promote resistance to tamoxifen and cytotoxic drugs by promoting cell 
proliferation and survival (Clark et al 2002) and to increase resistance to paclitaxel (Page 
et al 2000, VanderWeele et al 2004), further emphasising the importance of 
PI3K/AKT/FOXO pathway in determining drug sensitivity. The downstream AKT negative 
effector, FOXO3a, has been shown to mediate cytotoxic response of chemotherapeutic 
drugs such as anthracyclines (doxorubicin), taxanes (paclitaxel) and cisplatin (Fernandez 
de Mattos et al 2008, Hui et al 2008a, Hui et al 2008b, Krol et al 2007, Kwok et al 2008, 
McGovern et al 2009, Sunters et al 2003, Sunters et al 2006). Not many studies have 
addressed the predictive value of AKT-mediated FOXO3a subcellular localisation. 
However, one of the first reports that investigated this was by Hu et al, who reported that 
FOXO3a is localised mainly in the cytoplasm of breast cancer cells in a study of 113 breast 
cancer cases and that predominant cytoplasmic FOXO3a localisation is inversely 
associated with patient survival (Hu et al 2004). Contrary to these findings, my 
immunohistochemistry results showed that nuclear FOXO3a expression in invasive ductal 
carcinomas is significantly associated with lymph node metastasis (p=0.052) and 
shortened overall survival time (p=0.014). These data also indicate that consistent nuclear 
FOXO3a expression in patient samples is associated with shorter survival time after 
treatment, as most if not all of these patients were treated and monitored after diagnosis. 
Nevertheless, my findings are in keeping with another report showing that predominant 
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nuclear-targeted FOXO3a is significantly correlated with lymph node metastasis in invasive 
ductal breast carcinoma (Jin et al 2004). Furthermore, using the same scoring system as 
that of Hu et al (Hu et al 2004), I found that cases with higher nuclear to cytoplasmic 
FOXO3a expression ratio are also positively associated with P-AKT expression (p=0.039, 
Chi-square test). Consistent with this, predominant nuclear expression of FOXO3a has 
also been shown to correlate with enhanced PI3K/AKT activity and acquisition of 
chemoresistance in chronic myeloid leukaemia (CML) cell lines (Hui et al 2008a, Hui et al 
2008b).  
In this chapter, I investigated FOXO3a subcellular localisation in a panel of endocrine and 
cytotoxic chemotherapy resistant and sensitive breast cancer cell lines in order to establish 
the significance of my findings in vivo and to test the hypothesis that active FOXO3a is 
associated with resistance to chemotherapy. Similar to that observed in doxorubicin-
resistant CML cell lines (Hui et al 2008a, Hui et al 2008b), my tissue culture models 
showed enhanced basal phosphorylated AKT in tamoxifen-resistant cell lines compared 
with the parental sensitive cell line MCF-7. Interestingly, high levels of nuclear FOXO3a 
were only detected in doxorubicin (e.g. MCF-7 DoxR and MDA-MB-231) but not tamoxifen 
(e.g. LCC2, LCC9 and BT474) resistant breast cancer cell lines. After breast cancer 
patients develop resistance to the first line agent tamoxifen, other endocrine therapeutic 
(e.g. fulvestrant and aromatase inhibitors, including anastrozole, letrozole and 
exemestane) alternatives are available. In fact, approximately 30% of ERα positive breast 
patients do not respond to tamoxifen treatment, which is defined as de novo resistance. 
Furthermore, the majority of tumours that initially respond to tamoxifen treatment will 
acquire resistance over time even with maintained ERα expression (Riggins et al 2005a, 
Riggins et al 2005b). However, these endocrine resistant tumours still respond, at least 
initially, to cytotoxic chemotherapy regimens. Consistent with this notion, all the tamoxifen-
resistant cell models tested in this chapter, including LCC2, LCC9, BT474, are sensitive to 
doxorubicin treatment, whereas the doxorubicin resistant MCF-7 DoxR and MDA-MB-231, 
are not sensitive to tamoxifen. Notably, the MDA-MB-231 cells are also resistant to 
paclitaxel treatment (Sunters et al 2003, Sunters et al 2006). Although these cell line 
models cannot extrapolate into breast cancer types in the clinic, it is reasonable to think 
that, these tamoxifen-resistant breast cancer cells may model breast cancers that have 
failed endocrine therapy but remain sensitive to cytotoxic drug-based treatments, while the 
resistant cells may represent breast cancers that have progressed and become resistant to 
anthracyclines and taxanes. In fact, these advanced drug-resistant breast cancers could 
be thought as metastatic disease to which treatment options are extremely limited. The 
cytotoxic chemotherapeutic resistant cell lines and the invasive ductal breast carcinoma 
have numerous significant overlapping clinical and pathological features. In here, I showed 
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that they at least share a common molecular phenotype of sustained nuclear FOXO3a 
expression. Taken together my data from the cell culture models support and explain the 
immunocytochemistry findings that in advanced breast cancers FOXO3a is predominantly 
nuclear localised despite the presence of phosphorylated AKT. This also provides in vitro 
evidence suggesting sustained nuclear FOXO3a expression predicts poor survival and 
chemotherapy resistance.  
My in vitro data confirmed that overexpression of active FOXO3a(A3) in both MCF-7 
and MDA-MB-231 could indeed enhance AKT activity, supporting the feedback 
mechanism via the PI3K/AKT pathway. Yet, overexpression of the active FOXO3a(A3) can 
efficiently inhibit cell proliferation in the chemosensitive breast cancer MCF-7 but has little 
effect in the resistant MDA-MB-231 cells. Two of the very best characterised FOXO3a 
targets - p27Kip1 and Bim – have also been shown to be induced by FOXO3a in MCF-7 
breast cancer cells which resulted in an induction of proliferation arrest and apoptosis, 
respectively. In line with this, I have also shown that doxorubicin treatment of the sensitive 
MCF-7 cells also resulted in re-localisation of FOXO3a to the nucleus. Thus, the enhanced 
P-AKT expression resulting from FOXO3a induction in MCF-7 was insufficient to 
counteract the action of activated FOXO3a, resulting in an overall decrease in cell viability. 
However, in the chemoresistant cell line MDA-MB-231, the cells may have already 
adopted as yet unknown mechanisms to avoid the anti-proliferative effects of activated 
FOXO3a, remaining unresponsive to cell cycle arrest and apoptosis under drug treatment. 
It is important to note that the two chemoresistant cell lines used in my in vitro experiments 
– MCF-7 DoxR and MDA-MB-231 – may represent two different stages in the 
chemoresistance process in respect of FOXO3a activation and localisation. MDA-MB-231 
cells are already long-term intrinsic resistant cell lines whereas MCF-7 DoxR resistance 
reflects the process of acquired resistance by exposure to increasing amounts of the drug. 
This could help explain that despite both cell lines showing higher FOXO3a nuclear 
accumulation, upon treatment with doxorubicin the nuclear accumulation of FOXO3a in the 
nucleus is more pronounced in MCF-7 DoxR than in MDA-MB-231 cells. The fact that 
MDA-MB-231 are also ER and HER-2 negative cell lines draws a resemblance to the 
TNBC that are unresponsive to almost all available therapeutic drugs. Although this was 
not explored in this chapter, it would be relevant to further study the different mechanisms 
regulating FOXO3a expression in these two cell lines. It could be that in these cell lines 
that model intrinsic and acquired resistance, FOXO3a is targeted by different post-
translational modifications. The sustained nuclear localisation of FOXO3a may also 
contribute to the increased PI3K/AKT activity observed in the chemoresistant breast 
cancer cells. Treatment of MDA-MB-231-FOXO3a(A3):ER cells but not the MDA-MB-231 
with 4-OHT was sufficient to induce P-AKT expression, suggesting that the increase in 
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FOXO3a activity is causative for the induction of PI3K/AKT activity. Moreover, induction of 
FOXO3a activity also resulted in the induction of expression of PIK3CA and IGFR1, two 
key components of the PI3K/AKT signalling pathway. The increase in expression levels of 
PIK3CA and IGFR1 as well as other components of PI3K/AKT signalling pathway by 
FOXO3a may be sufficient for the induction of AKT phosphorylation and activity if their 
expression levels are limiting in these breast cancer cells. FOXO3a activity is likely to be 
deregulated in both the invasive ductal breast carcinoma associated with poor survival, as 
well as the anthracycline-resistant breast cancer cell lines as in both cell-types nuclear-
localised FOXO3a failed to elicit its anti-proliferative effects. Consistently, induction of 
FOXO3a activity and nuclear localisation using 4-OHT in the drug-resistant MDA-MB-231-
FOXO3a(A3):ER cells did not have an appreciable effects on the cell proliferation. The 
molecular basis for this is unclear but can be due to post-translational modifications and/or 
differential recruitment of co-factors. Nevertheless, sustained nuclear localisation of 
FOXO3a may be a crucial molecular marker for chemotherapy resistance and poor 
prognosis in breast cancer. Together these data suggest that lymph node metastasis and 
poor survival in invasive ductal breast carcinoma are linked to an uncouping of the 
AKT/FOXO3a signalling axis, as in these breast cancers active AKT fails to inactivate and 
re-localise FOXO3a to the cytoplasm and that nuclear-targeted FOXO3a does not induce 
cell death or cell cycle arrest. 
In summary, sustained nuclear FOXO3a expression in breast cancer may culminate in 
cancer progression and the development of an aggressive phenotype similar to that 
observed in cytotoxic chemotherapy resistant breast cancer cell models and, can 
significantly attenuate their response to tamoxifen and cytotoxic chemotherapy. Studying 
the expression profiles of the components of the AKT/FOXO3a axis, in breast cancer 
patients might help predict and monitor their response to chemotherapy. A better 
understanding of the mechanism by which AKT and FOXO3a are regulated, as well as 
their roles in cancer progression, drug sensitivity and resistance, may turn these proteins 
into crucial therapeutic targets and prognostic markers for breast cancer and other 
malignancies. 
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CHAPTER 4 
NEW POTENTIAL FOXO3A TARGETS 
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4.1 INTRODUCTION  
Over the past years, a plethora of studies have demonstrated that FOXO proteins play 
critical roles in a wide variety of cellular processes. Identification of their target genes will 
help unravel their functional outcome in these cellular processes. FOXOs regulate multiple 
genes such as, Bim and FasL, involved in apoptosis (Brunet et al 1999, Dijkers et al 
2000a); p27Kip1 and Cyclin D, essential for the cell cycle regulation (Dijkers et al 2000b, 
Schmidt et al 2002); B-cell lymphocytic leukaemia proto-oncogene 6 (Bcl-6), indispensable 
for the integrity of mitochondrial outer membrane (Tang et al 2002); GADD45a, important 
for DNA damage repair (Tran et al 2002) and manganese superoxide dismutase (MnSOD 
or SOD2), involved in stress responses (Kops et al 2002a). FOXO3a is a transcription 
factor that impacts in almost all different cell functions. However, the full extent of FOXO3a 
functions are yet to be understood. For this reason, it is imperative to further identify and 
characterise new putative FOXO3a targets that can reveal more information regarding its 
downstream roles. Some of the potential new targets are, JAK2, CXCR4, APOBEC3G, 
and FOXP1. 
 
4.1.1 JAK2 
JAK2 is a member of a tyrosine kinase family of proteins with an essential role in 
haematopoietic growth factors signalling pathways promoting cell growth, proliferation and 
differentiation (De Laurentiis et al 2008). Indeed, Jak2 knockout mice exhibit a lethal 
phenotype, which has been attributed to a block in definitive erythropoiesis (Vasileiadis et 
al 2011). The most common somatic alteration of JAK2 is a gain-of-function mutation 
(JAK2 V617F) that results in a constitutively active JAK2 protein which mediate oncogenic 
transformation in a wide array of myeloproliferative disorders (Fromantin et al 2011, 
Milman et al 2011, Petoukhova et al 2011). Furthermore, JAK2 is also involved in 
chromosomal translocations with the TEL gene, generating a constitutively active fusion 
gene TEL-Jak2 in lymphomas. However, in other malignancies including, colon, breast, 
and lung cancers, JAK2 amplification or mutations have not been found yet (Ho et al 
2011). Following the binding of cytokines, JAKs associate with the intracellular tails of 
cytokine receptors and activate members of the signal transducer and activator of 
transcription (STAT) family of transcription factors; STATs translocate into the nucleus, 
acting as transcriptional activators (Bao et al 2011). As a result of its activation, JAK2 
recruits STAT proteins, including STAT5, which translocate into the nucleus where they 
regulate expression of target genes that include Bcl-X, Mcl-1 and Cyclin D1/2, associated 
with survival and proliferation in CML cells (Brennan et al 2007, Gajalakshmi and Peto 
2007, Lewington et al 2007, Peto et al 2007). Moreover, constitutively active Jak2/Stat5 
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fusion protein was shown to be sufficient to induce neoplastic transformation of mammary 
epithelial cells in vivo (Giezen et al 2011).  
 
4.1.2 CXCR4 
Chemokines are expressed in various cell types and tissues and have a central role in the 
development and maintenance of the immune and hematopoietic systems (Go and Pollard 
2008). Stromal cell-derived factor-1 (SDF-1), also known as CXCL12, is a homeostatic 
chemokine highly expressed by bone marrow stromal cells (Pollard 2008). SDF-1 binds to 
a G-protein coupled seven-span transmembrane receptor (GPCR) - CXCR4 (Petersen et 
al 2008). Chemokines were initially identified as being constitutively expressed within 
lymphoid organs. These chemokines and their receptors were found to play an important 
role in the homing of leukocytes to sites of inflammation (Kirshbom et al 1999). Similarly, in 
non-haematopoietic neoplasias, chemokines were also found to be constitutively 
expressed. Functionally active CXCR4 receptors mediate cell migration and survival in 
vitro of cancer cells, including those of colorectal cancer (Unger 1999), prostate cancer 
(Min et al 1999) and melanoma (Lajtai et al 1999). The CXCL12/CXCR4 ligand/receptor 
pair is critical in bone marrow hematopoiesis and plays important roles in vascularisation 
and in heart and brain development. Thus, both CXCR4 and CXCL12 knockouts are 
embryonic lethal (Cully et al 2006, Huang et al 1999). Breast cancer metastasis typically 
involves spread of tumour to regional lymph nodes, lung, liver, and bone marrow. Stromal 
fibroblasts within these tissues were found to have higher expression of CXCR4 ligand, 
CXCL12 (Bianco et al 2006, Fresno Vara et al 2004). Contrary to normal breast tissues, 
breast cancer cells were shown to specifically express functionally CXCR4 receptors that 
direct chemotaxis and invasiveness. Blockage of CXCR4 with anti-CXCR4 monoclonal 
antibodies inhibited the metastatic spread to target organs in vivo (Fresno Vara et al 2004). 
Furthermore, high CXCR4 expression was found to be associated with poor overall 
survival in breast cancer patients (Neri et al 2002b). These findings suggest that CXCL12 
and its receptor CXCR4 play a crucial role in breast cancer metastasis. Moreover, CXCR4 
has also been shown to be involved in the metastasis of prostate cancer to the bone 
marrow (Taichman et al., 2002) and of colon cancer to the liver (Zeelenberg et al., 2003). 
The involvement of the CXCL12/CXCR4 axis in chemotaxis, tumour progression, 
metastasis and survival is mediated by activation of different signalling pathways including 
the PI3K (Fukami et al 2004) and the JAK/STAT cascades (Ii et al 2004). 
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4.1.3 APOBEC3G 
Apolipoprotein B mRNA-editing complex (APOBEC) constitutes a superfamily of cytidine 
deaminases which converts cytosine to uracil and includes 11 enzymes that edit RNA or 
single-stranded DNA (Lopes Ferreira et al 2006). This family of cytidine deaminases have 
been extensively studied for their important roles in the adaptive and innate immune 
systems (Vanchiere et al 2005). The different family members have diverse cellular 
functions. APOBEC1 plays a role in mRNA editing (Costanzo et al 2001), activation-
induced deaminase (AID) is required for antigen-specific antibodies (Greer and Shannon 
2005, Ren et al 2006) and APOBEC3 (A-H), especially APOBEC-3G and -3F, regulate 
innate immunity by protecting cells against important viral pathogens, including human 
immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) (Greer et al 2006, 
Wagner et al 2006, Wu et al 2005). The function of APOBEC2 and APOBEC4 remains 
unknown. APOBEC3G (A3G) has been found to block the replication of a specific HIV-1 
strain. This strain lacks its viral infectivity factor (Vif) protein. However, when Vif is present, 
it counteracts A3G by targeting it for proteasomal degradation (Calderwood and Greer 
2005). A3G importance in HIV-1 infection is demonstrated by the fact that its locus is 
screened for genetic variation to predict disease progression in HIV-positive patients 
(Buntain et al 2005). Enzymatic cytidine deamination is one of the sources of DNA 
mutations, which can eventually lead to carcinogenic DNA damage when the repair 
mechanisms fail. Thus, it is conceivable that APOBEC members in general, by their ability 
to generate mutations that are potentially tumorigenic, could have a role towards 
carcinogenesis (Ackerman et al 2005, Egea et al 2005, Zhang et al 2005). So far, there are 
no publications that show APOBEC3G as having a role in carcinogenesis; however, a 
study showed that overexpression of the family related AID resulted in T cell lymphomas in 
mice (Ackerman et al 2005).  
 
4.1.4 FOXP1 
FOXP1 was isolated and characterised in 2001 by Banham et al (Banham et al 2001). It 
shares 93% identity with the mouse homologue (Ensemble data). Interestingly, human 
FOXP1 has also been isolated from different sources by several groups. Shi et al identified 
the same FOXP1 (677 a.a.) as the 85kD MFH1 (Mac-1 regulated forkhead) that is down-
regulated in monocytic THP1 upon adhesion to fibrinogen due to Mac-1 clustering (Shi 
2004). Yamada et al identified the antigen thyroid and eye muscle shared protein G2s 
(55kD) as a fragment of FOXP1 (Yamada et al 2002). The full-length FOXP1 protein (677 
a.a.) contains 2 glutamine rich regions for transactivation, 2 coiled coils, 1 leucine zipper 
and 1 zinc finger domain for dimerisation; 2 NLS around the forkhead domain for nuclear 
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localisation; and an acidic region for ubiquitin-mediated proteolysis. Unlike FOXO, there 
are no AKT phosphorylation sites, but a few potential Cyclin-Cdk, protein kinase C, casein 
kinase and p70S6-kinase phosphorylation sites. Therefore, FOXP1 might be involved in 
cell cycle progression and nuclear factor kappa B (NF-ĸB) signalling. Of interest, two PKC 
and S6Kinase phosphorylation sites are close to the NLS, implying a possible role in 
regulating the subcellular localisation of the protein (Banham et al 2001). FoxP1 represses 
transcription through direct binding to FoxP consensus DNA-binding sequences 
(TTATTTRTRTTKKYKWKTWT, R=G/A, W=A/T, K=T/G, Y= T/C) (Wang 2003). The 
molecular mechanisms by which the transcription factor FOXP1 functions would be better 
understood by the identification of its target genes; however, only few have been identified 
so far. Its targets include the promoters of SV40, IL2 (Wang et al 2003), c-fms (encodes M-
CSF) (Shi 2004), mouse CC10 and human surfactant protein C (Shi 2004, Shu 2001). 
Although direct binding has not been confirmed, in Foxp1 knockout mice, there is 
differential expression of Sox4, p21Cip1 and p27Kip1 mRNA in cardiac tissues (Wang et al 
2004). It also binds to Erag enhancer in proB cells but not thymocytes, to upregulate gene 
expression but not promoter activity (Hu et al 2006). Recently, Foxp1 has also been shown 
to negatively regulate IL-7Rα expression critical for regulation of T cell quiescence and 
homeostasis (Feng et al 2011). Apart from interacting with other FoxP family members, 
FoxP1 has been reported to interact and bind DNA with other transcription factors, 
including the androgen receptor (Takayama et al 2008), and Nfat3 (Bai and Kerppola 
2011). Its interaction with co-repressor proteins has also been shown for SMRT and CtBP1 
(Jepsen et al 2008, Li et al 2004b). So far, there is a lack of information describing post-
translational modifications for FOXP1. However, FOXP1 expression in hepatocellular and 
lung cancer has been shown to be regulated by miR-1 (Datta et al 2008, Nasser et al 
2008). Additionally, miR-34a and miR-9 have also been found to regulate FoxP1 
expression in B cell development and motor neuron specification, respectively (Otaegi et al 
2011, Rao et al 2010). 
 
4.1.4.1 THE ROLE OF FOXP1 IN CANCER 
In humans, FOXP1 has been shown to be expressed in a variety of B cell lymphomas 
including MALT and diffuse large B cell lymphoma (DLBCL). Its strong nuclear expression 
has been noted in both these tumour types, which is associated with poor patient 
prognosis (Banham et al 2001, Banham et al 2005, Barrans et al 2004, Streubel et al 
2005). A recent study also correlates the presence of FOXP1 overexpression, in a 
considerable number of primary cutaneous large B-cell lymphomas (PCLBCL), with 
unfavourable prognosis (Espinet et al 2011). FOXP1 gene is frequently the target of 
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chromosomal translocations in DLBCL and MALT lymphomas (Wlodarska et al 2005). One 
such example is the translocation of t(3;14)(p14.1;q32), which renders the FOXP1 gene 
under the control of the IGH gene enhancer, and has been found to be responsible for 
FOXP1 aberrant expression in some occasions (Streubel et al 2005). This is detected in 
10% of MALT lymphoma outside the stomach (Streubel et al 2005) and in extra nodal 
presentation B cell lymphomas (Haralambieva et al 2006). In these lymphomas, increased 
FOXP1 expression has been suggested to result in the constitutive activation of the NF-ĸB 
pathway (Farinha and Gascoyne 2005). However, not all FOXP1 overexpressing DLBCL 
and MALT cases display FOXP1 gene rearrangements or duplication, suggesting that 
mechanisms other than genetic alterations can upregulate FOXP1 expression (Flossbach 
et al 2011, Haralambieva et al 2006). One possible explanation could come from the 
discovery of 9 alternatively spliced transcripts for the human FOXP1 gene (Brown et al 
2008a, Brown et al 2008b). Most of these truncated isoforms lack the N-terminal coiled-coil 
domain as well as their second poly-glutamine domain that has been shown to correlate 
with transcriptional repressor activity. However, this is not the case for isoform 1, which 
encodes the full-length protein (Brown et al 2008a, Wang et al 2003). These isoforms have 
been found to be significantly increased in follicular lymphoma when compared to the full-
length forms. Thus, these isoforms may inhibit the repressor function of the full-length 
protein on NF-ĸB signalling by competing for binding on target sequences enhancing this 
signalling pathway (Green et al 2009). Moreover, some of these isoforms are also 
overexpressed in primary central nervous system lymphomas (PCNSL), where the FOXP1 
full-length form is downregulated (Courts et al 2009). 
As yet, no clinical significance was found for these isoforms in lymphomagenesis. 
However, it seems likely that FOXP1 isoforms may play a determinant role in human 
malignancy. In a variety of B cell disorders, FOXP1 has been described as a potential 
oncogene due to its overexpression and subsequently poor prognosis predictor risk. 
However, FOXP1 has also been proposed to act as a tumour suppressor gene in solid 
tumours. Indeed, differentially FOXP1 mRNA expression has been confirmed between 
normal tissue and tumours in breast, prostate, pancreatic, colon and stomach, lung, head 
and neck squamous cell carcinomas as well as early endometrial adenocarcinomas. 
FOXP1 alterations in solid tumours are generally the result of a complete loss of 
expression or nuclear to cytoplasmic relocation (Banham et al 2001, Banham et al 2005, 
Giatromanolaki et al 2006). FOXP1 location on chromosome 3p14.1 maps to a locus, 
which is often disrupted and displays loss of heterozygosity (LOH) in a range of solid 
tumours. In addition, other tumour suppressor genes including FHIT, MLH1 and VHL 
(Banham et al 2001, Kok et al 1997) also reside in this location. Allelic loss at 3p or 3p12-
14 are reported in various pre-malignant solid tumours of breast (Euhus et al 1999, Moinfar 
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et al 2000), cervical (Fouret et al 1998) and lung (Wistuba et al 2000). Recent studies have 
revealed some of the elusive roles of FOXP1 in different human cancers. Patients with 
stage III serous ovarian cancer have downregulated FOXP1 expression (Kim et al 2010). 
In prostate cancer, FOXP1 is commonly associated with TMPRSS2-ERG fusion-positive 
tumours (Taylor et al 2010) and identified as a novel partner to ETV1 (Hermans et al 
2008). Interestingly, FOXP1 protein expression has been found to be associated with 
estrogen receptor alpha (ERα) in MCF-7 cells and with improved prognosis in breast 
tumours. However, its upstream regulation by ERα could not be confirmed. Since FOXP1 
contains a nuclear receptor box LXXLL (a.a. 126-130) at its N-terminus, it is conceivable 
that FOXP1 could be a co-regulator of ERα (Fox et al 2004). Furthermore, a correlation 
between FOXP1 and ERα is also documented in deep myometrium invasion in 
endometrial cancers along with cytoplasmic FOXP1 (Giatromanolaki et al 2006). Similar to 
ERα, FOXP1 is also found to be associated with nuclear but not cytoplasmic ERβ 
expression, and has eventually been established that nuclear ERβ rather than ERα are 
more related to FOXP1 expression (Bates et al 2008). In keeping with a role of FOXP1 as 
a tumour suppressor gene, the expression of FOXP1 has been correlated with survival in 
familial breast cancers. Loss of FOXP1 is associated with a shorter relapse free and 
overall survival (Rayoo et al 2009). As a result of the reported relationship between FOXP1 
with ERα and ERβ, interest has also emerged on the potential association of FOXP1 with 
the androgen receptor (AR). In prostate cancer, nuclear rather than cytoplasmic 
expression of FOXP1 correlates with AR expression (Banham et al 2007). Furthermore, 
FOXP1 is regulated on an androgen-dependent manner in LNCaP cells at both protein and 
transcriptional levels. In addition, FOXP1 has been also shown to directly interact with AR 
in the nucleus and negatively modulate AR transcription (Takayama et al 2008). There are 
still a number of questions to answer regarding the role of FOXP1 role in breast cancer. 
Additionally, to fully understand the function of FOXP1 and its mechanisms of action, it is 
pertinent to identify more of its physiological target genes in the context of cancer 
development. 
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4.2 AIMS & OBJECTIVES 
FOXP1, JAK2, CXCR4 and APOBEC3G have been proposed to be potential FOXO3a 
targets. These putative targets were identified in two DNA microarrays using 
overexpressed constitutive active FOXO3a in human colon carcinoma cell lines (Delpuech 
et al 2007). Little is known about the regulation and significance of these proteins in breast 
cancer. The aim of this chapter is therefore to investigate the regulation of these proteins 
by FOXO3a and their potential involvement in FOXO3a-mediated chemoresistance in 
breast cancer. 
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4.3 RESULTS 
4.3.1 FOXO3a and its targets expression in a panel of breast cancer cell lines 
To address whether FOXO3a expression correlates with FOXP1, APOBEC3G (A3G), 
CXCR4 and JAK2, I decided to build a cell panel with most of the breast cancer cell lines 
available in the laboratory. MCF-10A is a non-malignant human mammary epithelial cell 
line and was used as a non-tumour control. Western blotting analysis (Figure 18A) showed 
that, in general, FOXO3a was expressed in all cell lines investigated, although there was a 
large amount of heterogeneity amongst the cell lines. The levels of inactive phosphorylated 
FOXO3a vary between cell lines, with the highest in BT474 and MDA-MB-468. In general 
the results showed that, APOBEC3G, CXCR4 and JAK2 proteins were expressed 
throughout the whole cell panel. HBL-100, ZR751, ZR7530, CAMA1 and MDA-MB-453 
exhibited higher levels of A3G expression; CXCR4 was broadly expressed in all cell lines, 
whereas JAK2 expression was not detected in MCF-7, BT474 and T47D cell lines. This 
could indicate a negative correlation between JAK2 and ERα, as JAK2 expression was 
only found in ERα negative cell lines. In line with this, a study showed a negative 
correlation between P-JAK1 and ER status in breast cancer tissues (Yeh et al 2007). 
Furthermore, the in vitro results confirmed that the expression levels of P-JAK1 are 
inversely correlated with the ER presence in breast cancer cell lines (Yeh et al 2007). 
Despite a great heterogeneity between cell lines, a negative correlation between the 
inactive phosphorylated FOXO3a, and A3G, CXCR4 and JAK2 expression levels was 
noted. For example, in BT474 and MDA-MB-468 cells, phosphorylated FOXO3a correlated 
with lower levels for A3G, CXCR4 and JAK2. Conversely, HBL-100 and ZR751 cell lines, 
which displayed higher FOXO3a activity, assessed by the lower levels of P-FOXO3a 
(T32), had higher levels of all three proteins - A3G, CXCR4 and JAK2 (Figure 18A). 
Analysis of the transcript levels of JAK2 and CXCR4 also reflected the great heterogeneity 
between these cell lines and no obvious correlation can be drawn from this result. 
However, CXCR4 mRNA levels were lower when compared to JAK2 mRNA levels 
throughout the cell panel (Figure 18A). FOXP1 expression levels negatively correlated with 
P-FOXO3a levels for the majority of cell lines. For example, MCF-10A and MDA-MB-468 
expressed high levels of P-FOXO3a (T32) and lower levels of FOXP1, whereas HBL-100, 
ZR751, ZR7530 and CAMA-1 expressed lower levels of P-FOXO3a (T32) and higher 
levels of FOXP1. However, it is notable that BT474 and MDA-MB-231 expressed high 
levels of P-FOXO3a (T32) and high levels of FOXP1. The reason for this is not 
understood. Yet, in BT474 the higher expression of FOXP1 may be related to a strong 
ERα expression as ERα expression has been reported to have a correlation with FOXP1 in 
a previous study (Fox et al 2004). I also examined the transcript levels of both FOXO3a 
113 
 
and FOXP1 to assess whether they are regulated at the transcriptional level (Figure 18B). 
Study of the FOXO3a transcript levels showed that the non-cancerous cell line, MCF-10A 
exhibited higher levels of FOXO3a when compared to all other breast cancer cell lines in 
accordance of the tumour suppressor role of FOXO3a. FOXP1 transcript levels correlated 
well with its protein expression. In fact, there was a good correlation between FOXO3a 
activity, as revealed by the lack of P-FOXO3a (T32), and FOXP1 transcript levels. 
Together, these results suggest that, all the target proteins studied are in general 
expressed in breast cancer cell lines and notably that, FOXP1 expression correlates with 
FOXO3a activity in breast cancer.  
 
 
 
Figure 18. The expression of FOXO3a and its potential targets in breast cell panel.  
Whole cell lysates were prepared from the panel of breast cancer cell lines. A) The expression of 
the indicated proteins was analysed by Western blotting. Tubulin was used as a loading control. B) 
The mRNA levels of FOXO3a, FOXP1, JAK2 and CXCR4 were determined by RT-qPCR and 
normalised to the level of L19. 
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Figure 18. Continued. 
  
115 
 
4.3.2 Effect of FOXO3a induction and activation on its targets 
To further study the effect of FOXO3a induction on FOXP1, A3G, CXCR4, and JAK2 
expression levels, I used a stably transfected MDA-MB-231 cell line with an expression 
vector that encodes for the hormone binding domain of the estrogen receptor (ER) fused to 
FOXO3a(A3), a constitutive active FOXO3a mutant. In these MDA-MB-231-
FOXO3a(A3):ER cells, FOXO3a activity can be induced by treatment with 4-OHT. In these 
experiments MDA-MB-231 cells were used as a control. Both MDA-MB-231 cells and 
MDA-MB-231-FOXO3a(A3):ER stably transfected cells were treated with increasing 
amounts of 4-OHT, ranging from 0-100nM, for 24 h. Protein expression was determined by 
western blotting for FOXO3a, FOXP1, A3G, CXCR4, JAK2, p27Kip1 and Tubulin. 
FOXO3a(A3):ER induction was revealed by a mobility shift to a slower migratory band 
(indicated by the arrow). FOXP1 and CXCR4 expression was enhanced with 4-OHT 
treatment in MDA-MB-231-FOXO3a(A3):ER but not in the control cells. JAK2 levels were 
generally higher in FOXO3a induced cells, whereas A3G expression was abrogated by 
FOXO3a induction (Figure 19A). This result suggests a potential negative regulation of 
A3G by FOXO3a. The increased CXCR4 levels in MDA-MB-231-FOXO3a(A3):ER cells 
were also found to be significantly higher at the transcriptional level compared to MDA-MB-
231 cells (Figure 19B).  
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Figure 19. FOXO3a inducible system dose titration in breast cancer cells. 
MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with increasing amounts of 4-
OHT, ranging from 10-100nM, for 24 h. A) Expression levels of FOXO3a, FOXP1, APOBEC3G, 
CXCR4, JAK2, p27Kip1 and Tubulin were assessed by Western blotting. B) RT-pPCR was 
performed for CXCR4 transcript levels. L19 was used to normalised the mRNA levels. Error bars 
show the standard deviations. Statistical analysis was done using t-test. **, P<0.01, significant. 
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Next, I investigated the effect of the activation of FOXO3a over a timecourse of 0, 4, 8, 24 
and 48 h following addition of 4-OHT. Induction of FOXO3a was confirmed at protein level 
after 24 h by the increased levels of FOXO3a(A3):ER and P-FOXO3a (T32), respectively. 
FOXP1, CXCR4 and JAK2 expression levels were induced in MDA-MB-231-
FOXO3a(A3):ER, reaching a maximum level at 48 h, similarly to what was observed for 
FOXO3a. Moreover, the known FOXO3a downstream target, p27Kip1, was also increased 
after 24 h (Figure 20). Consistent with the previous result in Figure 19A, there was a 
marked decrease of A3G expression in MDA-MB-231-FOXO3a(A3):ER when compared to 
the control MDA-MB-231 cells, further confirming the idea that A3G is negatively regulated 
by FOXO3a. At transcriptional level, neither JAK2 nor CXCR4 transcript levels were 
increased in MDA-MB-231-FOXO3a(A3):ER. In fact, a decrease in CXCR4 mRNA levels 
was noted (Figure 20B). 
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Figure 20. FOXO3a induces some targets in a timecourse manner. 
MDA-MB-231 untransfected and FOXO3a(A3):ER transfected were treated at 1µM of 4-OHT for the 
indicated times. A) Western blotting was performed to assess the protein changes of FOXO3a and 
the targets throughout the timecourse for the indicated antibodies. B) RT-qPCR was performed to 
measure the transcript levels of JAK2 and CXCR4 using L19 to normalise the mRNA.  
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4.3.3 FOXO3a induces FOXP1 expression  
In order to examine the nuclear and cytoplasmic localisation of FOXO3a and its putative 
targets, I performed subcellular fractionation with the MDA-MB-231 and MDA-MB-231-
FOXO3a(A3):ER cells. The western blot results showed that, upon 4-OHT addition, 
FOXO3a(A3):ER accumulated in the nuclear compartment in MDA-MB-231-
FOXO3a(A3):ER cells. Importantly, FOXO3a nuclear accumulation resulted in an 
upregulation of both FOXP1 and p27Kip1 expression levels. This upregulation of FOXP1 and 
p27Kip1 was specifically mediated by FOXO3a as no such effect was observed in the MDA-
MB-231 control cells. No substantial difference was noted for CXCR4 and JAK2 levels 
after FOXO3a induction. The result also indicated that, JAK2 nuclear expression was 
increased in MDA-MB-231-FOXO3a(A3):ER cells after 4-OHT induction (Figure 21). This 
increase could reflect nuclear/cytoplasmic cross contamination as a result of ineffective 
fractionation as confirmed by the presence of tubulin expression in this set of nuclear 
extracts. Notably, A3G expression showed the same pattern of negative correlation upon 
FOXO3a induction in MDA-MB 231-FOXO3a(A3):ER cells (Figure 21). This result further 
suggests that FOXP1 expression is regulated by FOXO3a in MDA-MB-231-
FOXO3a(A3):ER cells.  
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Figure 21. Subcellular localisation of FOXO3a in MDA-MB 231 cells. 
Control and FOXO3a(A3):ER transfected MDA-MB-231 cells were treated in the absence or 
presence of 1µM of 4-OHT for the indicated times. Subcellular fractionation was performed and 
subsequent protein analysis was performed by western blotting. Tubulin and Lamin B were used as 
loading controls for cytoplasmic and nuclear fractions, respectively. 
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4.3.4 Impact of silencing FOXO3a on the targets 
To address the effect of silencing FOXO3a on its potential targets, MCF-7 cells were 
untransfected or transfected with a non-specific (NSC) or a FOXO3a-specific siRNA pool. 
Since NSC siRNA treatment also resulted in the knockdown of FOXO3a in this cell line, I 
compared the effect of Mock transfection with FOXO3a siRNA transfected cells. The 
results showed that FOXP1, JAK2 and p27Kip1 levels were markedly decreased following 
silencing of FOXO3a. However, neither CXCR4 nor A3G were affected by FOXO3a 
knockdown (Figure 22A). To study the effect of FOXO3a on putative target regulation in a 
FOXO null background, I used the wild-type (WT) and Foxo1/3/4 null mouse embryonic 
fibroblasts (MEFs). The expression levels of Foxo1, Foxo3a, Foxo4, Foxp1, A3g, Cxcr4, 
Jak2, p27Kip1, and Tubulin were assessed by western blotting. As expected, the expression 
of Foxo1, -3a and -4 was absent in the Foxo1/3/4 null MEFs. Consistently, CXCR4 levels 
were abolished in Foxo1/3/4-/- cells. However, A3G and JAK2 expression were not 
differentially expressed between WT and Foxo1/3/4-/- MEFs (Figure 22B). The results also 
showed that in Foxo1/3/4-/- cells both p27Kip1 and FOXP1 expression levels were markedly 
reduced. This effect was not observed in WT MEFs and so it was fully attributed to the 
absence of FOXO isoforms in these cells further confirming that the potential newly 
identified FOXP1 transcription factor is indeed a target of FOXO transcription factors. This 
regulation by FOXO was also confirmed at transcriptional level as demonstrated in Figure 
22. Similar to Foxo3a, both p27Kip1 and Foxp1 mRNA levels were significantly reduced in 
comparison to WT cells, suggesting that the regulation of FOXP1 by FOXO3a is at both 
protein and transcriptional levels (Figure 22C).  
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Figure 22. FOXO3a silencing in MCF-7 cells and Foxo1/3/4-/- MEFs confirm 
downregulation of FOXO targets. 
A) MCF-7 cells were transfected with a FOXO3a specific siRNA, NSC and Mock. Western blot 
analysis confirmed knockdown of endogenous of FOXO3a. The expression levels of FOXP1, 
APOBEC3G (A3G), CXCR4, JAK2, p27Kip1 and Tubulin were also assessed. B) WT and Foxo1/3/4 
null mouse embryonic fibroblasts cell lysates were collect to assess the expression levels of 
FOXO1, FOXO3a, FOXO4 and the targets mentioned above by western blotting. Tubulin was used 
as a control. C) Cells were collected and total RNA was isolated. Transcript levels of Foxo3a, Foxp1 
and p27Kip1 were analysed by real-time quantitative PCR normalised with mouse L19 mRNA levels. 
Error bars show the standard deviations. Statistical analysis was done using t-test. ***, P≤0.001, 
significant. 
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Figure 22. Continued. 
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To further study the effect of silencing FOXO3a on these targets regulation in other breast 
cancer cell lines, I silenced FOXO3a in BT474 cells. The efficiency of the FOXO3a siRNA 
transfection was confirmed at protein and transcript levels (Figure 23A & B). FOXP1 and 
p27Kip1 expression levels were decreased following FOXO3a knockdown, nevertheless 
A3G and CXCR4 levels were not affected. As previously observed in Figure 18A, JAK2 
was not expressed in BT474 cells (Figure 23A). There was no difference observed for the 
transcript levels of FOXP1 and CXCR4 following FOXO3a silencing (Figure 23B). 
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Figure 23. Effect of FOXO3a silencing in BT474 cells. 
A) A specific FOXO3a and a non-specific siRNA was transfected into BT474 cells. After 24 h, cell 
lysates were collected and protein expression of the indicated antibodies determined by western 
blotting. B) FOXO3a, CXCR4 and FOXP1 mRNA levels were determined by RT-qPCR and 
normalised to L19 levels. Error bars show the standard deviations. Statistical analysis was done 
using t-test. **, P<0.01, significant. 
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4.3.5 FOXO3a regulation of FOXP1 is not confined to breast cancer cells 
To investigate whether the regulation of the target proteins by FOXO3a is a universal 
mechanism and not cell type-dependent, I studied the effect of FOXO3a overexpression in 
a K562 leukaemic cell line. Similarly to MDA-MB-231-FOXO3a(A3):ER cells, these cells 
are stably transfected with an expression vector that encodes the hormone binding domain 
of a mutant ER fused to a constitutive active FOXO3a mutant - FOXO3a(A3). K562:ER 
cells were used as a control. Cell lysates from each cell line were collected and western 
blotting performed. FOXO3a overexpression was confirmed at protein level and this was 
accompanied by increases in FOXP1, JAK2 and p27Kip1 expression levels, whereas 
CXCR4 levels remained unchanged. Consistent with my previous observations, following 
FOXO3a overexpression A3G levels were downregulated in K562 leukaemic cells (Figure 
24). This result further suggests that FOXP1 is a FOXO3a target and this regulation is not 
exclusive to breast cancer cell lines. 
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Figure 24. FOXO3a overexpression regulates its targets. 
Untreated K562 ER and FOXO3a(A3):ER cells were subjected to western blotting for FOXO3a, 
FOXP1, APOBEC3G, CXCR4, JAK2, p27Kip1 and Tubulin.  
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4.3.6 FOXO3a has a role in doxorubicin-mediated resistance in leukaemic cells 
We have previously reported that FOXO3a plays an essential role in mediating doxorubicin 
resistance in leukaemic cell lines (Hui et al 2008b). In line with this, I made use of sensitive 
and resistant K562 and KD30 cell lines, respectively, to examine the protein expression of 
FOXO3a and its potential targets in a chemoresistant context. As expected, FOXO3a 
expression was upregulated in the resistant KD30 cells. Accordingly, FOXP1 and JAK2 
levels were also found to be upregulated. Surprisingly, p27Kip1 levels negatively correlated 
with FOXO3a whereas A3G showed for the first time an increase in its expression (Figure 
25A). A significant increase in JAK2 mRNA levels was also observed. CXCR4 mRNA 
levels were substantially reduced and no significant changes were detected for A3G 
transcripts (Figure 25B).  
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Figure 25. FOXO3a is upregulated in leukemic resistant cells. 
Both sensitive and resistant K562 and KD30, respectively, CML cell lines were analysed for 
FOXO3a and its targets expression. A) Western blotting was performed for the indicated antibodies. 
B) The transcripts levels of JAK2, CXCR4 and A3G were analysed by RT-qPCR. mRNA levels were 
all normalised with L19. Error bars show the standard deviations. Statistical analysis was done 
using t-test. **, P<0.01; , non-significant. 
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4.3.7 FOXO3a is targeted by epirubicin in both WT and epirubicin resistant (EpiR) 
MCF-7 breast cancer cells 
To establish the impact of FOXO3a activation in response to epirubicin treatment, on the 
putative target proteins expression, I analysed both sensitive (WT) and epirubicin-resistant 
(EpiR) MCF-7 breast cancer cell lines. Cells were treated with epirubicin or remained 
untreated for 24 h before harvested for western blotting analysis. In EpiR MCF-7 cells total 
FOXO3a levels were lower although these cells also displayed higher FOXO3a activity as 
seen by the lower levels of P-FOXO3a (T32). Although MCF-7 cells had higher levels of 
total FOXO3a, they also exhibited higher levels of inactive FOXO3a. Nevertheless, in both 
cell lines, following epirubicin treatment there was a notable increase in total FOXO3a 
levels. Upon treatment with epirubicin, FOXP1 and p27Kip1 expression levels increased in 
EpiR but not in WT MCF-7 cells. These proteins were already expressed at high levels in 
WT MCF-7 cells and probably FOXO3a cannot induce them further. Interestingly, A3G, 
JAK2 and to a less extend CXCR4, appeared to be upregulated in EpiR MCF-7 when 
compared to WT MCF-7 cells (Figure 26). This might suggest a role for these proteins in 
epirubicin-mediated resistance independent from FOXO3a. This result indicates that 
epirubicin elicited an increase in FOXO3a expression in both sensitive and resistant breast 
cancer cell lines. Furthermore, both FOXP1 and p27Kip1 displayed the same expression 
pattern as FOXO3a and therefore, FOXP1 is by far the most consistent FOXO3a target. 
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Figure 26. FOXO3a is targeted by epirubicin in sensitive and resistant breast cancer 
cell lines. 
MCF-7 and EpiR cells were treated with or without 1µM of epirubicin for 24 h. Cells were harvested 
and western blotting performed to examine the expression levels for the proteins represented by the 
indicated antibodies. Tubulin served as a control. 
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4.3.8 FOXO3a is targeted by lapatinib in BT474 and SKBR3 cells 
To determine the effects of other anti-cancer drugs, such as lapatinib, on FOXO3a, I 
examined the expression of FOXO3a and its putative targets in lapatinib responsive breast 
cancer cell lines – BT474 and SKBR3. Cells were treated with 1µM of lapatinib for the 
indicated timepoints and western blot analysis performed. Lapatinib treatment caused a 
decrease in the phosphorylation levels of FOXO3a although total FOXO3a levels remained 
relatively constant, suggesting FOXO3a activation. As expected, following FOXO3a 
activation, p27Kip1 levels were also increased. Furthermore, FOXP1 also showed an 
induction in both cell lines, although in SKBR3 cells after 8 h of treatment there was a 
reduction of its levels. A3G expression was decreased after FOXO3a induction, despite an 
increase at 4 h. In SKBR3 cells, A3G expression remained higher up to 24 h when 
compared to BT474 cells, in which A3G expression decreased 8 h after treatment. CXCR4 
levels remained unchanged in both cell lines throughout the timecourse whilst JAK2 
expression, confined solely to SKBR3 cells, appeared to peak at 4 h, after which the level 
remained unchanged (Figure 27A). FOXO3a transcript levels were also upregulated as a 
result of treatment with lapatinib in SKBR3 cells (Figure 27B). Together these results 
further support that FOXO3 is targeted by various anti-cancer drugs and upregulates some 
of its target genes, including FOXP1. 
  
133 
 
 
 
 
Figure 27. FOXO3a is activated by lapatinib in BT474 and SKBR3 cells. 
A) BT474 and SKBR3 cells were incubated with and without 1µM of lapatinib. Cell lysates were 
collected, 24 h after and prepared for western blotting. The expression levels of all the indicated 
antibodies were assessed. B) Total RNA was extracted from SKBR3 cells and FOXO3a mRNA 
levels were determined by RT-qPCR. L19 was used to normalise mRNA levels. 
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4.3.9 BT474 LapR cells express higher FOXO3a levels  
We and others have shown that FOXO3a is a downstream cellular target of both lapatinib 
and gefitinib and that FOXO3a activation results in cell cycle arrest and cell death in 
sensitive breast cancer cells (Hegde et al 2007, Krol et al 2007, Xia et al 2006). Moreover, 
we have previously confirmed the role of FOXO3a in promoting drug-resistance and 
survival through MDR1 activation in leukaemic cells (Hui et al 2008a). As a consequence, I 
hypothesised that FOXO3a also has a role towards lapatinib resistance. To test this idea, I 
generated a lapatinib resistant (LapR) BT474 cell line. BT474 cells were continually 
exposed to increasing concentrations of lapatinib for 8 weeks. After cell proliferation was 
established in the presence of 1µM lapatinib, cells were considered resistant. I then 
determined FOXO3a activity and expression after lapatinib addition in both WT and LapR 
BT474 cells by performing western blot analysis. As predicted, in sensitive WT BT474 
cells, AKT is inactivated following addition of lapatinib, resulting in an increase in FOXO3a 
activity (Figure 28A). Nevertheless, total FOXO3a levels also decreased, probably due to 
degradation as a result of cell death, as indicated by the decrease in tubulin levels after 24 
h of lapatinib treatment. FOXP1 showed once again a similar expression pattern to that of 
FOXO3a. A3G expression was higher when compared to CXCR4 expression, which is 
almost undetectable. The expression levels of p27Kip1 remained relatively unchanged. In 
resistant LapR BT474 cells following lapatinib addition, an increase in levels of 
phosphorylation of FOXO3a were observed, consistent with the enhanced AKT activity. 
Total FOXO3a levels were also increased after lapatinib treatment. Accordingly, FOXP1 
expression levels were also found to be increased in response to lapatinib. p27Kip1 
expression remained relatively unchanged, despite a marginal decrease at 48 h (Figure 
28A). This could be a reflection of the decreased FOXO3a activity in these cells and the 
reason for this is not fully understood. As shown earlier for EpiR resistant cells in Figure 26, 
the expression levels of A3G, CXCR4 and JAK2 were substantially higher in LapR BT474 
resistant cells, suggesting that these targets are involved in common drug-resistance 
mechanisms that are not only restricted to epirubicin. To further confirm the resistance of 
the generated LapR cells to lapatinib, SRB assays were performed to compare cell 
proliferation of LapR with WT BT474 cells over a timecourse in the presence and absence 
of lapatinib. For untreated LapR cells there was a significant increase in the proliferative 
rate compared to WT BT474 cells (Figure 28B). This finding is supported by the decreased 
activity of FOXO3a, which can ultimately favour increased cell proliferation. Yet, when both 
cell lines were treated with lapatinib the difference between proliferative rates was not as 
clear. LapR BT474 cells showed a decreased proliferation up to 48 h that was recovered at 
72 h, whereas WT BT474 cell proliferation was decreased throughout the timecourse 
(Figure 28B). To examine these results further, I also determined the cell viability of both 
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cell lines at 72 h following treatment with a dose titration of lapatinib. LapR BT474 cells 
showed that 1µM of lapatinib was the best concentration to differentiate their degrees of 
resistance. At lower concentrations, although resistant cells had a better advantage they 
still showed an overall decrease in their survival rate. However, at higher lapatinib 
concentrations (1.5µM) both cell lines had their survival rates decreased to a minimum 
(Figure 28C). These data indicate that FOXO3a has a role in lapatinib-mediated resistance 
in BT474 cells. Although in LapR BT474 cells FOXO3a activity is decreased, its total levels 
are substantially increased. Thus, it is reasonable to argue that the net FOXO3a activity is 
better assessed by its bona fide targets, such as p27Kip1 and FOXP1, rather than its 
expression. 
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Figure 28. BT474 LapR cells have higher inactivation of FOXO3a. 
BT474 WT and LapR cells were treated  with and without 1µM of lapatinib for 24, 48 and 72 h. A) 
Cell lysates were collected at 24 and 48 h for subsequent western blot analysis for the indicated 
antibodies. B) Cell proliferation was analysed by SRB assay in the absence or presence of lapatinib 
for the given time points. Results are the mean ±SD of eight replicates. **, P<0.01; ***, P < 0.001. 
C) Cells were treated with a dose titration of lapatinib and cell survival at 72 h analysed by SRB 
assay.  
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Figure 28. Continued. 
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4.3.10 Silencing of FOXO3a does not alter the proliferation of BT474 LapR cells 
To further understand the role of FOXO3a in lapatinib-mediated resistance, the effects of 
lapatinib treatment of resistant LapR BT474 cells following the knockdown of FOXO3a were 
investigated. LapR BT474 cells were untransfected (Mock) or transfected with a NSC or 
FOXO3a specific siRNA. Western blot analysis confirmed the efficient knockdown of 
endogenous FOXO3a (Figure 29A) and the subsequent SRB assays were performed to 
analyse the effects of this knockdown on LapR BT474 cells proliferation in the presence or 
absence of lapatinib (Figure 29B). It is notable, that the transfection itself had an effect in 
the proliferative rates of the cells. This can be demonstrated by the overall positive 
proliferative effect of both NSC and FOXO3a siRNA transfected cells in comparison to 
Mock untransfected cells. As observed in Figure 29B, FOXO3a silencing did not have 
discernable effect on the proliferation of LapR BT474, whereas when FOXO3a siRNA 
transfected cells were compared with Mock there was a marginal increase in the 
proliferative rate of these cells. Following lapatinib addition there was a substantial 
decrease in proliferation of Mock cells when compared to both NSC and FOXO3a siRNA 
transfected cells, suggesting that the lapatinib-induced decrease in cell proliferation was 
overcome in cells transfected with NSC or FOXO3a siRNA. This could indicate that 
FOXO3a is involved in the mediation of lapatinib-resistance in BT474 cells.  
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Figure 29. FOXO3a silencing increases proliferation in BT474 LapR cells. 
BT474 LapR cells were transfected with a NSC and FOXO3a specific siRNA and Mock. A) Western 
blot analysis confirmed knockdown of endogenous FOXO3a. Tubulin levels were also analysed. B) 
Following siRNA FOXO3a transfection, cells were re-plated into 96 well plates for 24 h and cell 
proliferation measured by SRB assay for the given time points with and without lapatinib. 
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4.3.11 FOXO3a expression in sensitive and resistant breast cancer cells 
Taking in consideration all the results obtained thus far, FOXP1 showed to be the most 
likely FOXO3a downstream target. For this reason all the experiments hereafter were 
focused on characterising FOXP1 regulation by FOXO3a. The experiment on Figure 3018 
enabled me to choose a cell line that expresses relatively high levels of FOXO3a and 
FOXP1. This could prove useful for studying the potential FOXO3a-mediated regulation of 
FOXP1 in the context of sensitivity and resistance by using MCF-7 as a breast cancer cell 
line model which is sensitive to chemotherapeutic drug treatment. 
To study the role of FOXO3a in the development of drug-resistance in breast cancer, I 
determined the expression and phosphorylation levels of AKT and FOXO3a in sensitive 
wild type (WT), cisplatin-resistant (CisR), and epirubicin-resistant (EpiR) MCF-7 cells. 
Western blot analysis showed that FOXO3a activity and expression levels were higher in 
sensitive WT and in CisR MCF-7 cells compared with EpiR cells. EpiR cells showed a 
reduction in the levels P-FOXO3 (T32), as revealed by the increased levels of 
phosphorylated FOXO3a, as well as a reduction in its expression. The increased levels of 
phosphorylated FOXO3a in EpiR cells, were associated with the increased levels of P-AKT 
(S473) compared to MCF-7 and CisR cells. FOXP1 expression is higher in WT and CisR 
MCF-7 cells and it was greatly reduced in EpiR MCF-7 cells (Figure 30).  
This result supports the previous finding that the MCF-7 breast cancer cell line has an 
increased activity and expression of FOXO3a and consequently FOXP1 expression 
(Figure 18A). Furthermore, these data also suggest that FOXP1 has a role in mediating 
drug-resistance, at least for epirubicin-resistance, in a FOXO3a dependent manner. 
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Figure 30. FOXO3a activity and expression levels are downregulated in epirubicin-
resistant MCF-7 (EpiR) cells. 
Western blotting was performed to compare the basal expression levels of P-FOXO3a (T32), 
FOXO3a, FOXP1, P-AKT (S473) and AKT in sensitive MCF-7 (WT), cisplatin-resistant MCF-7 
(CisR) and epirubicin-resistant MCF-7 (EpiR) cells. Tubulin was used as a loading control.  
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4.3.12 No correlations are found between FOXO3a expression and cisplatin 
resistance in MCF-7 cell lines 
To examine the potential role of FOXO3a and FOXP1 in cisplatin resistance, I further 
determined the effect of 1μM cisplatin on total and phosphorylated FOXO3a and FOXP1 
expression over a 48 h period in both MCF-7 and CisR cell lines (Figure 31A). Western blot 
analysis showed little difference in FOXO3a and FOXP1 expression pattern during the 
timecourse between sensitive and cisplatin-resistant cell lines. Moreover, treatment with 
cisplatin did not affected the expression levels of FOXO3a, FOXP1 and AKT. Despite this, 
an increase in P-FOXO3a (T32) was noted at 4 h in MCF-7 cells. I also determined FOXP1 
transcriptional levels by performing RT-qPCR. Similar to what was observed in Figure 31A, 
there were no significant changes on FOXP1 transcript levels throughout the cisplatin 
timecourse and between the cell lines (Figure 31B). In accordance to the previous result 
shown in Figure 30, no difference was observed between MCF-7 and CisR cell lines. 
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Figure 31. FOXO3a and FOXP1 expression levels remain constant throughout a 
cisplatin timecourse in sensitive and resistant cells. 
MCF-7 and CisR cells were treated with 1µM of cisplatin for the times indicated. A) The expression 
levels of P-FOXO3a (T32), FOXO3a, FOXP1, P-AKT (S473), AKT and Tubulin were assessed by 
Western blotting. B) Total RNA was isolated in parallel and the expression of FOXP1 transcripts 
was measured by RT-qPCR and normalised to the level of L19. All data shown represent the 
averages of data from three experiments, and the error bars show the standard deviations. 
Statistical analysis was done using t-test , P=non-significant. 
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4.3.13 FOXO3a is differentially expressed in sensitive and epirubicin-resistant cell 
lines 
To further investigate the role of FOXO3a in epirubicin-mediated resistance I subjected 
both MCF-7 and EpiR cells to treatment with 1µM epirubicin and performed Western 
blotting to assess the activity and expression of FOXO3a, AKT and FOXP1 in a timecourse 
over 48 h. As shown in MCF-7 cells (Figure 32A), there was a reduction in the 
phosphorylated forms of FOXO3a following 24 h of treatment. This suggests that epirubicin 
treatment was activating FOXO3a by increasing its activity, whilst total FOXO3a levels 
remained relatively constant throughout the timecourse. Furthermore, p27Kip1 - a direct 
target of FOXO3a - was also downregulated at 8 h which was accompanied by a decrease 
in the activity of FOXO3a. FOXP1 expression decreased after 24 h of treatment although 
at transcriptional level there was an increase in FOXP1 mRNA levels after 24 h (Figure 
32B). It is notable that FOXP1 expression mirrored the activity of FOXO3a, further 
suggesting that FOXP1 is regulated by FOXO3a. In EpiR MCF-7 cells, FOXO3a activity 
and expression levels were lowered when compared to sensitive cells. In line with our 
previous result in Figure 30, this result showed a pronounced difference in FOXP1 
expression in both cell lines, which correlates with FOXO3a expression levels. In EpiR 
cells, FOXO3a activity was higher and relatively constant after treatment, consistent with 
an increase in activity of the PI3K pathway, as revealed by the higher levels of P-AKT 
(S473). Moreover, p27Kip1 displayed the same expression pattern as the potential FOXO3a 
downstream target FOXP1, almost undetectable in this cell line. Examination of FOXP1 
transcript levels by RT-qPCR revealed that similarly to protein levels, FOXP1 transcripts 
were significantly lower in EpiR MCF-7 cells and remained at low levels after epirubicin 
treatment (Figure 32B). The results above further support the idea that FOXP1 is a 
transcriptional target of FOXO3a in breast cancer cells and that both FOXO3a and FOXP1 
are associated with epirubicin sensitivity. 
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Figure 32. EpiR cell line shows a sustained reduction in FOXP1 protein and mRNA 
levels.  
MCF-7 and EpiR were treated with 1µM of epirubicin for the indicated times. A) P-FOXO3a (T32), 
FOXO3a, FOXP1, P-AKT (S473), AKT and p27Kip1 expression levels were determined by Western 
blotting. Tubulin was used as a loading control. B) Total RNA was isolated in parallel and the 
expression of FOXP1 transcripts was measured by RTq-PCR and normalised to L19 levels. All data 
shown represent the averages of data from three experiments and the error bars show the standard 
deviations. Statistical analysis was done using t-test ***, P≤0.001, significant. 
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4.3.14 Nuclear FOXO3a and FOXP1 increases upon epirubicin treatment in MCF-7 
and EpiR cells 
Since FOXO3a activity is dependent on its localisation within the cell, I performed 
subcellular fractionation on both sensitive and resistant cell lysates to study the nuclear 
and cytoplasmic localisation of FOXO3a and FOXP1 in response to epirubicin treatment. 
Both WT and EpiR MCF-7 cells were treated with 1µM of epirubicin or remained untreated 
for 24 hours. Western blot analysis showed that nuclear FOXO3a expression increases 
upon treatment with epirubicin in both cell lines. Concordantly, FOXP1 and p27Kip1 levels 
also increased in the nuclear compartment following epirubicin treatment although in EpiR 
cells their levels are lower. It is noteworthy that equal amounts of nuclear and cytoplasmic 
proteins were analysed by western blotting. As a result, high levels of nuclear proteins 
compared with cytoplasmic proteins will be represented in the western blot (Figure 33). 
This could explain the considerable amounts of Tubulin found in the nuclear fractions. 
Consistent with what had been seen before in Figure 30 & 32, FOXP1 levels are lower in 
EpiR cells compared to MCF-7 cells. Importantly, this result further supports that FOXO3a 
is targeted by epirubicin and this leads to an increase in FOXP1 expression in both 
sensitive and resistant breast cancer cell lines. 
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Figure 33. Nuclear FOXO3a and FOXP1 increases upon epirubicin treatment in MCF-
7 and EpiR cells. 
MCF-7 and EpiR cells were treated with or without 1µM of epirubicin for 24 h. Cell pellets were 
subject to subcellular fractionation for each cell line. P-FOXO3a, FOXO3a, FOXP1 and p27Kip1 
expression levels were assessed by western blotting. Tubulin and Lamin B were used as loading 
controls for cytoplasmic and nuclear fractions, respectively. 
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4.3.15 FOXO3a activation enhances downstream FOXP1 expression 
I next explored whether FOXO3a induction has an effect on FOXP1 expression. I made 
use of a stably transfected MDA-MB-231 cell line with an expression vector that encodes 
for the hormone binding domain of the estrogen receptor (ER) fused to FOXO3a(A3), a 
constitutive active FOXO3a mutant. In these MDA-MB-231-FOXO3a(A3): ER cells, 
FOXO3a activity can be induced by treatment with of (4-OHT. MDA-MB-231 cells were 
used as a control. As shown in Figure 34A, 4-OHT treatment of MDA-MB-231-
FOXO3a(A3):ER cells, but not of control cells, induced the expression of FOXO3a target 
p27Kip1. The result also confirmed the previously described PI3K/AKT negative feedback 
mechanism loop, in which FOXO3a enhances AKT phosphorylation through inducing 
p110α (Hui et al 2008b). Importantly, FOXP1 induction was observed in MDA-MB-231-
FOXO3a(A3):ER cells and no such effect was seen in the control cells, suggesting that this 
induction of FOXP1 expression is specifically mediated by FOXO3a. I also examined 
whether FOXO3a induction would regulate FOXP1 at the transcriptional level. As 
illustrated by the results in Figure 34 B, FOXP1 increased following treatment with 4-OHT 
in the cells transfected with the active form of FOXO3a, whereas in control cells FOXP1 
levels remained unchanged. This result further supports the notion that FOXP1 is 
regulated by FOXO3a at both transcriptional and translational levels in MDA-MB-231 cells. 
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Figure 34. FOXO3a induces FOXP1 at protein and mRNA levels in MDA-MB-231 
cells. 
MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 1µM 4-OHT for the 
indicated times. A) Whole cell extracts were prepared at the times indicated and subjected to 
immunoblotting. Expression levels of FOXO3a, FOXP1, P-AKT (S473), AKT, p27Kip1 and Tubulin 
were analysed by Western blotting. The known FOXO3a target (p27Kip1) was used as a readout of 
the inducible system. B) Total RNA was extracted from these cells and analysed for FOXP1 mRNA 
expression using RT-qPCR and normalised to the level of L19. All data shown represent the 
averages of data from three experiments, and the error bars show the standard deviations. 
Statistical analysis was done using t-test ***, P≤0.001, significant. 
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4.3.16 FOXP1 is transactivated by FOXO3a in vivo 
Next, I investigated whether FOXO3a regulates FOXP1 expression at the gene promoter 
level. To this end, I studied FOXP1 endogenous promoter occupancy by FOXO3a using 
chromatin immunoprecipitation (ChIP). MCF-7 cells were cultured in the absence or 
presence of epirubicin for 24 h and the chromatin was precipitated with a specific FOXO3a 
antibody and analysed by PCR. Three sets of primers were used to target three potential 
forkhead DNA binding sequences. These primers were optimised using genomic MCF-7 
DNA. The ChIP result confirmed that FOXO3a binds to the FOXP1 promoter within the 
forkhead containing region (-634/-557) following epirubicin treatment. However, using the 
same precipitated DNA with the other two sets of primers failed to amplify a PCR product, 
showing that the corresponding two sites are not occupied by FOXO3a in response to 
epirubicin (Figure 35). This result showed that FOXO3a regulates FOXP1 expression 
through binding and transactivation of its promoter region in MCF-7 cells.  
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Figure 35. FOXO3a transactivates FOXP1 promoter in vivo.  
A) Chromatin immunoprecipitation (ChIP) was performed in MCF-7 cells either in the absence or 
presence of epirubicin to analyse the human FOXP1 promoter. A FOXO3a specific antibody (H-
144) was used. After crosslink reversal, the co-immunoprecipitated DNA was amplified by PCR 
using primers amplifying the FOXP1 FHRE containing region (-634/-557) and resolved in 2% 
agarose gel. Representative data from three independent experiments are shown. B) Schematic 
representation of the three putative FHRE binding sites on FOXP1 promoter. 
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4.3.17 Effect of FOXO3a silencing on FOXP1 expression levels  
To further confirm that FOXP1 is a target of FOXO3a I decided to investigate the effect of 
FOXO3a silencing on FOXP1 expression in MCF-7 breast cancer cell line. 
To this end, cells were Mock transfected or transfected with NSC or FOXO3a siRNA and 
harvested at 24 h post-transfection. Western blot results showed that FOXO3a knock-
down was partially achieved, and the effects on FOXP1 expression levels were only 
marginal. There was a reduction in FOXP1 levels when comparing Mock against both NSC 
and FOXO3a siRNA (Figure 36).  
 
 
 
Figure 36. Silencing of FOXO3a does not impact on FOXP1 expression levels.  
Cells were transfected with Mock or siRNA specifically targeting FOXO3a or a NSC. 24 h post-
transfection, Western blot analysis was performed to confirm efficient FOXO3a knockdown and 
FOXP1 expression levels.  
  
153 
 
4.3.18 FOXP1 overexpression induces p27Kip1 in EpiR cells 
To investigate the function of FOXP1, I transiently transfected EpiR cells with FOXP1 
expression vector. Previously, I showed that FOXP1 protein was expressed at lower levels 
in EpiR cells when compared to CisR and MCF-7 cells (Figure 30 & 32). Therefore, MCF-7 
EpiR cells is a more suitable model to examine the effects of FOXP1 overexpression. I 
assessed the expression patterns of FOXO3a, AKT and p27Kip1 in cells transfected with 
FOXP1 construct (pcDNA3-FOXP1) and with the control empty vector (pcDNA3) in the 
absence or presence of 1µM epirubicin treatment for 24 h (Figure 37). The results 
confirmed FOXP1 overexpression. The exogenous FOXP1 protein was expressed at a 
higher molecular weight band compared with the endogenous protein. FOXP1 
overexpression had no effect on total FOXO3a and AKT levels. However, a marginal 
increase was observed in P-FOXO3a (T32) and P-AKT (S473) levels suggesting that 
FOXP1 may function in a similar manner as FOXO3a possibly by engaging in feedback 
mechanisms with PI3K. Surprisingly, FOXP1 overexpression resulted in an induction of 
p27Kip1. This induction was mainly due to FOXP1 as FOXO3a activity was decreased, as 
revealed by the increased levels of P-FOXO3a (T32). Previously, loss of FOXP1 has been 
showed to increase p21Cip1 and decrease p27Kip1 levels in the development of the heart. 
Therefore, this result suggests that FOXP1 may share common downstream targets with 
FOXO3a.  
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Figure 37. FOXP1 overexpression induces p27Kip1 levels in EpiR cell line.  
EpiR cells were transiently transfected with FOXP1 overexpression vector (pcDNA3-FOXP1) or 
empty vector pcDNA3 (pcDNA3) for 24 h. Cells were treated with and without epirubicin for 24 h. 24 
h after treatment and analysed by Western blotting against P-FOXO3a (T32), FOXO3a, FOXP1, P-
AKT (S473), AKT and p27Kip1 expression levels were determined. Tubulin was used as a loading 
control. 
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4.3.19 FOXP1 overexpression in Foxo1/3/4-/- MEFs leads to an induction of p27Kip1 
Since previously I have observed an induction of p27Kip1 by FOXP1 in EpiR cells, I 
overexpressed FOXP1 in Foxo1/3/4-/- MEFs to show definitely that FOXP1 has a role in 
inducing p27Kip1 independently of FOXO3a. To this end, WT and Foxo1/3/4-/- MEFs were 
transfected with 0, 4, 6 and 8µg of FOXP1 expression vector (pcDNA3-FOXP1). 
Overexpression was confirmed at protein levels (Figure 38A) and at mRNA levels (Figure 
38B). In Foxo1/3/4 deficient MEFs, p27Kip1 and also FOXP1 expression levels were lower 
when compared to the same condition in WT MEFs. However, when FOXP1 was titrated 
into cells lacking all three FOXO isoforms, an increase in p27Kip1 was observed suggesting 
that FOXP1 by itself can induce p27Kip1 expression levels (Figure 38A). 
At transcriptional level, FOXP1 overexpression was also confirmed in both cell lines 
although this overexpression was higher in WT MEFs probably, due to the presence of 
FOXO3a. In Foxo1/3/4-/- cells, FOXP1 overexpression was able to restore the induction of 
p27Kip1 mRNA levels, as observed in WT MEFs. However, there was a reduction in p27Kip1 
mRNA levels (Figure 38B). This can be due to an increase in global protein and mRNA 
degradation as a result of cell death in the Foxo1/3/4 deficient cells. It is possible that in 
WT MEFs, FOXO3a and FOXP1 act together to regulate p27Kip1 expression. In summary, 
this result showed that like FOXO3a, FOXP1 can also induce p27Kip1 expression. 
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Figure 38. Transfection of FOXP1 induces p27Kip1 expression in FOXO1/3/4 null 
mouse embryonic fibroblasts. 
WT and Foxo1/3/4 null MEFs were transfected with increasing amounts of empty pcDNA3 vector 
and pcDNA3-FOXP1. 24 h post-transfection whole cell lysates were collected. A) Western blotting 
was performed to determine the expression levels of FOXP1, FOXO3a, p27Kip1 and Tubulin. B) 
RNA was extracted and RT-qPCR performed to evaluate the transcript levels of foxo3a, foxp1 and 
p27Kip1. L19 was used for normalisation. 
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4.3.20 FOXP1 silencing enhances cell cycle progression in MCF-7 cells 
In order to provide insights into the functional role of FOXP1 in breast cancer cells, MCF-7 
cells were either Mock-transfected, or transfected with a non-specific control siRNA pool 
(NSC) or a FOXO3a-specific siRNA pool. Cells were transfected in dishes, seeded into 
different format plates after a period of approximately 16 h and harvested for western 
blotting and RT-qPCR, cell proliferation and FACS analysis. Western blotting and RT-
qPCR analysis confirmed knockdown of endogenous FOXP1 (Figure 39A & B). Since the 
role of FOXP1 in breast has not yet been elucidated, I assessed the impact of its silencing 
on different cell cycle regulator proteins. Interestingly, p27Kip1 levels were higher in the 
NSC siRNA transfected cells suggesting that the transfection itself induced stress in the 
cell and caused this upregulation, whereas in FOXP1 siRNA transfected cells, its levels 
were decreased in comparison with the non-specific siRNA. For this reason, the effect of 
FOXP1 silencing henceforth was compared with that of the non-specific siRNA transfected 
cells. FOXP1 silencing increased the phosphorylation levels of P-pRB (S807/811), P-pRB 
(S795) and also the total pRB levels, indicating an increase in proliferation. Accordingly, 
there was also an increase in CyclinD1, CDK4, CyclinE1 and CDK2, as well as a decrease 
in p27Kip1 expression (Figure 39A). Together these results indicate that FOXP1 is 
necessary for cell cycle arrest and that its downregulation may result in the promotion of 
cell cycle progression. 
To establish the effect of FOXP1 knockdown on the sensitivity of the MCF-7 cell line to 
epirubicin, SRB assays were performed to assess cell proliferation with or without 
epirubicin treatment over a timecourse of 72 h (Figure 39C). In non-treated MCF-7 cells, 
the non-specific control siRNA caused a decrease in the rate of proliferation compared to 
Mock-transfection. This was associated with the increased p27Kip1 levels observed in 
Figure 39A. Knockdown of FOXP1 enhanced cell proliferation significantly when compared 
to the non-specific control siRNA, and this was again associated with a decrease in p27Kip1 
levels. Following treatment with epirubicin, the proliferation of both the Mock and siRNA 
transfected cells was impaired whereas FOXP1 knockdown initially enabled cells to 
proliferate better although that effect disappeared after 48 h of treatment (Figure 39C). 
Next, to study the effects of FOXP1 silencing on the cell cycle profile, FACS analysis was 
performed (Figure 39D). The cell cycle profile showed that FOXP1 silencing caused more 
cells to enter S and G2/M phases. Moreover, when FOXP1 siRNA transfected cells were 
treated with epirubicin, in comparison with NSC siRNA transfected cells, there were fewer 
cells in G1. It was notable that there was an increase in the number of cells in G2/M 
phase. This can be attributed to the treatment with epirubicin. Unexpectedly, an increase in 
cell death is also noted following 72 h of epirubicin treatment in FOXP1 siRNA transfected 
cells (Figure 39D).  
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In summary, the proliferative effect of knocking-down FOXP1 in MCF-7 cells suggests a 
role in cell cycle and cell proliferative arrest for FOXP1. Silencing FOXP1 leads to 
phosphorylation and inactivation of pRB, which in turn results in cell cycle progression. The 
proliferation assay further supports that FOXP1 is necessary for cell proliferation arrest. 
Together these results suggest that FOXP1 may be necessary for cell cycle arrest and cell 
proliferation inhibition in response to epirubicin in drug-sensitive breast cancer cells. 
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Figure 39. FOXP1 silencing enhances cell cycle progression and proliferation in 
MCF-7 cells. 
MCF-7 cells were transfected either with Mock, NSC siRNA or FOXP1 siRNA. A) Whole cell lysates 
were collected 24 h post-transfection for the indicated timepoints and western blotting was 
performed for the indicated antibodies. B) Total RNA was extracted 24 h post-transfection to 
confirm FOXP1 knock-down at mRNA level by RT-qPCR. L19 was used for normalisation. Error 
bars show the standard deviations. Statistical analysis was done using t-test **, P≤0.01, significant. 
C) Cells were counted and seeded into 96 well-plates and treated for 0, 24, 48 and 72 h in the 
absence and presence of 1µM of epirubicin. Cell proliferation was determined by SBR assay. Each 
point represents the mean of three independent experiments, each done at least in triplicate; bars, 
SD. Statistical analysis has been done using Student’s t test. ***, P < 0.001; **, P<0.01; , non-
significant. D) Cells were fixed at the indicated timepoints and cell cycle phase distribution was 
analysed by flow cytometry after propidium iodide staining. Percentage of cells in each phase of the 
cell cycle are indicated (<G1, G1, S and G2/M). 
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Figure 39. Continued. 
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Figure 39. Continued. 
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4.3.21 Effect of FOXP1 silencing in MDA-MB-231 breast cancer cell line 
To further characterise the effect of silencing FOXP1 in breast cancer cells, I performed 
FOXP1 knockdown by siRNA in a different breast cancer cell line – MDA-MB-231. Western 
blotting analysis confirmed FOXP1 silencing as indicated by the arrow showing the loss of 
the slower migrating FOXP1 band. Importantly, loss of FOXP1 caused an abrogation of 
p27Kip1 levels (Figure 40). Unlike what was observed previously in MCF-7 cells, 
phosphorylation of pRB along with total pRB expression levels were decreased in MDA-
MB-231 cells after FOXP1 depletion. One possible explanation is that the loss of FOXP1 
could facilitate pRB degradation by regulating MDM2 expression. Accordingly, pRB has 
been shown to be targeted by MDM2 proteosome-dependent degradation (Sdek et al 
2005). Although there was a decrease in CDK4 and CyclinD1 levels, little change was 
observed in CyclinE1 levels and a marginal increase was seen in CDK2 levels. In line with 
my previous observations in MCF-7 cells, silencing of FOXP1 in MDA-MB-231 cells, the 
silence of FOXP1 favoured cell cycle progression.  
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Figure 40. FOXP1 knock-down in MDA-MB-231 cells impairs proteins necessary for 
cell progression. 
MDA-MB-231 cells were transfected with a FOXP1 or NSC specific siRNA and Mock. Western blot 
analysis confirmed knockdown of endogenous FOXP1. The expression levels of various cell cycle 
protein regulators were analysed and Tubulin was used as a loading control. 
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4.3.22 Effects of FOXP1 overexpression in EpiR cells 
To delineate the effect of FOXP1 overexpression in epirubicin-resistant breast cancer 
cells, EpiR cells were either transfected with empty vector (pcDNA3) or pcDNA3 encoding 
FOXP1 cDNA (pcDNA3-FOXP1). Cells were transfected for 24 h and later harvested for 
FACS analysis (Figure 41A) and Western blotting (Figure 41B). FACS results showed that, 
in untreated cells over the timecourse, there were no significant differences between 
untransfected, empty vector-transfected and FOXP1 overexpressing cells. Furthermore, 
when cells were treated with epirubicin for the different times, no changes were again 
observed. However, at 0 h, FOXP1 overexpressing EpiR MCF-7 cells exhibited a higher 
percentage in S phase and fewer G2/M phase cells in comparison with untransfected and 
empty vector transfected cells. Western blot analysis showed that there was no difference 
in FOXP1 levels between the control and FOXP1 transfected cells. An increase in p27Kip1 
levels was observed in FOXP1 overexpressing cells, although in the transfected control 
cells a slight decrease was noted (Figure 41B). The reason for this is unclear. Due to EpiR 
cells lower transfection efficiency, I performed FOXP1 stable rather than transient 
transfections.  
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Figure 41. Effects of FOXP1 overexpression in EpiR cells in the cell cycle profile. 
Cells were either untransfected or transfected with a FOXP1 overexpressing vector (pcDNA3-
FOXP1) and the control vector (pcDNA3). A) 24 h post-transfection, cells were fixed in ethanol and 
stained with propidium iodide then analysed by FACS. The % of cells in each phase of the cell cycle 
is indicated. B) Whole cell lysates were also collected to assess the overexpression of FOXP1 at 
protein level by Western blotting. The expression levels of FOXP1, p27Kip1 and Tubulin were 
analysed. 
  
166 
 
 
 
Figure 41. Continued. 
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4.3.23 Generation and characterisation of EpiRFOXP1 stable cell line 
As it proved difficult to transiently overexpress FOXP1 in EpiR cells, I decided to generate 
MCF-7 EpiR cell line stably overexpressing FOXP1. For this purpose, two different pools of 
EpiR cells were transfected with pcDNA3-FOXP1 vector and then selected with an 
optimised concentration of neomycin. After 3 weeks, cells were pooled and subjected to 
western blotting to assess FOXP1 expression. As observed in Figure 42 the two different 
pools of transfected cells showed higher FOXP1 expression levels when compared to 
control cells transfected only with empty pcDNA3 vector. Additionally, an induction in 
p27Kip1 levels was observed, further supporting our hypothesis that FOXP1 upregulates this 
cell cycle regulator (Figure 42). 
 
 
 
Figure 42. FOXP1 stable cell line generation. 
Cells were transfected with the empty control vector (pcDNA3) or with the neomycin-resistant 
(pcDNA3-FOXP1) vector. 24 h post-transfection cells were selected with neomycin for a period of at 
least 2 weeks until cell proliferation was established. Cells were tested for the stable overexpression 
of FOXP1 by western blotting. The expression of the FOXP1, p27Kip1 and Tubulin was analysed. 
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4.3.24 Functional effect of EpiR FOXP1 stable cell lines  
Next, in order to study the effect of FOXP1 on cell proliferation and cell cycle, I used the 
MCF-7 EpiR-FOXP1 stable cell line and compared them to the empty vector transfected 
stable cell lines (EpiR pcDNA3). To this end, cells were treated with a dose titration of 
epirubicin ranging from 500nM to 10μM for 0, 24, 48 and 72 h. MCF-7 EpiR-FOXP1 and 
the control stable cell lines continued to proliferate even in the presence of concentrations 
as high as 10µM. Across all doses, no significant cytotoxic effects were observed, further 
confirming the resistant profile of these cells (Figure 43A, B, C). I also examined the 
viability of these cells in terms of cell survival at 72 h. MCF-7 cells were included as the 
drug-sensitive control. Surprisingly, the FOXP1 stably overexpressing cells showed an 
increased cell proliferative rate in comparison to control cells (Figure 43C). To study the 
effects of FOXP1 on the cell cycle, both the control and FOXP1 overexpressing cells were 
analysed by FACS (Figure 43D). Cells were treated for 0, 24 and 48 h with the same range 
of epirubicin used for the proliferation assays. For the untreated cells, the cell cycle profile 
showed that sustained FOXP1 overexpression led to a decrease of cells in G1 phase – 
54.4% compared to 33.6% in the controls - and an accumulation in G2/M phase – 23.8% 
compared to 39.3% in the controls. The epirubicin doses used did not result in a 
substantial difference in the proliferative rate between the two cell lines. Nevertheless, a 
reduction was noted in the percentage of cells in G1 phase and an increase in the 
percentage of G2/M cells, which was more prominent at 24 h. At 48 h with both 5 µM and 
10µM of epirubicin, the controls had higher numbers of cells in G2/M, whilst MCF-7 EpiR-
FOXP1 maintained their cell cycle profile as the untreated cells (Figure 43D).  
Taken together, these results suggest that the stable cell line overexpressing FOXP1 is 
more resistant to epirubicin than the MCF-7 EpiR. This is contradictory to my earlier data 
and it appears that these cells can cope better with the cytotoxic effects of epirubicin. The 
MCF-7 EpiR-FOXP1 cells generated may represent a pool of cells that can tolerate high 
levels of FOXP1 and may have downstream signalling mechanisms deregulated. To 
circumvent this problem, I decided to clone FOXP1 cDNA into a GFP-vector so that 
FOXP1 can be analysed by FACS after sorting for GFP expression. 
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Figure 43. FOXP1 stable overexpression confers a protective effect to EpiR cells.  
EpiR pcDNA3 and EpiR FOXP1-pcDNA3 cells were treated with a dose titration of 0, 500, 1000, 
5000 and 10000nM of epirubicin for 0, 24, 48 and 72 h. A, B) Cell proliferation was determined by 
SRB assay. C) Cell survival at 72 h was assessed. The sensitive MCF-7 cell line was included. D) 
Cell cycle analysis of the same samples was performed after propidium iodide staining for 0, 24 and 
48 h.  
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Figure 43. Continued. 
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4.3.25 Sub-cloning FOXP1 into a GFP vector 
To generate the GFP-FOXP1 vector, a cDNA fragment (270-2297) encoding the full length 
FOXP1 protein was amplified by PCR from the parent vector (pcDNA3-FOXP1) (see 
Appendix 4, Appendix 5 and Appendix 6 for detailed sequence and vectors used). The 
primers were designed to clone FOXP1 cDNA in frame with the receiver vector (pEGFP-
C1). The PCR product was analysed and purified on an agarose gel (Figure 44A), and 
sub-cloned into pCR 2.1-TOPO vector. The insert was then excised from the TOPO vector 
and sub-cloned into the XhoI/HindIII digested pEGFP-C1 vector (Appendix 5). After sub-
cloning into pCR 2.1-TOPO (Appendix 6), the plasmid was then digested with XhoI/HindIII 
to confirm for the presence of FOXP1 in the different TOPO clones (indicated by the arrow) 
(Figure 44B). Clone number 3 was selected for sub-cloning into pEGFP-C1 vector. To 
confirm that I had successfully cloned FOXP1 into the pEGFP-C1 vector, both 
TOPO:FOXP1 and pEGFP-C1:FOXP1 were double digested with XhoI and HindIII and the 
digests resolved in a 1.5% agarose gel. The sizes of the empty vectors, TOPO and 
pEGFP-C1, 3.9kb and 4.7kb respectively, were confirmed in the agarose gel.  
The FOXP1 fragment released by the double digestion, from both vectors harbouring 
FOXP1 construct is indicated by an arrow (Figure 44C). 
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Figure 44. Subcloning FOXP1 into a GFP vector. 
A) Agarose gel with the fragments originated from the PCR amplification of the parental pcDNA3-
FOXP1. Lanes 1 and 2 result from the amplification of 0.5µg and 1µg of the parental vector, 
respectively. B) Following subcloning of FOXP1, TOPO vector was double digested with 
XhoI/HindIII to confirm for the presence of insert in different colonies ranging from 1 to 8. Arrow 
indicates the colonies positive for FOXP1. C) An agarose gel was run to confirm for the presence of 
construct in the final receiver vector. Both vectors, TOPO 2.1 and pEGFP-C1, harboring FOXP1 
construct were double digested with XhoI/HindIII. 
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Next, I transfected both MCF-7 and EpiR cells with GFP and pEGFP-C1:FOXP1 vectors. 
Following 24 h of transfection, cells were analysed by western blotting and 
immunofluorescence. FOXP1 overexpression was confirmed at the protein level by the 
presence of a higher molecular weight band as indicated by the arrow (GFP:FOXP1) 
(Figure 45A). The Western blot results were confirmed by confocal microscopy, where the 
transfected MCF-7 and EpiR cells were co-stained with DAPI. GFP:FOXP1 was detected in 
the nucleus in both cell lines in contrast to the control GFP which was confined to the 
cytoplasmic compartment (Figure 45B). This result further supports the previous finding 
shown in Figure 33 that FOXP1 protein is preferentially localised in the nucleus. In line with 
this, a previous immunohistochemical staining study of solid tumours, including breast 
cancer, showed that FOXP1 expression is predominantly nuclear (Banham et al 2001). 
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Figure 45. FOXP1 overexpression shows its nuclear subcellular localisation in both 
EpiR and MCF-7 cell lines. 
MCF-7 and EpiR cells were transiently transfected with FOXP1 overexpression vector pEGFPC1-
FOXP1 (GFP:FOXP1) or empty vector pEGFP-C1 (empty GFP) for 24 h. A) Cell lysates were 
collected 24 h post-transfection for western blot analysis to determine the expression levels of 
FOXP1. Tubulin was used as a loading control. B) MCF-7 and EpiR cells were seeded in four-well 
chamber culture slides, fixed with formaldehyde and mounted with vectashield into a slide. Cell 
nuclei was stained with DAPI (blue) and GFP positive cells were visualised using the 488nm 
excitation laser.  
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4.3.26 FOXP1 overexpression results in a G1 arrest in MCF-7 EpiR cells 
In order to study the effect of FOXP1 on cell proliferation and cell cycle, the GFP:FOXP1 
transfected cells were sorted for GFP expression by FACS analysis. For this purpose, 
MCF-7 EpiR cells were Mock transfected or transfected with the GFP:FOXP1 
overexpression vector. After 24 h post-transfection, cells were incubated in the absence or 
presence of epirubicin. FOXP1 overexpression was confirmed both at protein and 
transcriptional levels (Figure 46 A & B, respectively). Western analysis showed that for 
untreated cells, p27Kip1 levels were upregulated in FOXP1 overexpressing cells, in 
agreement to what was seen previously. FOXP1 overexpression resulted in a decrease in 
p21Cip1, CDK4 and CyclinE1 levels but increased PLK and CyclinB1 levels. Although CDK4 
were decreased, a marginal increase was observed for CyclinD1 levels. However, in 
epirubicin treated cells, there was little difference in the expression levels of p27Kip1, 
CyclinD1, PLK, and CyclinB1 between untransfected and transfected cells. This suggests 
that these cell cycle regulators are induced by epirubicin. An increase was noted for 
CyclinE1, CDK4 and p21Cip1 levels (Figure 46A). This may be due to the fact that these 
genes can further be induced by FOXP1 expression.  
In parallel, SRB assays and FACS analysis were performed to examine the impact of 
epirubicin on FOXP1 overexpressing cells. For this purpose, cells were transfected with 
GFP and GFP:FOXP1 following incubation in the absence or presence of epirubicin over a 
timecourse of 0, 24, 48 and 72 h.  
In untreated cells, there was little difference in the growth rate of Mock transfected and 
GFP transfected cells. Nonetheless, a marginal but not significant increase was noted for 
GFP:FOXP1 expressing cells. Following epirubucin treatment, no substantial difference in 
the proliferative rate was observed between Mock transfected and GFP or GFP:FOXP1 
transfected cells (Figure 46C). This is supported by the previous western blotting results, 
showing that, in epirubicin treated cells FOXP1 expression is induced.  
GFP and GFP:FOXP1 transfected cells were analysed by FACS and the total and the GFP 
positive cell populations (GFP+) were studied (left- and right-hand side, respectively). The 
cell cycle profile of untreated cells at 0 h, showed a dramatic increase in the percentage of 
cells in G1 phase in the GFP:FOXP1 transfected cells (81.1%) compared to the GFP 
controls (68.6%). In addition, a substantial decrease was noted in the number of cells 
accumulated in the G2/M phase in GFP:FOXP1 transfected cells (5.2%) when compared 
to GFP transfected cells (12.2%). Notably, there was an enhanced G1 accumulation, in 
GFP:FOXP1 expressing cells, especially at 72 h (66.6%) in comparison with the GFP 
transfected cells (75.7%). However, when cells were treated with epirubicin, the 
differences in the G1 phase between GFP and GFP:FOXP1 transfected cells, became less 
obvious (Figure 46D). This further supports the previous western blotting and SRB results 
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showing that FOXP1 expression/activity is induced by epirubicin. The total cell population 
cell cycle profiles did not show much difference between the GFP and GFP:FOXP1 
transfected cells. This could be due to the high percentage of untransfected cells. 
Moreover, there were no obvious differences between Mock transfected and GFP or 
GFP:FOXP1 transfected cells in the presence or absence of epirubicin (Figure 46D). 
Figure 46E illustrates a simpler representation of the percentage of the GFP positive cells 
in G1 phase. This graph is relative to the GFP and GFP:FOXP1 transfected cells. The 
graph shows a clearer G1 accumulation for GFP:FOXP1 overexpressing cells in 
comparison to GFP cells. This result was further supported by Figure 46F where there was 
a significant increase in G1 phase accumulation caused by FOXP1 overexpression. 
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Figure 46. FOXP1 overexpression results in a G1 accumulation without affecting the 
proliferation of EpiR cells. 
EpiR cells were either untransfected or transfected with GFP:FOXP1 vector and then for each 
condition cells were either non-treated or treated with epirubicin. A) Protein expression of FOXP1 
and various cell cycle proteins was elucidated using western blot analysis. B) Total RNA was 
isolated. FOXP1 mRNA levels were analysed by RT-qPCR and normalised with L19 mRNA levels. 
Data shown represent the averages from two experiments. C) 24 h post-transfection, cells were 
counted, seeded into 96 well-plates and treated for 0, 24, 48 and 72 h in the absence and presence 
of epirubicin. Cell proliferation was determined by sulforhodamine B assay. Each point represents 
the mean of three independent experiments, each done at least in triplicate. D) Cell cycle profile 
was analysed by FACS for 0, 24 and 48 h in the presence and absence of epirubicin. Profiles 
acquired reflect the general cell population and the GFP positive population (GFP cells). E) Graphic 
illustration of the GFP cells accumulated at the G1 phase for both control (empty GFP) and 
GFP:FOXP1 cells throughout the timecourse and F) percentage of untreated cells at G1 phase, 24 
h post-transfection. Error bars show the standard deviation. Statistical analysis has been done 
using Student’s t test. **, P≤0.01. 
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Figure 46. Continued. 
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Figure 46. Continued. 
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Figure 46. Continued. 
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4.3.27 FOXO3a and FOXP1 are inversely correlated in clinical samples 
To determine the physiological significance of our cell culture findings, I analysed the 
expression patterns of FOXO3a and FOXP1 by IHC staining in breast cancer patient 
samples. Samples were obtained from Queen Mary Hospital in Hong Kong and together 
with our collaborators, IHC staining was performed on formalin-fixed, paraffin-embedded 
tissue sections using specific FOXO3a and FOXP1 antibodies. The intensity of staining for 
FOXO3a and FOXP1 was scored as low = 0 and high = 1. Figure 47 represents FOXO3a 
and FOXP1 patterns of staining. The majority of the cases analysed exhibited positive 
FOXO3a cytoplasmic staining (n=69) compared to nuclear FOXO3a staining (n=28). 
Stronger FOXP1 staining was also observed in the cytoplasm compared to the nucleus (62 
versus 59). The correlation between FOXP1 and other clinical-pathological parameters, 
such as ER and PR status, tumour-grade, age and lymph-node involvement, was not 
statistically significant in invasive ductal cases.  
The correlation between cytoplasmic FOXO3a and FOXP1 was not statistically significant 
(P=0.419, Chi-square test) however, nuclear FOXO3a was negatively associated with 
nuclear FOXP1 in a significant manner (P=0.012, Chi-square test) (Appendix 12). The 
correlation between FOXP1 expression and disease specific survival was studied using 
Kaplan Meier analysis in invasive ductal cases only. The result showed that high FOXP1 
staining was significantly associated with a better survival time (p=0.032, log-rank test) 
whereas low FOXP1 expression was associated with poor survival (Figure 48). In 
accordance with my in vitro results, this further suggests that FOXP1 acts as a tumour 
suppressor. In summary, an inverse correlation was identified between FOXO3a and 
FOXP1 as high nuclear FOXO3a correlates with low nuclear FOXP1. In line with this, our 
previous report showed that the constitutively expression of nuclear FOXO3a predicts a 
worse prognosis. This suggests that, in order for cancer cells to proliferate and, at the 
same time, sustain a prolonged nuclear accumulation of FOXO3a, the downstream 
signalling regulation of FOXO3a targets, including FOXP1, must be disabled. Consistently, 
FOXP1 association with improved survival further corroborates the idea that FOXO3a-
FOXP1 axis is deregulated in cancer cells. 
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Figure 47. FOXO3a and FOXP1 have a negative correlation in breast cancer patient 
samples. 
IHC staining was performed on tumour tissue samples obtained from breast cancer patients that 
had been formalin-fixed and paraffin-embedded were immunohistochemically stained with FOXO3a 
and FOXP1 antibodies using the streptavidin-biotin-peroxidase technique. Representative 
expression patterns corresponding to FOXO3a and FOXP1 illustrate the findings. 
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Figure 48. Survival analysis with cytoplasmic FOXP1 staining in invasive ductal 
carcinoma cases.  
Of the 120 cancer samples assessed, there were 94 cases of invasive ductal carcinoma. The 
correlation between nuclear FOXO3a expression and survival was studied using Kaplan Meier 
analysis (P=0.032) and was considered significant at p<0.05.  
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4.4 DISCUSSION 
The aim of this chapter is to validate new transcriptional targets of FOXO3a. From all the 
four targets investigated - FOXP1, JAK2, CXCR4 and APOBEC3G – only FOXP1 is 
consistently shown to be a target of FOXO3a. CXCR4 was found to be consistently 
upregulated in MDA-MB-231-FOXO3a(A3):ER cells in comparison to MDA-MB-231 cells. 
In addition, in Foxo1/3/4-/- MEFs CXCR4 levels were abrogated. However, FOXO3a 
depletion by siRNA in MCF-7 and BT474 cells did not have an effect on CXCR4 
expression. Furthermore, there was not a difference in expression of CXCR4 between 
sensitive and EpiR MCF-7 cells nor between K562 and the resistant leukaemic KD30 cells. 
As for JAK2 and A3G, the only notable difference was found in resistant cells. JAK2 levels 
were found upregulated in the leukaemic K562 cells overexpressing FOXO3a, however no 
such effect was observed when FOXO3a was inducibly expressed in MDA-MB-231 cells. 
In all resistant cell line models used – MCF-7 EpiR, KD30 and BT474 LapR – JAK2 levels 
were consistently upregulated. The same result was observed for A3G. This could suggest 
that these proteins are in general involved in the development of resistant mechanisms 
probably independent of FOXO3a. A3G levels were abrogated when FOXO3a was 
constitutively induced in MDA-MB-231 cells. However, no changes in A3G levels were 
found in other FOXO3a overexpression or knock-down experiments. It is likely that the 
expression of these targets is differentially regulated but in a cell type-dependent manner. 
Because of the inconsistent results regarding these targets regulation by FOXO3a, I 
decided to focus on the study of FOXP1. 
Over the last decade, there has been increasing evidence for a role for FOXP1 in human 
cancers. However, FOXP1 expression has been shown to predict different clinical 
outcomes in different human cancers. A number of studies have identified FOXP1 as an 
oncogene, especially in B cell lymphomagenesis, whereas studies of solid tumours, 
especially those of the breast and prostate, pointed to FOXP1 acting as a tumour 
suppressor. However, the molecular mechanisms that regulate FOXP1 expression, 
particularly in breast cancer, are unclear. Therefore, further characterisation of the function 
of FOXP1 and its impact on drug sensitivity would prove essential for determining whether 
FOXP1 may be a therapeutic target or may be used to guide therapy. 
One objective of this chapter was to validate whether or not FOXP1 is a downstream target 
of FOXO3a in breast cancer. FOXP1 has previously been shown to be a potential 
FOXO3a target in a study using colon cancer cells expressing an inducible FOXO3a 
(Delpuech et al 2007). This work shows that FOXP1 is targeted by epirubicin, FOXO3a 
regulates FOXP1 expression, and FOXP1 has a role in cell cycle arrest. 
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In this chapter, I confirm that FOXP1 is a downstream target of FOXO3a in breast cancer 
cell lines by a number of different experiments. Firstly, FOXP1 protein and mRNA levels 
were impaired in Foxo-null MEFs and there was a slight decrease in FOXP1 protein after 
silencing FOXO3a in MCF-7 cells. Secondly, FOXO3a activation by 4-OHT was sufficient 
to increase FOXP1 protein expression in MDA-MB-231-FOXO3a(A3):ER cells. Moreover, 
in sensitive and resistant breast cancer cell lines, FOXO3a protein expression mirrored 
that of FOXP1.  
My results also show that FOXO3a upregulates FOXP1 at mRNA and protein levels 
(Figure 34A & 3B). In addition, I have also shown that FOXO3a binds to FOXP1 promoter 
in vivo (Figure 35). With regards to a possible role of FOXP1 in chemoresistance, FOXP1 
expression is found to be downregulated in epirubicin-resistant cells in comparison with 
sensitive cells. Therefore, FOXP1 function was further analysed in the context of 
epirubicin-mediated resistance. I also observed that silencing FOXP1 in both MDA-MB-231 
and MCF-7 cells resulted in a downregulation of p27Kip1 levels. It is possible that this 
accounts for the enhanced cell proliferation and cell cycle progression observed following 
the knock-down of FOXP1. Moreover, in resistant cells, FOXP1 overexpression not only 
enhanced p27Kip1 expression levels but also resulted in a substantial G1 arrest of the cell 
cycle. The finding that p27Kip1 is a target of FOXP1 was surprising as FOXP1 has 
previously been described as a transcription repressor (Banham et al 2001, Shu et al 
2007), and there are no publications as yet to suggest that FOXP1 can also be a 
transactivator. Concomitant with my findings, the related member, FOXP3 has been shown 
to act as a transcriptional activator of p21Cip1 (Liu et al 2009). One could argue that FOXP1 
regulates p27Kip1 expression directly as a transactivator or indirectly through repressing an 
inhibitor of p27Kip1. It is well established that FOXO3a regulates p27Kip1 expression (Dijkers 
et al 2000b) and it could be that the regulation of p27Kip1 by FOXP1 is FOXO3a-
independent or that FOXO3a and FOXP1 cooperate to regulate p27Kip1 expression. Further 
studies are required to decipher this regulation mechanism. Indeed, FOXP family members 
have the ability to heterodimerise, adding even more complexity to how these transcription 
factors regulate gene expression. Several studies have now shown that Foxp1, Foxp2, and 
Foxp4 expression overlaps in various tissues, including the lung and brain (Banham et al 
2001, Lu et al 2002a, Shu 2001). Thus, it is possible that one FOXP member affects the 
activity of another through binding cooperately at promoter level or by acting as a partner 
either with a positive or negative regulation purpose via direct protein interaction (Wang 
2003). It would be interesting to assess whether FOXP1 and FOXO3a could form 
heterodimers and study their impact on breast cancer chemoresistance. With this work, I 
also provided evidence that FOXP1 levels in breast cancer cell lines is preferentially 
nuclear regardless of FOXP1 basal levels, in agreement with previous publications 
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(Banham et al 2001, Takayama et al 2008). Unlike FOXO transcription factors, which have 
their localisation negatively regulated by the PI3K/AKT pathway, FOXP1 lacks AKT 
phosphorylation sites. This suggests that FOXP1 escapes direct regulation by PI3K/AKT 
pathway. However, FOXP1 can be indirectly regulated by PI3K/AKT via FOXO3a. The 
FOXO3a/FOXP1 axis appears to have a role in breast cancer chemoresistance. I have 
shown that FOXP1 is a good prognostic marker in breast cancer survival. In line with our 
previous report, where nuclear FOXO3a predicts a worse prognosis (Chen et al 2010a), I 
have also shown that FOXO3a and FOXP1 expression are inversely correlated in breast 
cancer patient samples, suggesting that for cancers which are resistant to chemotherapy, 
the FOXO3a/FOXP1 axis has been uncoupled, resulting in cell cycle progression and 
proliferation. This suggests that FOXP1 plays a key role in the control of the cell cycle and 
cell proliferation. The fact that FOXP1 overexpression fails to impair the proliferation of 
epirubicin-resistant MCF-7 cells, indicates that in these clonal FOXP1 overexpressing 
cells, the downstream signalling is deregulated, resulting in a further defection in cell 
proliferation control. These data suggest that FOXP1 could be useful as an additional 
marker to predict clinical outcomes. Another aspect that was not addressed is the 
presence and significance of FOXP1 isoforms in breast cancer. The majority of these 
isoforms are N-terminal truncated species of the full-length protein, which have been 
implicated as having an oncogenic role in DLBCL (Brown et al 2008a). It would be of 
informative to identify them in breast cancer cell lines as well as ascertain their clinical 
implications. It would also be interesting to test whether FOXP1 regulates other known 
FOXO3a targets. Moreover, one could test whether FOXP1 and FOXO3a cooperate for 
the binding of potential common targets. ChIP-Sequencing (ChIP-Seq) would prove a 
useful technique to map and sequence these FOX protein interaction binding sites within 
the genome of cancer cells. This will inform us if FOXO and FOXP1 share overlapping 
gene target and their identities. 
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CHAPTER 5 
VEGF IS A TARGET OF FOXO3A 
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5.1 INTRODUCTION 
5.1.1 ANGIOGENESIS 
Angiogenesis is by definition the process that generates new blood vessels. Angiogenesis 
is not only crucial during development but it also occurs in adulthood, after injury during 
wound healing. This process occurs daily in our body and so it is essential for it to be 
tightly regulated. It comes as no surprise that, when this regulation fails, the abnormal 
blood vessel formation sets stage for “feeding” numerous diseases such as cancer 
(Folkman and Shing 1992). By supplying tumour cells with oxygen and nutrients, 
angiogenesis becomes indispensable for tumour growth, invasion and metastasis 
(Folkman 1990). Angiogenesis is triggered by different angiogenic factors that are secreted 
by a variety of cells, including tumour cells. Interleukins, fibroblast growth factor (FGF), 
transforming growth factor β (TGF-β), tumour necrosis factor α (TNF-α) and platelet-
derived growth factor (PDGF) are some of the different soluble inducers of angiogenesis. 
However, the angiogenic factor most intensively studied is the vascular endothelial growth 
factor (VEGF) (Papetti and Herman 2002, Presta et al 2005).  
 
5.1.2 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) FAMILY  
The Vascular Endothelial Growth Factor (VEGF) is a family of growth factors that includes 
5 proteins: VEGF-A (herein referred as VEGF), -B, -C, -D, and Placenta Growth Factor 
(PLGF) (Ferrara 2004, Lohela et al 2009). Once secreted these growth factors mediate 
their biological roles by binding to three distinct tyrosine kinase primary receptors: Flt-1 or 
VEGFR-1, Flk-1 or VEGFR-2 and Flt-4 or VEGFR-3. VEGFR-1 is expressed in monocytes, 
macrophages and vascular endothelial cells (ECs) (Jakeman et al 1992) whilst VEGFR-2 
is mainly expressed in the cell surface of vascular ECs and have been showed to be 
involved in blood vessel growth (Koch et al 2011). VEGFR-3 is restricted to lymphatic EC 
and has been showed to be involved in haematopoiesis and lymphangiogenesis (Partanen 
et al 1999, Rockson 2001). These receptors trigger VEGFs mediated cellular responses 
and have different affinities for the different VEGF ligands. For example, VEGFR-1 
mediates the responses of VEGF, VEGFB and PLGF. Although VEGF binds with higher 
affinity to VEGFR-1, its tyrosine activity is weaker than VEGFR-2 (Shinkai et al 1998). 
Therefore, VEGFR-1 have been considered a “trap” for VEGF by negatively regulating its 
binding to VEGFR-2 (Chappell et al 2009). VEGFR-2 is expressed ubiquitously on almost 
all endothelial cell types (Quinn et al 1993) and binds to VEGF, VEGFC and VEGFD 
(McColl et al 2003) whereas VEGFR3 is activated by the binding of VEGFC and VEGFD 
(Makinen et al 2001). Due to the similarity of phenotypes between Vegfr2-/- and Vegfa-/- 
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mice, VEGFR-2 is considered to be the main receptor of VEGF (Ferrara et al 1996). The 
neuropilin-1 and -2 receptors are co-receptors that can enhance the binding affinity of the 
various VEGF ligands to the previously mentioned primary receptors. For example, 
neuropilin-1 receptor has been shown to complex with VEGFR-2 to enhance VEGFR-2 
mediated permeability (Becker et al 2005). Upon ligand-binding, VEGF receptors trigger 
downstream signalling cascades, including the PI3K, the p38-MAPK, and the Raf 
pathways, which in turn control the endothelial cell survival, proliferation and migration 
(Lamalice et al 2006, Lentzsch et al 2004, Pytel et al 2009). 
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5.1.3 VEGF 
The importance of VEGF in angiogenesis has been demonstrated in knockout mice where 
disruptions of a single allele of the VEGF gene resulted in abnormal angiogenesis and led 
to embryonic lethality (Carmeliet et al 1996, Ferrara et al 1996). VEGF gene is located on 
6p21.3 and is organised in eight exons that by alternative exon splicing generate different 
mRNA species (Vincenti et al 1996). Until recently only seven VEGFxxx isoforms had been 
identified, where xxx refers to the number of amino acids within a given isoform. These 
isoforms have 121, 165, 145, 148, 183, 189 and 206 amino acids, respectively (Charnock-
Jones et al 1993, Neufeld et al 1999, Tischer et al 1991). From these VEGF splice 
variants, many were found to be overexpressed in a variety of cancers, including renal-cell 
(Tomisawa et al 1999), lung and colon (Cheung et al 1998) carcinomas and act as pro-
angiogenic factors. The first of these isoforms to be identified was VEGF165 which is the 
most abundant splice variant and is considered to be the predominant regulator of 
angiogenesis (Ferrara and Henzel 1989). The finding of different isoforms have drawn the 
attention to the misconception that VEGF165 is a measure of total VEGF and many 
antibody-based assays have been developed specifically to detect VEGF165. The VEGF165 
isoform is essential for cell migration and proliferation in vitro and is upregulated in many 
cancers such as colorectal (Uthoff et al 2002) and hepatocellular (Li et al 2006) 
carcinomas. Moreover, VEGF165 expression is correlated with tumour progression and poor 
prognosis in breast cancer (Gasparini 2000). Comparative studies of the different VEGF 
isoform properties have led to the concept that indeed, VEGF165 is the major VEGF isoform 
(Houck et al 1992). Aside from the above mentioned isoforms, another family of 
unconventional VEGF isoforms - VEGFxxxb – has been found to exist and have anti-
angiogenic properties, counterbalancing the pro-angiogenic activity by other VEGF 
isoforms (Woolard et al 2004). In 2002, Bates et al identified and characterised VEGF165b. 
VEGF165b was found downregulated in renal cell (Bates et al 2002), prostate (Woolard et al 
2004), and colon (Varey et al 2008) carcinoma and malignant melanoma (Pritchard-Jones 
et al 2007). Additionally, VEGF121b isoform has also been identified and reported to inhibit 
cell migration and tumour growth in colorectal cancer (Rennel et al 2009), further 
suggesting that this entire family of VEGFxxxb acts as a brake for excessive angiogenic 
activity. It is now well established that both oxygen and nutrient deprivation are the main 
processes that drive angiogenesis so it is not surprising that under hypoxia or 
hypoglycaemia, cells respond by stimulating VEGF mRNA expression (Gogitidze Joy et al 
2010, Shweiki et al 1992, Shweiki et al 1995). In fact, hypoxia is such an important event 
that a low oxygen gradient is necessary for wound-healing angiogenesis and whenever 
this gradient is destroyed, angiogenesis ceases (Knighton et al 1981). Whenever hypoxia 
occurs, the hypoxia-inducible factor-1 α (HIF-1α) binds to hypoxia-response elements 
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(HREs) in their target gene promoters restoring oxygen homeostasis. One of the genes 
that is transcriptionally activated by HIF-1α is VEGF (Semenza 2003). Several studies 
have shown that tumour vascularisation is launched by HIF-1α-dependent upregulation of 
VEGF. In different cell lines hypoxia has been found to both increase VEGF transcription 
mRNA expression and at the same time decrease degradation mechanisms of VEGF 
mRNA (Carmeliet et al 1998, Ikeda et al 1995, Liu et al 1995). VEGF upregulation by HIF-
1α has been found not only in hypoxic niches in solid tumours (Stein et al 1995) but also in 
the context of other tissue ischemia in vivo (Banai et al 1994, Pe'er et al 1995). Although 
hypoxia is the most important regulator of VEGF expression other factors, including 
oncogene expression can also stimulate VEGF expression (Rak et al 1995). Interestingly, 
inactivation of the tumour suppressor von Hippel-Landau (vHL) also leads to 
overexpression of VEGF in tumour cells and consequently increased angiogenesis 
(Siemeister et al 1996). This tumour suppressor gene has also been shown to regulate 
VEGF expression by transcriptional and post-transcriptional mechanisms (Iliopoulos et al 
1996). Cytokines and growth factors such as transforming growth factor α (TGF-α), insulin-
like growth factor (IGF-I) and IL-6 were also shown to stimulate VEGF mRNA expression 
(Ferrara and Davis-Smyth 1997, Neufeld et al 1999). 
 
5.1.4 VEGF THERAPIES 
Neovascularisation stimulated by VEGF occurs in several important clinical contexts, 
including myocardial ischemia, retinal disease, and importantly in tumour growth. In fact, 
the growth of tumour vessels is one of the hallmarks of cancer (Hanahan and Weinberg 
2011) and so, VEGF has been extensively studied in human cancers. VEGF and its 
receptors have been frequently found to be overexpressed in human tumours such as 
breast (Schneider and Sledge 2007), non-small cell lung (Heist et al 2008), colorectal 
(Yamaguchi et al 2007), and prostate cancers (Ferrer et al 1998). Moreover, VEGF 
expression has been associated with tumour metastasis and increased levels of VEGF 
have been shown to correlate with poor prognosis in colon (Takahashi et al 1995), non-
small cell lung (Imoto et al 1998) and breast (Gasparini et al 1997) cancers. In line with all 
these data, VEGF has become an attractive target in the clinical development of 
pharmacologic agents. Different approaches have been developed to block VEGF 
signalling, including anti-VEGF antibodies and VEGF tyrosine kinase inhibitors. 
Bevacizumab (trade name Avastin) is a recombinant monoclonal antibody that binds and 
neutralises VEGF (Yang et al 2003) and has been shown, in combination with 
chemotherapy to increase survival in patients with metastatic colorectal (Hurwitz et al 
2004), HER-2 negative breast (Miller et al 2007) and lung cancer (Sandler et al 2006). 
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Another VEGF neutralising monoclonal antibody, 2C3, selectively blocks VEGF from 
VEGFR-2 but no VEGFR-1 and inhibits growth of ECs in vitro (Brekken et al 1998). 
Similarly, other antibodies, including Sunitinib and Sorafenib, target VEGF receptors or 
downstream signalling pathways. These two small molecule inhibitors target a variety of 
tyrosine kinases and are used in patients with solid tumours such as renal cell carcinomas 
(Escudier et al 2007, Motzer et al 2007). Sunitinib-mediated inhibition of the VEGF 
signalling has been shown to decrease proliferation of different cancer cells in vitro (Ikezoe 
et al 2006a, Ikezoe et al 2006b). Despite all the advances in VEGF directed therapy, 
VEGF signalling is still not fully understood so elucidation of the mechanisms that fine-tune 
VEGF production is needed. 
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5.2 RESULTS 
5.2.1 FOXO3a activation correlates with downregulation of FOXM1 and VEGF 
expression  
FOXO3a is known to activate gene expression; however, the data from the cDNA 
microarray that identified potential novel FOXO3a targets revealed that VEGF is repressed 
by this transcription factor. Consistent with this, FOXM1 has recently been suggested to 
control VEGF expression (Zhang et al 2008) and to be regulated by FOXO3a (Francis et al 
2009). This led me to hypothesise that FOXO3a could regulate VEGF expression by a 
mechanism involving FOXM1. To this end, I assessed the expression of cytoplasmic and 
nuclear fractions of VEGF, FOXM1, and FOXO3a upon lapatinib treatment of responsive 
and resistant breast cancer cell lines. I have also investigated the expression levels of 
FGF7, another mitogenic growth factor as a control. Western blot analysis showed that 
lapatinib treatment of sensitive BT474 and SKBR3 cells caused a decline in the 
phosphorylation levels of FOXO3a but an increase in nuclear FOXO3a levels, indicating 
activation of this transcription factor (Figure 49A). In both BT474 and SKBR3 cells, 
FOXO3a activation upon lapatinib treatment was accompanied by a decrease in VEGF 
and FOXM1 levels. In contrast, in the lapatinib-resistant MDA-MB-231 cells FOXO3a 
phosphorylation levels were higher and consequently FOXM1 expression was increased in 
comparison with sensitive cells. The result also showed that FGF7 was not downregulated 
by lapatinib, suggesting that the repression of VEGF expression by lapatinib and FOXO3a 
was specific (Figure 49A). Notably, all factors were downregulated in sensitive BT474 cells 
after 48 h of treatment, probably reflecting global protein degradation and cell death. The 
total levels of VEGF, FOXM1, and FOXO3a also recapitulated the fractionation results. 
FOXO3a was activated by lapatinib treatment in lapatinib-sensitive BT474 and SKBR3 
cells and VEGF and FOXM1 levels were decreased. Instead, in the lapatinib-resistant 
MDA-MB-231 cells there were no appreciable changes in the total levels of P-FOXO3a 
(T32), nuclear FOXO3a, FOXM1, or VEGF levels upon treatment. 
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Figure 49. Expression of FOXO3a, FOXM1 and VEGF in response to lapatinib 
treatment in breast cancer cell lines. 
A) Cells were collected and analysed for P-FOXO3a (T32), FOXO3a, FOXM1, VEGF, FGF7, Lamin 
B and Tubulin expression by western blotting of the nuclear/cytoplamic (left panel) and total (right 
panel) lysates. B) VEGF and FGF-7 concentrations in supernatants were measured by ELISA and 
the concentrations normalised using standard curves. C) In parallel, VEGF, FOXM1 and FOXO3a 
mRNA levels were also analysed by RT-qPCR and normalised to L19 RNA expression. All 
experiments were performed in triplicate. 
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To confirm that lapatinib represses VEGF expression, I determined the secreted levels of 
VEGF by ELISA in the three previously used cell lines. Whereas secreted VEGF levels 
remained unchanged upon lapatinib treatment of resistant MDA-MB-231 cells, its levels 
declined markedly after 24 h of treatment of the lapatinib-sensitive BT474 and SKBR3 
cells. The secreted levels of FGF7 were included as a negative control (Figure 49B). The 
results showed that the concentrations of the control FGF7 did not alter significantly 
following lapatinib treatment in BT474, SKBR3 and MDA-MB-231 cells, suggesting that the 
repression of VEGF by FOXO3a and lapatinib is specific. In order to test whether lapatinib 
treatment regulates VEGF, FOXM1 or FOXO3a expression at the transcriptional level, I 
performed RT-qPCR analysis (Figure 49C). In accordance to the Western blot results, 
lapatinib inhibited VEGF and FOXM1 mRNA expression in the sensitive BT474 and 
SKBR3 cells but not in the lapatinib-resistant MDA-MB-231 cells. Notably, FOXO3a 
transcript levels were also upregulated in sensitive BT474 and SKBR3 cells (Figure 49C). 
Together these results demonstrate that lapatinib treatment of sensitive breast cancer cells 
induces and activates FOXO3a but inhibits FOXM1 and VEGF expression.  
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Figure 49. Continued. 
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5.2.2 FOXO3a represses VEGF and FOXM1 expression  
In order to study the mechanism underlying the reciprocal relationship between FOXO3a 
activation and VEGF and FOXM1 inhibition, I used the 4-OHT dependent FOXO3a(A3):ER 
inducible system in MDA-MB-231 cells described in the previous chapters. Subcellular 
fractionation was performed with control MDA-MB-231 and MDA-MB-231-FOXO3a(A3):ER 
cells treated with 4-OHT over a timecourse. As shown in Figure 50A, 4-OHT not only 
induced nuclear accumulation of activated FOXO3a but also inhibited expression of both 
VEGF and FOXM1. This downregulation of VEGF and FOXM1 upon 4-OHT treatment was 
dependent upon FOXO3a activation, as no such response was observed upon treatment 
of control MDA-MB-231 cells (Figure 50A). I also determined the impact of FOXO3a 
activation in these cell lines in the secreted levels of VEGF by ELISA. Expectedly, 
induction of FOXO3a activity also decreased secreted VEGF levels, apparent after 8 h of 
4-OHT stimulation, whereas this response was absent in control MDA-MB-231 cells 
(Figure 50A). FOXM1 and VEGF transcript levels were also measured by RT-qPCR 
analysis upon 4-OHT stimulation. Importantly, 4-OHT stimulation resulted in a 
downregulation of VEGF and FOXM1 mRNA levels in MDA-MB-231-FOXO3a(A3):ER 
cells, relative to control MDA-MB-231 cells (Figure 50B). These results suggest that 
FOXM1 and VEGF expression are negatively regulated by FOXO3a at both transcriptional 
and translational levels. 
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Figure 50. FOXO3a represses the expression of FOXM1 and VEGF in the breast 
carcinoma cells MDA-MB-231 and MCF-7. 
MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200nmol/l of 4-OHT for 
the indicated times. A) Nuclear and cytoplasmic extracts were prepared at the times indicated. The 
expression levels of FOXO3a, P-FOXO3a (T32), FOXM1, VEGF, FGF7, Tubulin and Lamin B were 
analysed by western blotting. The supernatants of the cells were collected and VEGF 
concentrations were measured by ELISA. B) Total RNA was extracted and the mRNA expression of 
FOXM1 and VEGF was determined by RT-qPCR and normalised to the level of L19. The FOXO3a, 
FOXM1, VEGF and Tubulin proteins levels were assessed in MCF-7 cells by western blotting 
following the C) transient transfection with the constitutively active FOXO3a(A3) or control vector 
and the D) transient transfection with a specific FOXO3a and NSC siRNA, or Mock. C, D) VEGF 
and FOXM1 mRNA expression was determined by RT–qPCR. All data shown represent the 
averages of data from three experiments, and the error bars show the standard deviations. 
Statistical analyses were done using Student’s t test. *P<0.05, significant; **P<0.01, significant; , 
non-significant. 
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Figure 50. Continued. 
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To corroborate these observations, I transiently transfected MCF-7 cells with the 
constitutively active FOXO3a(A3) or control empty expression vectors, and determined 
both VEGF and FOXM1 expression levels. Western blot and RT-qPCR analyses 
demonstrated that the FOXO3a(A3) mutant inhibited FOXM1 and VEGF expression, at 
protein and mRNA levels, respectively (Figure 50C). This was further supported by the 
reverse experiment of transiently transfecting MCF-7 cells with a FOXO3a targeting siRNA 
pool or NSC siRNA. Silencing FOXO3a increased VEGF and FOXM1 expression at both 
protein and mRNA levels (Figure 50D). 
 
 
 
Figure 50. Continued. 
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To demonstrate further that FOXO3a has a role in the downregulation of FOXM1 and 
VEGF by lapatinib treatment, I silenced FOXO3a in BT474 cells. Cells were transfected 
with either a FOXO3a-specific or a NSC siRNA pool and the expression levels of VEGF 
and FOXM1 were determined following lapatinib treatment (Figure 51). Western blot 
analysis confirmed the efficient knock-down of the endogenous FOXO3a in BT474 cells. 
Consistent with previous data (Nelson and Dolder 2006) lapatinib treatment led to a 
decrease in P-HER2 levels in both NSC and FOXO3a siRNA cells. Silencing of FOXO3a 
resulted in increased basal levels of FOXM1 and VEGF, and alleviated the downregulation 
of FOXM1 and VEGF by lapatinib (Figure 51). Notably, the expression levels of FOXM1 
and VEGF eventually declined at 48 h after lapatinib treatment, which could be due to the 
functional compensation by other FOXO isoforms or the fact that FOXM1 and/or VEGF are 
also repressed by lapatinib through other transcription factors or at the post-transcriptional 
level. Together these data further confirmed that FOXO3a negatively regulates VEGF and 
FOXM1 expression, through a mechanism likely to involve transcriptional inhibition. 
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Figure 51. Silencing FOXO3a induces the expression of FOXM1 and VEGF in BT474 
cells. 
BT474 cells were transfected with a specific FOXO3a and NSC siRNA, or Mock transfected and 
treated with lapatinib for 0, 16, 24 and 48 h. The expression levels of the indicated antibodies was 
analysed by western blot. 
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5.2.3 FOXO3a and FOXM1 modulate VEGF promoter activity  
Next, I hypothesised that FOXO3a could suppress VEGF transcription, either by 
modulating promoter activity or, indirectly, by inhibiting FOXM1 expression. To differentiate 
between these scenarios, the VEGF promoter luciferase reporter was analysed (Figure 
52A). Sequence analysis identified two consensus forkhead transcription response 
elements (FHREs) in the proximal VEGF promoter region (see Appendix 7). Each of these 
sites, designated as FHRE1 and FHRE2 were then mutated and used to study VEGF 
promoter activity in the presence of a constitutively active form of FOXO3a or FOXM1, 
FOXO3a(A3) or FOXM1(ΔN) expression vectors, respectively. MCF-7 cells were co-
transfected with the wild-type (VEGF pro-WT), the mutant FHRE1 (VEGF pro-mut1) or 
mutant FHRE2 (VEGF pro-mut2) VEGF promoter together with a titration of FOXO3a(A3) 
and FOXM1(ΔN) expression vectors. The results showed that the expression of the 
FOXO3a(A3) mutant represses the activity from the putative VEGF WT promoter whereas 
exogenous expression of FOXM1 transactivated the reporter construct in a dose-
dependent manner (Figure 52B). Mutation of the distal (-319) but not the proximal (-178) 
FHRE abrogated the ability of FOXO3a(A3) and FOXM1 to inhibit and activate, 
respectively, this promoter-reporter construct. Thus, a single response element, 
designated FHRE2, appears to mediate the effects of both transcription factors on the 
VEGF promoter.  
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Figure 52. FOXO3a represses and FOXM1 induces VEGF promoter through a FHRE 
consensus site proximal to the transcription start site. 
A) Schematic representation of the VEGF-luciferase reporter construct, showing the two consensus 
FHRE sequences. B) MCF-7 cells were transiently transfected with 20ng of the WT, mutant FHRE1 
or mutant FHRE2 VEGF promoter/reporter and 0, 5, 10 or 20ng of either the constitutively active 
FOXO3a(A3) or FOXM1(ΔN) expression vector. Cells were assayed for luciferase activity. All 
relative luciferase activity values are corrected for co-transfected Renilla activity. All data shown 
represent the averages of data from three independent experiments, and the error bars show the 
SD. 
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5.2.4 FOXO3a and FOXM1 compete for binding to FHRE2 
To get more insights into the mechanism by which FOXO3a and FOXM1 regulate VEGF 
promoter transcription, I next performed oligonucleotide pull-down assay with nuclear 
lysates from MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells untreated or treated 
with 4-OHT for 8 and 24 h. The nuclear lysates were incubated with biotinylated wild-type 
(WT) or mutant FHRE2 (mut) oligonucleotides . Western blot analysis of the pulled-down 
complexes showed that both FOXO3a and FOXM1 bind to the wild-type FHRE2 of VEGF, 
but not the mutated FHRE2 site (Figure 53A). The binding of FOXO3a and FOXM1 to the 
FHRE2 could be competed off by excess amounts of the wild-type but not mutated FHRE2 
oligonucleotides, indicating that both transcription factors bind directly to this response 
element (Figure 53A). The results also revealed that FOXM1 is constitutively bound to 
FHRE2 in untreated MDA-MB-231-FOXO3a(A3):ER and the MDA-MB-231 cells. However, 
FOXM1 was replaced by the FOXO3a(A3):ER in response to 4-OHT stimulation of MDA-
MB-231-FOXO3a(A3):ER but not of MDA-MB-231 cells, suggesting that activated 
FOXO3a downregulates VEGF expression by competitive displacing FOXM1 bound to 
FHRE2.  
This FHRE pull-down experiment was repeated in the BT474 cells following lapatinib 
treatment in the presence of molar excess of mutated FHRE oligonucleotides (Figure 53B). 
Parallel Western blot analysis of nuclear and cytoplasmic lysates showed that lapatinib 
induces nuclear accumulation of FOXO3a after 2 to 4 h, concomitant with the 
downregulation of VEGF expression but without discernible change in FOXM1 levels at 
these timepoints (Figure 53B). The pull-down results, however, could indicate that the 
lapatinib-activated FOXO3a displaces FOXM1 from the FHRE2 of the VEGF promoter at 
these timepoints. Thus, although prolonged activation of FOXO3a will downregulate 
FOXM1 levels, inhibition of VEGF expression is an early event and mediated, at least in 
part, by displacing FOXM1 and binding to FHRE2.  
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Figure 53. FOXO3a competes off FOXM1 from the VEGF promoter. 
A) MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200nmol/L of 4-OHT 
for the indicated times. Pull-down assays were performed and protein expression was analysed by 
western blot using specific antibodies as indicated. B) The nuclear and cytoplasmic extracts 
prepared from BT474 cells treated with lapatinib for 0, 2 and 4 h were western blotted for the 
indicated proteins (right panel). The nuclear extracts from the lapatinib-treated cells were also 
examined by pull-down assays using biotinylated WT or mutant FHRE2 oligonucleotides.  
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To further study the binding of FOXO3a and FOXM1 to FHRE2 on VEGF promoter, I have 
performed FHRE pull-down and ChIP assays in MCF-7 cells. Cells were transiently 
transfected with or without FOXO3a(A3) expression vector and nuclear extracts were 
incubated with biotinylated wild-type (WT) or mutant FHR2 (mut) oligonucleotides with or 
without 5x molar excess of non-biotinylated wild type (WT) or mutant FHR2 (mut) 
oligonucleotides. Proteins bound to the biotinylated oligonucleotides were pull-down and 
analysed by Western blotting (Figure 54A). The results showed that FOXO3a was able to 
attenuate FOXM1 binding to the FHR2 site on VEGF promoter. To definitely show that 
FOXO3a competes FOXM1 off VEGF promoter, ChIP analysis of VEGF promoter was 
performed. MCF-7 cells were transfected with increasing amounts of FOXO3a(A3) 
expression vector and used for ChIP assays and western blotting (Figure 54B). The results 
showed that an increase in FOXO3a-binding caused a decrease in the binding of FOXM1 
on VEGF promoter, further suggesting that the two transcription factors compete for 
binding. To test whether FOXM1 was able to compete FOXO3a off the VEGF promoter, I 
transfected MCF-7 cells with a fixed amount of FOXO3a(A3) and increasing amounts of 
FOXM1 expression vectors. The ChIP assay and Western blot results showed that, 
although FOXO3a can displace FOXM1 from binding VEGF promoter, the opposite is not 
true (Figure 54C).  
The finding that FOXO3a can displace FOXM1 from the VEGF FHRE2 and not vice versa 
is further supported by a recent structural study of the FOXM1 DNA-recognition domain, 
showing that FOXM1 has a lower DNA-binding affinity to the consensus 'TAAACA' 
recognition sequence compared with other forkhead proteins (Littler et al 2010). 
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Figure 54. DNA pull-down and ChIP assays showing that FOXO3a can displace 
FOXM1 in MCF-7 cells. 
A) Cells were transfected with 0 and 10µg of FOXO3a(A3) expression vector. Nuclear extracts 
incubated with the WT or mutant FHRE2 oligonucleotides in the presence or absence of 5x molar 
excess of non-biotinylated WT or mutant FHRE2. Proteins were pull-down and analysed by western 
blot using the indicated antibodies. B) Cells were transfected with 0, 2, 10g of the constitutively 
active FOXO3a(A3) vector and ChIP assays were performed (right). The transfected cells were also 
western blotted for FOXO3a, FOXM1 and Tubulin expression (left). C) Cells were transfected with 
0, 2 or 10g of FOXM1 and 2g of the FOXO3a(A3) vector, ChIP was performed the indicated 
antibodies (right). FOXO3a, FOXM1 and Tubulin expression was assessed by Western blot 
analysis (left). 
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5.2.5 FOXO3a is recruited to the proximal region of the VEGF promoter in vivo  
I then performed chromatin ChIP assays to determine the in vivo occupancy of the VEGF 
promoter by FOXO3a and FOXM1 in the BT474 cells in response to lapatinib treatment 
and in the MDA-MB-231 control and FOXO3a(A3) transfected cells in response to 4-OHT. 
The anti-FOXO3a antibody, but not the control antibody (IgG), precipitated the proximal 
region, encompassing FHRE2, of the VEGF promoter in BT474 cells (Figure 55). The 
amount of precipitated DNA increased significantly following 2 h of lapatinib treatment, 
reflecting an enhanced FOXO3a occupancy of this region of the VEGF promoter in vivo, 
consistent with the previous DNA pull-down results. In contrast, the binding of FOXM1 
decreased at 2 h following lapatinib treatment. Notably, the binding of both the FOXO3a 
and FOXM1 to the VEGF promoter decreased substantially by 4 h, probably suggesting 
decreased accessibility to the proximal region of the VEGF promoter (Figure 55). This 
observation suggested that FOXO3a could play a role in recruiting chromatin remodelling 
enzymes, such as HDACs, to repress the VEGF transcription. 
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Figure 55. FOXO3a is recruited to VEGF promoter. 
MDA-MB-231-FOXO3a(A3):ER, MDA-MB-231 and BT474 cells were treated with 200nmol/L of 4-
OHT and 1µM of lapatinib for the indicated times. ChIP assays were performed using 
immunoglobulin G (IgG), anti-FOXO3a, anti-ERα and anti-FOXM1 antibodies as indicated. 
Representative data from three independent experiments are shown. 
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5.2.6 FOXO3a recruits HDAC2 to the VEGF promoter  
To test the hypothesis that FOXO3a recruits HDACs to repress VEGF transcription, I 
treated MCF-7 cells with the HDAC inhibitor TSA and monitored VEGF expression. RT-
qPCR and Western blot analyses showed that following TSA incubation, VEGF mRNA and 
protein levels were strongly enhanced (Figure 56A). In order to investigate the impact of 
TSA and HDAC2 expression on VEGF promoter activity, MCF-7 were transfected with the 
WT, mutant FHRE1, or mutant FHRE2 VEGF promoter. The cells were either untreated or 
treated with TSA, or co-tranfected with increasing amounts of either the wild-type 
(HDAC2WT) or constitutively active HDAC2 (HDAC2C262A/C274A) expression vector. The 
luciferase assay showed that TSA triggered a marked induction in VEGF promoter activity, 
which was abolished upon mutation of the FHRE2, but not FHRE1, site. In contrast, 
overexpression of the dominantly active HDAC2C262A/C274A mutant, but not the WT HDAC2, 
repressed VEGF promoter activity in a dose-dependent manner. This ability of HDAC2 to 
repress VEGF promoter activity was again dependent on a functional FHRE2 (Figure 56B). 
The inability of WT HDAC2 to repress VEGF promoter activity could be due to the high 
levels of endogenous HDAC2 in MCF-7 cells. ChIP assay was performed in MCF-7 cells 
untreated or treated with TSA for 24 h to determine HDAC2 binding on VEGF promoter. 
The assay further demonstrated that TSA induced a decrease in HDAC2 binding to the 
proximal VEGF promoter (Figure 56C). Finally, to study which HDAC species contributes 
the most to regulate VGEF expression, MCF-7 cells were transfected with NSC and smart 
pool siRNA against either HDAC1 or HDAC2 and analysed by western blotting. HDAC2 
knockdown using siRNA significantly upregulated VEGF expression whereas silencing of 
HDAC1 had little or no effect on VEGF expression (Figure 56D). All together, these data 
provides compelling evidence that HDAC2 mediates transcriptional inhibition of the VEGF 
promoter in breast cancer cells. 
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Figure 56. Effects of HDAC2 overexpression and depletion on the expression of 
VEGF in MCF-7 cells.  
A) Cells were treated with vehicle or 100nM TSA for 24 h and harvested for analysis of VEGF 
expression by RT-qPCR (left) and western blot analysis for VEGF, HDAC2 and Tubulin expression 
(right). B) Cells were transfected with 20ng of the WT, mutant FHRE1 or mutant FHRE2 VEGF 
promoter/reporter and either untreated or treated with 100nM TSA, or co-transfected with 0, 5, 10 or 
20ng of either the WT or constitutively active HDAC2 expression vector. The cells were harvested 
for luciferase assays after 24 h. C) Cells were untreated or treated with TSA for 24 h were analysed 
for HDAC2 binding on the VEGF promoter by ChIP assays. D) Cells were transiently transfected 
with NSC and specific siRNA against either HDAC1 or HDAC2 and were analysed by western 
blotting for protein expression as indicated. 
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Figure 56. Continued. 
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To examine if FOXO3a recruits HDAC2 to the VEGF promoter, I performed 
immunoprecipitation and ChIP experiments on BT474 cells treated with lapatinib. HDAC2 
and FOXO3a co-immunoprecipitated and this interaction was enhanced upon lapatinib 
treatment, probably reflecting the previously observed nuclear translocation of FOXO3a in 
Figure 53B. The ChIP assays showed increased recruitment of HDAC2 to the proximal 
VEGF promoter following 2 h of treatment with lapatinib (Figure 57B). Since acetylated 
histone H3 and H4 are epigenetic marks associated with activated promoters (Bernstein et 
al 2005, Davie and Candido 1978), I examined whether the HDAC2 recruitment coincided 
with a decrease in acetylated histones H3 and H4. As seen in the two lower panel of 
Figure 57B, HDAC2 was recruited only after a decrease in bound acetylated histones H3 
and H4 was noticed, indicating active chromatin remodelling and compaction of the 
proximal VEGF promoter. Further, siRNA-mediated FOXO3a knockdown (Figure 57C, 
right and left panels) in BT474 cells abolished the recruitment of HDAC2 to the proximal 
VEGF promoter upon lapatinib treatment as well as the concomitant decrease in 
acetylated histones H3 and H4. These findings demonstrate that FOXO3a activation in 
breast cancer cells results in displacement of DNA-bound FOXM1 from FHRE2, 
recruitment of HDAC2, and transcriptional repression of VEGF. 
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Figure 57. FOXO3a recruits HDAC2 to the VEGF promoter in response to lapatinib in 
BT474 cells. 
A) Cells were treated with 1µM lapatinib for 0, 2 and 4 h. Cells were immunoprecipitated and 
examined for FOXO3a and HDAC2 expression. B) Cells were transfected with specific siRNA 
against FOXO3a or NSC siRNA for 24 h, treated with lapatinib and then analysed for HDAC2, 
acetylated histone H3 and H4 binding on the VEGF promoter by ChIP assays. C) Western blot and 
RT–qPCR analyses were performed to confirm effective and specific FOXO3a knockdown. 
Statistical analyses were done using Student’s t test, and were considered significant at **P<0.01. 
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5.2.7 Inverse correlation between FOXO3a and VEGF expression in breast cancer  
To determine the regulation of VEGF by FOXO3a in vivo, I analysed the expression 
patterns of FOXO3a, FOXM1 and VEGF in a panel of breast cancer samples by IHC, 
together with our collaborators from Queen Mary Hospital in Hong Kong. Representative 
patterns of staining are shown in Figure 58. FOXO3a immunoreactivity was predominantly 
cytoplasmic in most tumour samples and correlated positively with VEGF (P = <0.001, Chi-
square test) and FOXM1 (P = 0.011, Chi-square test) staining irrespective of histological 
type, suggesting that the activated nuclear FOXO3a inhibits FOXM1 and VEGF expression 
in vivo in most breast cancer samples. Notably, there was also an inverse association 
trend between nuclear FOXO3a and VEGF expression but it was not statistically 
significant. Moreover, FOXM1 expression also significantly correlated with the expression 
of VEGF (P=0.015, Chi-square test) (Figure 58; see also Appendix 9, Appendix 10 and 
Appendix 11), suggesting FOXM1 promotes VEGF expression in breast cancer cells. 
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Figure 58. Representative expression patterns of FOXO3a, FOXM1 and VEGF in 
tissue microarray. 
Tumour tissue samples were stained by IHC with FOXO3a, FOXM1 and VEGF antibodies. A) Three 
representative tumour cases showing corresponding FOXO3a FOXM1 and VEGF staining patterns 
(magnification x100). The three cases 1, 2 and 3 represent low, medium and high FOXO3a 
cytoplasmic staining. B) Correlation analysis of FOXO3a, FOXM1 and VEGF staining in 116 breast 
carcinoma cases. The correlation between predominant nuclear/cytoplasmic FOXO3a expression 
with FOXM1 and VEGF expression and FOXM1 with VEGF expression was studied using Chi-
square tests and was considered significant at *P<0.05 and very significant at **P<0.01.  
218 
 
5.3 DISCUSSION 
VEGFs and their receptors are essential for breast cancer carcinogenesis, angiogenesis 
and metastasis (Lohela et al 2009). VEGF signals through different pathways including the 
PI3K/AKT, the p38-MAPK, and Raf however, the molecular mechanisms regulating VEGF 
expression in cancer cells are not fully understood. Yet, two studies have shown that 
inhibition of PI3K/AKT and MEK/ERK pathways lead to activation of FOXO factors which in 
turn mediated the anti-angiogenic effects of the chemopreventive agent epigallocatechin 
gallate (EGCG) present in green tea (Shankar et al 2008) and enhanced the anti-
angiogenic effects of resveratrol in HUVEC cells (Srivastava et al 2010). The previously 
described cDNA microarray study suggested that VEGF is a potential negatively regulated 
target of FOXO3a (Delpuech et al 2007). The analysis of breast cancer patient samples 
showed that FOXO3a nuclear localisation is significantly but inversely associated with 
VEGF expression, suggesting FOXO3a negatively regulates VEGF expression in vivo in 
breast cancer.  
Anti-angiogenic therapies that target both VEGF and its main receptor (VEGFR-2) are 
effective adjuvants to the treatment of solid tumours. Currently, the anti-VEGF antibody - 
bevacizumab - is being used for treatment of different carcinomas in combination with 
cytotoxic chemotherapy and has been shown to prolong the progression-free survival 
(Hurwitz et al 2004, Miller et al 2007, Sandler et al 2006). In addition, some tyrosine kinase 
inhibitors (TKIs) have also been developed to target VEGFR, including sunitinib and 
sorafenib. Despite the promising results of these VEGF and VEGFR targeting drugs, 
evidence of resistance has been described. This resistance mechanism may involve other 
receptor tyrosine kinases (RTKs) such as EGFR and HER-2. Antibody-therapies against 
these RTKs have been shown to decrease VEGF expression (Petit et al 1997) whereas 
tumour cells with enhanced HER-3/HER-4 ligand expression increased the production of 
VEGF (Yen et al 2000). Similarly, the EGFR ligand – EGF – has been shown to induce the 
expression of VEGF in glioma cells (Goldman et al 1993). Importantly, the EGFR specific 
monoclonal antibody cetuximab, decreased VEGF expression in a dose-dependent 
manner in squamous carcinoma cells (Petit et al 1997). Moreover, similar results were 
obtained with gefitinib and erlotinib (Ciardiello et al 2001, Pore et al 2006). The link that 
promotes the cross-talk between EGFR and VEGF is most likely HIF-1, as this 
transcription factor is a known regulator of VEGF and moreover, was showed to engage in 
a bidirectional regulation with EGFR (Swinson et al 2004). It has been shown that in 
tumour ECs, EGFR-specific TKIs switch from EGFR to VEGFR signalling in a feedback 
mechanism (Amin et al 2008) thus, indicating that EFGR inhibition enhances VEGF 
signalling (Bianco et al 2008, Naumov et al 2009, Viloria-Petit et al 2001). Whether VEGF 
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inhibition can promote EGFR signalling is not known. In fact, vandetanib, a new small 
molecule TKI of both EGFR and VEGFR may prove a useful tool for overcoming this mode 
of resistance (Heymach et al 2007). In this chapter, the dual inhibitor lapatinib was used to 
block the downstream signalling cascades of both EGFR and HER-2, such as the 
PI3K/AKT, which in turn results in FOXO3a activation (Hegde et al 2007). Using the 
lapatinib sensitive breast cancer cell lines BT474 and SKBR3 as models for FOXO3a 
activation, I tested and examined the underlying mechanism of VEGF regulation by 
FOXO3a. Lapatinib treatment results in nuclear translocation and activation of FOXO3a 
and ultimately reduction in VEGF expression at protein, mRNA and gene promoter levels. 
Transient transfection and inducible FOXO3a expression experiments show that FOXO3a 
represses while FOXM1 activates VEGF expression through a proximal FHRE site of the 
VEGF promoter, as mutation of this FHRE abrogated the regulation by FOXO3a and 
FOXM1. ChIP and oligonucleotide pull-down assays further demonstrate that both 
FOXO3a and FOXM1 bind directly to the FHRE of the VEGF promoter and that activated 
FOXO3a can displace FOXM1 from the FHRE, suggesting that FOXO3a can repress 
VEGF expression through competing off the transcriptional activator FOXM1. Consistently, 
FOXO3a accumulated and replaced FOXM1 at the FHRE as early as 2 h after lapatinib 
treatment; however, it was also noted that neither FOXO3a nor FOXM1 bound to the 
FHRE by 4 h. The lack of occupancy of the proximal VEGF promoter region by FOXO3a 
and FOXM1 at 4 h suggests that FOXO3a accumulation might lead to exclusion of 
transcription factors through chromatin remodelling. Histones are known targets of post-
translational modifications, including methylation and acetylation (Kouzarides 2007). The 
later chromatin modifications have been shown to regulate transcription factor binding (Li 
et al 2007a). Indeed, some studies have shown that the promoter regions of VEGFR-1 and 
VEGFR-2 are targets of epigenetic alterations and this leads to altered gene expression 
(Kim et al 2009, Yamada et al 2003). Histone acetylation decondenses the chromatin, 
making nucleosomal DNA more accessible to transcription factors, whereas inhibition of 
histone deacetylase activity by HDACs leads to condensation of the chromatin and 
exclusion of transcription factors (Strahl and Allis 2000). Consistently, I found that upon 
activation, FOXO3a recruits HDAC2 to the proximal region of the VEGF promoter, as 
revealed by ChIP analysis. Recently, the levels of acetylated histones H3 and H4 located 
in the nucleosomes have been proposed to be proportional to the levels of transcriptionally 
active DNA (Pokholok et al 2005). Consistently, the ChIP assays showed that in response 
to lapatinib treatment in BT474 cells, there was an increase in FOXO3a and HDAC2 
binding, concomitant with a decrease in acetylated histones H3 and H4 levels. In order to 
examine the amount of HDAC2 binding to FOXO3a in response to lapatinib in BT474 cells, 
I also performed co-immunoprecipitation experiments. The results show that the amount of 
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HDAC2 interacting with FOXO3a increased substantially at 2 h but declined by 4 h 
following lapatinib treatment. The increase in FOXO3a binding to HDAC2 in response to 
lapatinib is likely to be due to the relocation of FOXO3a to the nucleus, while the declined 
in FOXO3a binding to HDAC2 was probably a result of the disassociation in binding 
between the two proteins as well as a decline in HDAC2 levels, as revealed by 
immunoprecipitaion and western blot analyses, respectively. 
Overexpression of FOXM1 has been implicated with metastasis and angiogenesis in a 
number of malignancies, including glioma (Dai et al 2007), colon (Uddin et al 2011) and 
pancreatic (Wang et al 2007) cancer. Consistent with my findings, a recent study has also 
demonstrated that FOXM1 transcriptionally regulates VEGF expression in glioma cells 
(Zhang et al 2008). However, the FOXM1 responsive sites identified previously are located 
over 500 bp 5’-upstream of the FOXO/FOXM1 binding site defined in this study and neither 
of these sites appears to have a consensus FOXO-binding element. Importantly, deletion 
of site 2 in the present VEGF promoter abolished responsiveness to FOXO3a, FOXM1 and 
HDAC, suggesting this FHRE is targeted by both FOXO3a and FOXM1. Consistent with a 
previous report (Francis et al 2009), I further demonstrated that FOXM1 functions 
downstream of FOXO3a, and its activity and expression are negatively regulated by 
FOXO3a. Nevertheless, FOXM1 is not the sole mediator of FOXO3a function. FOXO3a 
can also negatively regulate gene expression through FOXM1 independent mechanisms, 
such as by means of HDAC recruitment. The ability of FOXO proteins to repress VEGF 
expression has been documented in Foxo1 null cells where VEGF is overexpressed and 
angiogenesis deregulated (Furuyama et al 2004, Park et al 2009). In fact, the loss of 
FoxO1 causes embryonic lethality as a result of severe defects in vascular development 
(Hosaka et al 2004). The notion that FOXO proteins are involved in the regulation of VEGF 
is now further supported by my finding that expression of nuclear FOXO3a expression 
significantly correlates with VEGF expression in breast cancer patient samples. Moreover, 
the fact that FOXO3a activity is enhanced in a HIF1-dependent way in response to hypoxia 
(Bakker et al 2007) suggests that HIF-1 could serve a role in another level of regulation of 
VEGF by a mechanism FOXO3a-dependent. 
In summary, together these results suggest that FOXO3a can potentially repress VEGF 
expression, through at least two mechanisms. First, activated FOXO3a can compete off 
the transcription activator FOXM1 from binding to the FHRE of the VEGF gene promoter. 
Second, FOXO3a can recruit HDACs to the VEGF promoter to induce chromatin 
condensation and transcription factor exclusion. Furthermore, FOXO3a has also been 
shown previously to be able to repress FOXM1 expression at the transcriptional level 
(Francis et al 2009). Consequently, FOXO3a can repress VEGF expression indirectly via 
regulating FOXM1 expression. The mechanisms by which FOXO3a represses VEGF 
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expression may represent common means whereby FOXO3a negatively regulates target 
gene expression. Thus, these data also provide novel understanding on the mechanisms 
by which FOXO transcription factors repress target gene expression. In addition, the 
findings from this chapter further suggest that therapeutic strategies targeting FOXO3a or 
FOXM1 can be used as an alternative or in parallel with anti-VEGF targeted agents as well 
as conventional chemotherapy in rational and effective treatment of tumours (Fernandez 
de Mattos et al 2008, Gomes et al 2008, Srivastava et al 2010). 
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CHAPTER 6 
FINAL DISCUSSION 
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Over the last two decades, advances have been made in the development of new and 
more effective drugs for different cellular targets in the treatment of cancer. However, 
cancer cell clones are always one step ahead, responding by generating new mechanisms 
to tolerate, evade or compensate the lethal effect of drugs.  
One of the signalling pathways most commonly deregulated during tumorigenesis and in 
the development of cancer drug-resistance is the PI3K/AKT/FOXO signalling axis. This 
signalling cascade has been found to be frequently hyperactivated in cancer, leading to 
FOXO inactivation. The PIK3/AKT/FOXO signalling pathway plays a critical role in a wide 
variety of cellular processes. One such example is the well characterised role that this 
pathway plays towards increased resistance to apoptosis and thus, in mediating drug-
resistance responses. Indeed, enhanced AKT activity has been showed to promote 
resistance to endocrine and cytotoxic drugs, further emphasising the importance of 
PI3K/AKT/FOXO axis in determining the outcome of drug sensitivity. Furthermore, many 
studies showed that the PI3K/AKT/FOXO cascade mediates both directly and indirectly the 
anti-survival and anti-proliferative effects of cancer drugs, such as paclitaxel, doxorubicin, 
cisplatin, gefitinib and lapatinib (Fernandez de Mattos et al 2008, Hui et al 2008b, Sunters 
et al 2003, Xia et al 2006). However, the functional role, the mechanism of action and the 
control of this signalling axis in mediating cancer drug sensitivity and resistance have not 
been fully elucidated.  
Several studies have provided insights into the mechanisms of FOXO regulation by AKT; 
however, not much is known regarding the relationship between FOXO and AKT, and its 
contribution to the development of breast cancer drug-resistance as well as the potential 
clinical relevance of the AKT/FOXO axis as both prognostic and predictive tools that could 
be used to “sort” patients in order to provide the most beneficial treatment combinations. 
This was explored in chapter 3, where I investigated not only the activity, subcellular 
localisation and impact of the PI3K/AKT/FOXO axis in different breast cancer drug 
sensitive and resistant cell lines but I further validated my in vitro results in breast cancer 
patient samples. I have shown that PI3K/AKT has definitely a role in mediation of cytotoxic 
chemotherapeutic drug-resistance, similarly to what has been described in numerous 
literature reports (Knuefermann et al 2003, Neri et al 2003, Tsuruo et al 2003, West et al 
2002). However, in contrast to a previous publication (Hu et al 2004), I have shown that in 
breast cancer patient samples, nuclear FOXO3a localisation predicts poor survival as well 
as chemotherapy resistance and associates with bad prognosis in breast cancer. 
Moreover, I found that higher nuclear FOXO3a expression, in vitro as well as in advanced 
breast cancer patient samples, is positively associated with P-AKT expression. This finding 
is contradictory to the well-established mechanism of regulation of FOXO proteins by AKT. 
Nonetheless, a negative feedback mechanism loop, in which FOXO3a upregulates 
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PI3K/AKT activity, has been previously described by our group in leukeamic cell lines. 
Consistently, I confirmed that this FOXO/AKT negative feedback mechanism is in place in 
both sensitive and resistant breast cancer cell lines, yet with different functional outcomes 
to what concerns FOXO mode of action. In sensitive cells FOXO could efficiently inhibited 
cell proliferation whereas in resistance cells, although nuclear FOXO expression is higher, 
its tumour suppressive function is deregulated (Error! Reference source not found.). The 
mechanism that allows FOXO3a to evade PI3K/AKT-dependent cytoplasmic 
sequestration, resulting in higher nuclear FOXO3a expression, is yet unknown but it could 
involve different post-translational modifications. For example, JNK pathway has been 
shown to phosphorylate FOXO and mediate its nuclear accumulation and promote the 
recruitment of SIRT1, leading to the activation of a specific subset of genes (Brunet et al 
2004). In accordance, SIRT1 has been shown to mediate FOXO activity by deacetylating 
FOXO3a resulting in the activation of genes involved in survival. For instance, it is possible 
that in sensitive breast cancer cells FOXO is enabled to activate a pro-apoptotic and anti-
proliferative gene programme, thus acting as a tumour suppressor whilst in resistant breast 
cancer cells, the PI3K/AKT-insensitive FOXO3a is regulated by different co-factors that act 
on FOXO to deregulate their known pro-apoptotic and anti-proliferative functions and 
favour the expression of genes determinant for cell survival and drug-resistance (Figure 
59). 
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Figure 59. Proposed model of FOXO subcellular localisation, differential effects and 
clinical impact in sensitive and resistant breast cancer cells. 
 
This work provides evidence that sustained nuclear FOXO3a expression may attenuate 
the response to endocrine and cytotoxic chemotherapy. Therefore, the study of the 
phosphorylation status and subcellular localisation of both AKT and FOXO proteins are 
two parameters that could determine whether these two proteins would be useful 
prognostic and predictive markers of chemotherapy response in breast cancer. The 
mechanism responsible for the differential regulation of FOXO3a activity in sensitive and 
resistant cells is still unknown; however it is likely that FOXO3a activity is regulated by 
other posttranslational modifications, including their acetylation status. As previously 
mentioned, deacetylation of FOXO by SIRT1 is known to shift FOXO-induced responses 
away from apoptosis towards survival (Brunet et al 2004). Moreover, SIRT1 has been 
shown to have a role in tumorigenesis. Overexpression of SIRT1 is found in a variety of 
cancers, including leukaemia and lymphomas, prostate, lung and colon carcinomas (Fraga 
et al 2007, Fraga and Esteller 2007, Lim 2007). Importantly, SIRT1 has been shown to be 
overexpressed in drug-resistant cancer cell lines and mediate cisplatin resistance (Liang et 
al 2008, Olmos et al 2011, Shiota et al 2010). In fact, cisplatin treatment has been shown 
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to induce SIRT1-dependent deacetylation of FOXO3a (Shiota et al 2010). This has led to 
the development of small synthetic molecules that can specifically target SIRTs influencing 
their activity, including sirtinol (Napper et al 2005), salermide (Grozinger et al 2001) and 
EX527 (Lara et al 2009) which have been shown to inhibit cancer cell growth. For 
example, treatment with sirtinol resulted in increased efficacy of cisplatin, in part by the 
reactivation of FOXO1 and induction of a growth arrest in prostate cancer cells (Jung-
Hynes et al 2009). It would be interesting to use these inhibitors to model FOXO3a 
acetylation status and restore the pro-apoptotic and anti-proliferative functions of FOXO3a 
in resistant breast cancer cells, which ultimately would result in overcoming drug-
resistance.  
To better understand the functional significance of the PIK3/AKT/FOXO signalling pathway 
and its role in tumorigenesis, it is also important to define the downstream network of 
FOXO targets. The identification of FOXO targets will help decipher its function, for 
example in sensitive as well as resistant cancer cells. Additionally, by identifying and 
characterising novel downstream targets of FOXO, which are differentially regulated in 
sensitive and resistant cancer cells, could also represent new therapeutic targets for the 
development of anti-cancer drugs. In chapters 4 and 5, I focused on characterising some 
of the new potential FOXO targets in breast cancer, previously validated on a microarray 
study (Delpuech et al 2007), including, FOXP1, FOXM1 and VEGF. 
I have shown not only that FOXO3a regulates FOXP1 expression but also that FOXP1 is 
targeted by the chemotherapeutic drug epirubicin and plays a crucial role towards cell 
cycle arrest. Furthermore, FOXP1 expression was differentially regulated in sensitive and 
epirubicin-resistant breast cancer cell lines, resembling the one of FOXO3a. This clearly 
suggests that the FOXO3a-dependent FOXP1 regulation could have a determinant role 
towards drug-resistance in breast cancer. Importantly, I have also found that p27Kip1 is a 
target of FOXP1. This finding was unexpected and raises some possibilities regarding the 
regulation of p27Kip1 by FOX proteins, specifically FOXO and FOXP. FOXO3a has been 
shown in a definite way to be a regulator of p27Kip1 expression. Since I validated FOXP1 as 
a downstream target of FOXO3a in breast cancer, two pertinent questions were raised. Is 
p27Kip1 expression regulated directly by FOXP1, in a FOXO3a-independent manner? Or do 
FOXO3a and FOXP1 cooperatively regulate the expression of p27Kip1? Unfortunately, my 
time-scale did not allow me to further investigate these conjectures however, the two 
scenarios are possible. In arguement of a potential FOXP1 direct regulation of p27Kip1, lays 
the fact that FOXP1 is not under the negative regulation of AKT, i.e., no AKT 
phosphorylation sites were found in FOXP1 sequence to date. Additionally, the tumour 
patient samples showed that FOXO3a is inversely correlated with FOXP1. Therefore, in 
cases where PI3K/AKT pathway is activated leading to FOXO3a cytoplasmic 
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sequestration, FOXP1 can proclaim the role of the principal regulator of p27Kip1. In support 
of this conjecture is also the fact that FOXP1 is mainly nuclear localised. On the other 
hand, FOXP family are known to form homo- and hetero- dimers (Wang et al 2003). It 
could be that a complex of FOXO3a:FOXP1 would cooperatively regulate p27Kip1 
expression. Yet, FOXO proteins have been described to bind DNA as monomers. 
Nevertheless, I have demonstrated that FOXP1 has an anti-proliferative through induction 
of p27Kip1 expression. Furthermore, in epirubicin-resistant cells characterised by low levels 
of FOXP1 and p27Kip1, overexpression of FOXP1 was able to restore p27Kip1 expression 
while silencing FOXP1 in sensitive MCF-7 cells abrogated p27Kip1 expression. Consistent 
with the role of FOXP1 in the cell cycle, FOXP1 is associated with a good prognosis, 
increasing the survival time of breast cancer patients. Nevertheless, the mechanism of 
regulation of FOXP1 expression and activity is still remains poorly understood. However, 
the family member FOXP3 has been shown to be targeted by post-translational 
modifications, including acetylation. In fact, SIRT1 has been shown to deacetylate Foxp3, 
resulting in its proteasomal degradation (van Loosdregt et al 2011).  
Similarly to FOXP1, in Chapter 5 I also validated VEGF as a downstream target of 
FOXO3a in breast cancer. In this chapter, lapatinib was used as a drug that blocks the 
PI3K signalling pathway and subsequently activates FOXO3a expression. Consistent with 
this notion, I found that lapatinib treatment induces FOXO3a nuclear translocation and 
activation. Contrary to what I found for FOXP1, FOXO3a negatively regulates VEGF 
expression at protein, mRNA and promoter levels. Consistently, IHC staining showed that 
nuclear FOXO3a expression significantly correlates with VEGF expression in breast 
cancer patient samples. Additionally, I have elucidated a mechanism of regulation of VEGF 
that encompasses a competition between FOXO3a and FOXM1 binding to VEGF 
promoter. These two transcription factors are able to recognise and bind the same FHRE 
sequence site on VEGF promoter. While the constitutively active FOXO3a overexpression 
results in downregulation of VEGF levels, FOXM1 was found to induce VEGF expression. I 
found that upon lapatinib treatment, FOXO3a becomes activated and competes off 
FOXM1 from the common FHRE site. However, four hours upon lapatinib treatment 
neither FOXO3a nor FOXM1 were found bound to the FHRE site. This led me to 
hypothesise that the early FOXO3a-mediated occupancy of VEGF promoter could serve 
as a recruitment base for transcriptional repressor complexes. In a global perspective, I 
have shown that lapatinib promotes the nuclear accumulation and activation of FOXO3a, 
which in turn recruits HDAC to the VEGF promoter, resulting in transcriptional repression 
through chromatin remodelling. In line with previous observations, I have further 
demonstrated that FOXM1 activity and expression is negatively regulated by FOXO3a in 
breast cancer cell lines. My findings lead to three potential FOXO3a-mediated 
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mechanisms of VEGF regulation: the first encompasses regulation of target expression 
indirectly via repression of FOXM1 expression; secondly, FOXO3a can recruit HDACs to 
target promoters to induce chromatin condensation and transcription factor exclusion, 
including FOXM1; finally, activated FOXO3a can displace FOXM1 from binding the FHRE 
site on target gene promoters. To my knowledge this is the first study demonstrating how 
class I HDACs are involved in gene repression through FOXO3a. It is also possible that 
the proposed mechanism of regulation of VEGF by FOXO3a may well represent the 
general mechanism by which FOXO transcription factors repress gene expression. 
In summary, this work has highlighted the importance of the FOXO/FOXM1 axis in 
tumorigenesis and drug-resistance. I have also elucidated the mechanism of action of 
FOXO and FOXM1, through studying the downstream effectors, FOXP1 and VEGF. 
Furthermore, my work has revealed that these forkhead transcription factors, FOXM1, 
FOXO3a and FOXP1, are not only frequently deregulated in cancer but also in the cancer 
resistant clones. Finally, my data suggests that these transcription factors could be useful 
targets for therapeutic interventions to treat cancer and ultimately to revert resistance. 
Since these transcription factors are regulated by post-translational modifications, such as 
acetylation one could potentially explore HDAC inhibitors to model their activity. The 
indisputable role of the PI3K/AKT/FOXO pathway in mediating many anti-cancer drug 
effects makes both this pathway and the newly identified effectors network an attractive 
axis to use in the diagnosis of cancer, prognosis to treatment as well as for monitoring the 
drug effects. However, the clinical potential of these proteins should not be assessed 
independently. For example, the phosphorylation status of both AKT and FOXO should be 
integrated with its expression. Ultimately, the use of these proteins as biomarkers and 
therapeutic tools in breast cancer will warrant further studies regarding their mechanisms 
of action and regulation as well as the expression and function of their downstream 
components, and this will be subject of future projects seeking to obtain further success on 
cancer therapy and avoiding drug-resistance.  
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Appendix 1. List of primary antibodies. 
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Resolving gel 
0.375M Tris pH 8.8, acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) APS, 
0.1% (v/v) TEMED 
 
Stacking gel 
0.126M Tris pH 6.8, acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) APS, 
TEMED 
 
SDS-PAGE Electrophoresis Buffer (1x) 
25mM Tris base, 250mM glycine, 0.1% (w/v) SDS 
10x stock 
 
Transfer Buffer (1x) 
24mM Tris base, 193mM glycine, 20% (v/v) methanol 
10x stock 
 
 
 
 
 
 
 
 
 
Appendix 2. Gel and buffer recipes for SDS-PAGE. 
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TAE Buffer (1X) 
40mM Tris·acetate, 1mM EDTA [50x stock (57.1ml glacial acetic acid in 1L)] 
 
0.5 M EDTA, pH 8 
Adjust pH to 8 with NaOH~20g 
 
TE, pH 8 
10mM Tris-HCl, pH 8, 1mM EDTA 
 
TBS-Tween Buffer pH 7.5 
40mM Tris-HCl, 300mM NaCl, 0.05% (v/v) Tween 20 (20x stock) 
 
Buffer I 
0.25% Triton X-100; 10mM EDTA; 0.5mM EGTA; 10mM HEPES pH 6.5 
 
Buffer II 
200mM NaCl; 10mM EDTA; 0.5mM EGTA; 10mM HEPES pH 6.5 
 
Lysis Buffer (ChIP) 
1% SDS; 10mM EDTA; 50mM Tris-HCl pH 8.1 
 
TSE I 
0.1% SDS; 1% Triton X-100; 2mM EDTA; 20mM Tris-HCl pH 8.1; 150mM NaCl 
 
Scraping Buffer 
100mM Tris-HCl pH 9.4; 0.1% SDS 
 
Elution Buffer 
0.1M NaHCO3; 1% SDS 
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Appendix 4. Map of the FOXP1 cDNA in pcDNA3 vector and primer sequence used 
for sub-cloning. 
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Appendix 5. pEGFP-C1 vector map. 
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Appendix 6. pCR2.1 TOPO vector. 
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Appendix 7. VEGF promoter sequence. 
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Appendix 8. Histological types of tumour samples and characteristics of the 116 
patients with breast cancer used in tissue microarray (TMA) study.  
  
270 
 
 
 
 
 
Appendix 9. Analysis of correlations between cytoplasmic FOXO3a and VEGF or 
FOXM1 staining (using SPSS programme).  
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Appendix 10. Analysis of correlations between nuclear FOXO3a and VEGF or 
FOXM1 staining (using SPSS programme).  
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Appendix 11. Analysis of correlations between VEGF and FOXM1 staining (using 
SPSS programme).  
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Appendix 12. The correlation between nuclear FOXO3a and FOXP1 and cytoplasmic 
FOXO3a and FOXP1 was assessed by using SPSS program. 
 
